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Reduced susceptibility in some C. difficile isolates has been observed to metronidazole, a 
frontline antibiotic for C. difficile infection. Therefore, this study was performed to 
characterize reduced metronidazole susceptibility in UK C. difficile isolates, using phenotypic 
and genotypic approaches. This research focused on strains of three UK C. difficile ribotypes 
027, 001, 106 including metronidazole reduced susceptible (CDRM) and metronidazole 
susceptible (CDSM) C. difficile strains, and 2 control strains from ribotype  010 (CDRM) and 
038 (CDSM). An agar incorporation method (AIM) was used to determine the susceptibility 
and heterogeneity of minimum inhibitory concentrations (MICs). Ribotype 001 CDRM 
strains was observed for metronidazole to have the highest MIC90 (8mg/L) and the highest 
MIC hetereogeneity distributed across 2 MICs was observed in ribotype 106 at 22% and 11% 
for metronidazole and vancomycin respectively. All strains were susceptible to vancomycin 
at MIC ≤ 2mg/L which reflected in the high area under the curve (AUC) results. Population 
analysis profiling (PAP) incorporating total viable counting on antibiotic-containing agar 
plates was also employed and ribotype 001 had the lowest AUC (2.32) for metronidazole. 
Serial passage experiment (5 passages) with and without sub-inhibitory concentrations of 
metronidazole was performed using AIM and decline in MIC50 from 4mg/L – 0.5mg/L after 5 
passages without subinhibitory concentrations of metronidazole was observed. Nitroreductase 
activity was also evaluated using a spectrophotometric assay and only 3 CDRM strains 
showed detectable nitroreductase activity at very low levels. Subsequently, metronidazole 
uptake capacity was determined by employing a microbiological bioassay and AIM was used 
to evaluate the effect of hemin on the CDRM phenotype using both Wilkins Chalgren and 
Brucella Agar +/- 5mg/L hemin. Hemin in Brucella agar significantly increased 
metronidazole MIC (P>0.05) for ribotype 001 and 027 only. The metronidazole uptake assay 
indicated that the CDRM phenotype was not related to deficiencies in drug reduction and 
uptake. It does not however eliminate possibility of metronidazole being reduced to its non-
toxic amino radical by nim genes.  Then analysis was done on the whole genome of two C. 
difficile reduced susceptible strain, E4 and a clinical strain of ribotype 001 ribotype, 
compared with C. difficile 630 (CDSM). Whole genome analysis showed single nucleotide 
polymorphisms (SNPs) in nimB, glyC, nifJ thiH and hemN genes, linked to electron transfer, 
activation, oxidative stress and DNA repair which could predispose to CDRM phenotype as 
they are linked with metronidazole mechanism of action. The SNP detected in nimB gene 
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could activate the conversion of metronidazole to its non-toxic amino radical thus 
contributing to the CDRM phenotype.   
This study has provided the focal areas that has the potential for predisposing to 
metronidazole reduced susceptibility. Which are factors affecting DNA repair, oxidative 
stress and metronidazole reduction. Which is of significance due to the CDRM phenotype 
compounded by the heterogeneity and stability profile that can give false susceptibility results 
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1.0 LITERATURE REVIEW/INTRODUCTION  
Clostridium difficile a spore forming, Gram positive anaerobic bacterium, has been observed 
to be the most prevalent infectious cause of antibiotic associated diarrhoea (AAD) (Mutlu et 
al., 2007, Lynch et al., 2013).   
Though C. difficile infection is caused through ingestion of C. difficile spores acquired from 
within or outside hospital environment (Shaughnessy et al., 2011), the bacterium can be 
referred to as a nosocomial pathogen because it is more prevalent in the hospitalized situation. 
This is due to the fact that in hospitals antibiotics are used to treat infections, thus facilitating 
C. difficile colonisation (Bartlett, 1992, Fawley, 2005, Lynch et al., 2013) and leading to C. 
difficile infection (CDI). Since C. difficile spores are unaffected by the stomach acidic 
environment, these spores germinate and outgrow into vegetative cells in the small intestine 
(Lessa et al, 2012). C. difficile has also been isolated in animals where it is observed as a 
pathogen or a commensal. As a result, transmission of C. difficile from animals to humans and 
vice versa is possible (Janezic et al, 2012). There are over 400 PCR C. difficile ribotypes that 
have been identified, and different ribotypes are prevalent in different countries and areas 
(Janezic et al., 2012).  C. difficile was first identified as Bacillus difficillis by Hall and O’Toole 
1935 who encountered the organism in the intestinal contents of neonates. B. difficilis was 
observed to be a pathogen in animals, and such infection could result in mortality. Hall and 
O’Toole linked pathogenicity in the organism to toxin production (Baines, 2006).  
1.1 Risk Factors  
There are certain factors associated with C. difficile infection termed risk factors. These factors 
are old age or increasing age, long hospital stay, gastrointestinal procedures that do not involve 
surgery, chronic diseased situations, long exposure to antibiotics and use of varieties of 
antibiotics (Bignardi, 1998). Chalmers et al., 2016 associated community acquired pneumonia 
(CAP) with CDI by examining 1883 CAP patients in UK, 61 CDI cases were identified from 
365 CAP patients that developed diarrhoea. The CDI risk factors was studied, and it was 
identified that, long hospital stay predisposed patients to CDI than the class of antibiotic 
administered. Same CDI risk was observed for all broad spectrum antibiotics used and it was 
also observed that results from 2005-2010 showed that the replacement of cephalosporins with 
amoxicillin/clavulanic acid has led to increase in CDI defeating the purpose for the 
replacement. Thus it was concluded that switching antibiotic classes may have the same effect 
in CDI decline as shortening treatment duration, and hospital stay (Chalmers et al., 2016).  
Age has been observed to be a risk factor for CDI especially those of 65 years and above, also 
age is a risk factor for recurrence and CDI severity (Louie et al., 2013).  A 2013 study observed 
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that these adverse development actually commences at a much younger age of 40 years, with 
increasing severity as age increases (Louie et al., 2013). The study consisted of 999 participants 
who tested positive for CDI, from Canada, US, and Europe, the efficacy of vancomycin and 
fidaxomicin were as well examined in this study. It was observed that increasing age resulted 
in decrease of the effectiveness of the therapeutics used, irrespective of type, vancomycin or 
fidaxomicin (Louie et al., 2013).     
Contaminated food, close association with infected individuals and zoonotic transmission have 
been listed to be potential risk factors for community acquired CDI (Lee and Cohen 2013). 
Though any antibiotic can lead to CDI but a few have been observed to incite CDI much more.  
These are fluoroquinolones, Clindamycin and cephalosporin (Slimmings and Riley, 2014).    
1.2 Community acquired CDI  
C. difficile was historically considered predominantly as a nosocomial infection, however in 
recent years, research has demonstrated that CDI occurs equally in the community setting. So, 
other than hospital acquired CDI (HA-CDI), there is also community acquired CDI. 
Community acquired CDI can be described as the onset of CDI occurring not more than 48 
hours after being hospitalised or a case where by the CDI symptoms were observed while still 
in the community (McDonald et al 2007). Transmission of C. difficile spores is usually from 
faeces of infected patients to the uninfected individuals via ingestion. The spores of C. difficile 
make it possible for CDI to be acquired even outside the hospital because it can survive on 
surfaces for an increased length of time, thus it can be picked by healthy individuals and 
ingested in the absence of proper hygiene (Lee and Cohen, 2013).  Though the advancement 
from colonisation with C. difficile to the infection is determined by the disruption of normal 
intestinal microflora by antibiotics and immune compromised cases, so the bacteria will grow 
and produce toxins which will negatively affect individuals in the absence of antibodies against 
the toxins of C. difficile (Lee and Cohen, 2013). Since antibiotics are used also outside 
hospitals, community acquired CDI (CA-CDI) is also on the increase (Lee and Cohen, 2013), 
a 2017 US report has highlighted that though the community was earlier observed as being at 
a reduced risk of having CDI, CA-CDI acquisition were being noted (Kim and Zhu, 2017). 
This report has identified a case of a 45 year old woman without prior antimicrobial exposure, 
having diarrhoea, who was laboratory diagnosed of CDI (Kim and Zhu, 2017). Also, those with 
CA-CDI have been observed to have milder symptoms in comparison with those with HA-CDI 
(Lee and Cohen, 2013). Some CA-CDI do sometimes become severe and it has been reported 
that reoccurrence rate of this infection is similar to that of HA-CDI. However due to differences 
in research reports this has not been resolved. C. difficile has been isolated from a wide range 
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of animals including pets such as dogs, though zoonotic cause of CDI in humans is yet to be 
established (Lee and Cohen, 2013). Food sources of CDI is also been observed and there has 
been cases of C. difficile in retail beef which could be as a result of the resistance of spores to 
heat. Other than meat, C. difficile has been isolated in some vegetables, diary and fish produce. 
Though C. difficile transmission via contaminated food is a potential source of acquisition of 
the organism, it is still yet to be established definitively as a route of transmission (Lee and 
Cohen, 2013). CA-CDI clinical manifestations is similar to HA-CDI though as earlier 
mentioned, rates of severe symptoms in CA-CDI are lower than HA-CDI, for instance 
fulminant colitis is rare in CA-CDI. To prevent CA-CDI, antibiotics should only be used as 
prescribed or when required (Lee and Cohen, 2013).  
A model was made in the United States (US) to examine transmission routes from different 
CDI sources: community, hospital with and without symptoms, as well as from long term care 
facilities (LTCF) (Durham et al., 2016).  It was observed that compared to hospitalised patients 
with CDI similar cases in wards with LTCF had a 27% transmission rate, while similar cases 
in community had <0.1% (Durham et al., 2016). This report also recorded that under isolation 
and with effecting control measures against infection, individuals without symptoms transfer 
at a lower rate (15 times) than those with symptoms (Durham et al., 2016).   
1.3 C. difficile Life cycle   
C. difficile is a spore producing microbe, so though the vegetative cells cannot withstand the 
aerobic environment outside the host and acidity of the stomach, the spores can withstand both 
conditions. Thus, in the case of an infection via a faecal oral route, C. difficile spores may be 
acquired from animal, human or environmental sources as illustrated in Figure 1.1 (Deakin et 
al, 2012). The spores are easily transported through the stomach environment into the 
duodenum where they may become metabolically active depending on the nutrients in the 
environment such as taurocholate and glycine (Sorg and Sonenshein, 2008). Additionally, the 
spores can attach itself to inert surfaces and also the intestinal wall via an exosporial membrane 
(Paredes-Sabja and Sarker, 2012). Though the functional role of the exosporium is not well 
understood, but experiments by Panessa-Warren and colleagues have indicated that the 
exosporial membranes of both C. difficile and C. sporogenes have projections facilitating their 
adhesion to agar surfaces and also to colonic epithelial cells (Panessa-Warren et al., 1997; 
Panessa-Warren et al., 1999).    
The clearing of the intestinal microbiota mostly due to antibiotic therapy is a factor that aids 
the colonisation by C. difficile (Buffie et al., 2015). The attachment of C. difficile to colon walls 
is aided by surface layer proteins and mucolytic enzymes that degrade mucosa of the colon for 
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example cell surface proteins/cell wall proteins (Cwp84). These two factors are induced by 
subinhibitory concentrations of ampicillin and penicillin in the environment (Deneve et al., 
2008). It was reported that ampicillin and clindamycin influenced the elevation of the 
expression of Cwp84 from 2-27 folds and 2-41 fold respectively (Deneve et al., 2008). A 2-10 
fold elevation of expression of SlpA and other colonisation factors Cwp66, Fbp68, was 
observed to ampicillin. To clindamycin, Cwp66 and SlpA elevation was less than 7 fold and 
Fbp68 was 1-11 (Deneve et al., 2008).  
  
Then the host immune response is activated differentially based on the virulence factors 
produced by C. difficile for example surface layer proteins (SLP) activate the immune response 
via toll like receptor 4(TLR4) (Ryan et al, 2011). Lysozyme and cationic antimicrobial peptides 
(Ho et al., 2014) are usually the first means of defence to be produced against C. difficile (Smit 
et al., 2016). These defence mechanisms are resisted by C. difficile via different mechanisms 
such as the modulation of cell charge, thus giving C. difficile  a charge that is net positive which 
lowers the effect of antibiotics  (Mc Bride & Sonenshein., 2011) and the extracytoplasmic 
function sigma factor Csfv which aids lysozyme resistance in C. difficile  (Ho et al., 2014). 
With increase in C. difficile cells, each cell produces a signal until it gets to a threshold which 
stimulates toxin production that causes CDI. This is also the stationary phase where sporulation 
occurs as a result of the SpoA gene, which has also been linked as a negative regulator to toxin 





Figure 1. 1 C. difficile life cycle in the gut from faecal oral transmission to CDI onset and sporulation in 













 1.4 Clinical manifestations of CDI  
  
Asymptomatic carriers are individuals that are infected with C. difficile but do not have 
diarrhoea. Carriers can be healthy or hospitalised patients however it has been reported that the 
potential to be a carrier increases with more hospital exposure (Goudarzi et al, 2014).  
Symptomatic carriers have varying levels of complication from mild diarrhoea, paralytic ileus, 
pseudomembranous colitis and fulminant colitis.  
Antibiotic associated diarrhoea (AAD) can be caused by a number of pathogens such as 
Staphylococcus aureus (Gravet et al, 1999), and Clostridium prefringens (Modi and Wilcox, 
2001) but most AAD with colitis as a feature, is caused by C. difficile. In CDI, the diarrhoea 
commences during antibiotic therapy or up until 8 weeks after the end of antibiotic therapy. 
Most patients with mild to moderate CDI only have slight cramps in abdominal region along 
with diarrhoea as a symptom with about 10 bowel movements daily. The stool would have 
specific bad odour and could be watery, soft or mucoid. Low levels of serum albumin caused 
by albumin leakage, leucocytosis, cramps and fever are also observed in CDI of moderate 
severity. Fever, cramps, detection of leucocytosis in faeces, as well as, occult blood 
(Sunenshine, 2006) and an enlarged colon indicate the presence of colitis (Bartlett and Gerding, 
2008) in severe CDI.  
The pathophysiology of diarrhoea involves the bowel undertaking a balanced absorptive and 
secretory processes that on interruption leads to diarrhoea (Whyte & Jenkins; 2012). There are 
osmotic and secretory diarrhoea. Osmotic diarrhoea occurs when there is a high level of 
osmotically active particles in the lumen thus increasing the fluid moving into bowel lumen 
beyond the ability of the gut to absorb the fluid (Whyte & Jenkins; 2012).  Secretory diarrhoea 
is when there is an initiation of excessive secretion of fluid from the bowel mucosa by the 
presence of an abnormality or a toxin (Whyte & Jenkins; 2012). The fluid production is beyond 
the capacity of the bowel to absorb, resulting to diarrhoea. Thus the damage of the intestinal 
mucosa that occurs during colonisation of C. difficile or by the C. difficile toxins affect the gut 
ability to absorb fluid which causes diarrhoea. Diarrhoea lasting for over 4 days has been 
observed to mostly be caused by C. difficile (Gerding & Bartlett, 2008)  
Paralytic ileus which may progress to toxic megacolon is another feature of severe CDI along 
with vomiting, lethargy, shock, renal failure and abdominal pains. Paralytic ileus may prevent 
the passage of stools and so induce constipation. (Gerding & Bartlett, 2008).  
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Also a complication of CDI is pseudomembranous colitis, a disease of the intestinal mucosal 
characterised by individual obvious multiple yellow plaques containing a pseudo membrane of 
mucus debris and swollen cells. It seeps out overlying groups of partially damaged glands and 
each plaque is obviously discrete using an adjacent plaque mucosa. Cell death may eventually 
take place causing the plaques to amass (Price & Davies, 1977). This is caused by toxin A and  
B produced by C. difficile that activate the immune system’s signal transduction pathways and 
damage cell cytoskeleton (Surawicz & McFarland et al., 1999).  
More still is fulminant colitis, this type of colitis has a very low prevalence as it is observed in 
just 3% of CDI patients. It involves most of the seriously adverse clinical conditions such as 
megacolon, long term ileus, perforation and mortality (Goudarzi et al, 2014).  
 
 Figure 1.2 Colon lining in a healthy and C. difficile infected condition (Fusco; nd, Carrion et 
al; 2010) 
1.5 Diagnosis of CDI  
There are a number of ways to diagnose CDI such as stool culture, enzyme immunoassay (EIA), 
cell cytotoxicity assays, endoscopy and computerised tomography scanning. Laboratory 
diagnosis is chosen rather than CT, radiography, due to their lack of specificity and sensitivity 
and cost.   
Cell toxicity is usually the preferred assay due to its high sensitivity but it is technically 
demanding and takes more than 24hrs to get a positive result (Gerding and Bartlett 2008). Cell 
culture neutralization assay is noted to be the standard for toxigenic C. difficile identification 
though it takes a long time of about 1-3 days and its labour intensive (Carroll, 2011, Stamper 
et al, 2009). False positives has been observed and its sensitivity is less than 90% (Carroll, 
2011).  
Stool culture is next in sensitivity but it also takes above 24hrs and has a low toxin specificity 
which is required to detect asymptomatic CDI. This method thus requires the use of the culture 
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broth for further test using cytotoxicity testing or EIA to detect toxin. This method is however 
useful for typing of organisms molecularly, antibiotic susceptibility testing and studying 
molecular epidemiology of C. difficile (Gerding and Bartlett 2008). The preferred media for 
selection of C. difficile from stool samples is cycloserine – cefoxitin – fructose agar (CCFA).  
Enzyme immunoassays (EIA) are less sensitive than the above mentioned methods but they are 
faster and less costly and produce results within hours. This is a test for glutamate 
dehydrogenase(GDH) enzyme produced by C. difficile. Thus indicating the presence of C. 
difficile not necessarily CDI. This method is used to screen stools that will then be tested using 
EIA for toxin or cytotoxicity (Lyerly et al, 1991, Gerding and Bartlett 2008).  
Two immunoassays were involved in a 2015 research on the capacity to identify C. difficile in 
stools (Davies et al, 2015). Enzyme immunoassay (EIA) commercially available also referred 
to as Quik Chek-60 and Vidas C. difficile GDH automated Enzyme –Linked fluorescence 
immunoassay (ELFA) were evaluated in this study (Davies et al, 2015). Similarity in 
performance (95%) was observed in the Quik Chek-60 and Vidas C. difficile GDH assay. 
Though the Quik Chek-60 was observed to require lower quantity of sample and was faster, 
the Vidas C. difficile GDH assay had good traceability, was automated and had a greater than 
93% sensitivity as a result was reported to be appropriate as an initial test for CDI diagnosis in 
a 2 stage algorithm (Davies et al, 2015).  
CDI can also be diagnosed using Nucleic acid amplification diagnostic methods. This type of 
diagnostic method is also referred to as real time PCR and known to target C. difficile toxin B. 
In 2011 four types were reported to be in use in the US amongst which the first to be FDA 
approved was the BD –GeneOhmTM Cdiff assay. It had a quick turnaround time of 2hours and 
requires manual extraction. It has a specificity and sensitivity of over 94% and 84% 
respectively (Carroll, 2011).  
Furthermore Endoscopic diagnosis can be employed for diagnosing CDI but it is only used in 
an emergency when no stool sample is available and there is an ileus or negative results were 
obtained for other test and C. difficile is highly suspected (Avila et al., 2016)  
1.6 CDI Recurrence   
Recurrence of CDI is a subsequent incidence of the disease after the initial episode in the same 
patient has been successfully treated. Recurrent CDI can be as a result of reinfection with a 
genotypically distinct C. difficile strain, or relapse of infection due to the same PCR ribotype 
that caused the initial episode. Recurrent CDI is a challenging problem in hospitals which could 
be as a result of prolonged use of antibiotics (Choi et al., 2011) and CDI recurrence rates have 
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been observed to range from 5% to 20% (Hedge et al., 2008). Amongst 14,472 CDI Medicare 
patients that survived therapy, recurrence was observed in 4775 patients (Zilberberg, et al, 
2017). A report analysed the recurrence prevention capacity in metronidazole and vancomycin. 
No difference between antibiotics in recurrence rates but significant reduction in the mortality 
risk of 30 days, was observed with vancomycin than metronidazole (Stevens et al, 2017).  
The risk factors for CDI such as age and antibiotic exposure are same for its recurrence 
(Shanon-lowe et al 2010).The growth of the microbial flora in the colon could be affected by 
the antibiotic used to treat the initial C. difficile case thus resulting to a second C. difficile case 
(Shanon-lowe et al 2010).  
1.7 Virulence Factors  
1.71 Toxin A and Toxin B (TcdA and TcdB)  
Toxigenic C. difficile may produce two major toxins which act as glycosyltransferases, toxin 
A (308 kDa) and toxin B (270 kDa). TcdA and TcdB are part of the Clostridial glucosylating 
toxin family and inhibit the action of Rho, Rac and Cdc42 which are of the GTPases family 
within colonic epithelial cells (Voth and Ballard, 2005). Cellular activities such as actin 
cytoskeleton organisation are controlled by the Rho GTPase family.   
C. difficile possess a pathogenicity locus on its chromosome on which both toxin genes are 
encoded. The toxin are approximately 66% similar and the genes have a low G+C content 
compared to the rest of the C. difficile genome. The similarity between toxins can be seen in N 
and C terminals (Voth and Ballard, 2005).    
 







Figure 1.4a Structure of C. difficile toxin A (Chumbler et al, 2016) with the red portion as 
glucosyltransferase domain (GTD), the white coded the CROPS domain, the autoprotease 
domain (APD) coded as purple, yellow coded the delivery domain. Same structure in C is 
rotated 90 degrees (Chumbler et al, 2016) 
 
 
Figure 1.5 Structure of C. difficile toxin B (Reinert et al, 2005) magneta colour code is the 
active center, blue is the glycosyl typA while the toxinB additions are green 
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On the pathogenicity locus both toxin genes are separated by a 1350 nucleotide sequence and 
on the same locus there are 3 other open reading frames that might aid the regulation of toxin 
removal from the cell or toxin synthesis. Both genes of the toxins are transcribed in the same 
direction. The tcdC gene is also present in the pathogenic locus and is expressed in the early 
exponential phase, its gene transcription is in the opposite direction to tcdA and tcdB and is 
situated downstream of tcdA (Voth and Ballard, 2005).  TcdC has been suggested to be a 
negative regulator to the production of these two toxins because the onset of stationary phase 
leads to a decrease in the production of TcdC and increase in production of the two toxins. 
However there has been some dispute on the role of TcdC, it was reported that TcdC in C.  
difficile 630∆erm did not significantly regulate toxin expression (Bakker et al, 2012). One 
major positive regulator of both toxins is TcdD whose gene is found upstream of tcdB. TcdD 
is a sigma factor whose response is dependent on environmental factors (Hundsberger et al., 
1997, Voth and Ballard, 2005). TcdE has been reported to possibly promote toxin release 
through C. difficile cell wall and it is structurally similar to a bacteriophage holin protein. The 
tcdE gene is located between tcdA and tcdB. Environmental factors also contribute to the toxin 
production which could be classified under catabolite repression and stress. Subinhibitory 
levels of some antibiotics such as vancomycin could lead to toxin production, in limiting levels, 
biotin has also been observed to induce toxin production (Yamakawa et al, 1996, Voth and 
Ballard 2005)  
These toxins on release from the cell, modify through glycosylation of the Ras superfamily of 
small GTPases enterocyte, thus inactivating these proteins, thus hindering important cell 
signalling pathways. The toxins need an acidified endosome for translocation and access the 
interior of the cell by receptor mediated endocytosis. On gaining entrance into the cell the 
inactivation of GTPases involves the monoglucosylation of an active threonine responsible for 
the binding to GTP thereby causing actin condensation, cell rounding and death (Voth and 
Ballard, 2005). Recent studies have succeeded in generating mutants for both toxins virulence 
in single toxin knockouts, meaning both toxins can act independently to cause disease, as 
demonstrated by Toxin A-B+ strains in vivo (e.g. ribotypes 078). Kuehne et al., (2010) 
generated a strain lacking both toxins and the double knockout was avirulent (Kuehne et al., 
2010).  
1.72 CDT toxin  
Perelle et al (1997), reported in C. difficile CD196 the presence of protein encoded by a binary 
toxin gene cdtA and cdtB. This protein was an ADP–ribosyltransferase, was observed to 
function in initiating actin alterations. Both genes encode for different function in the protein, 
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cdtA encodes for CDTa which functions as the ADP-ribosyltransferase enzyme, whereas the 
binding component is carried out by CDTb (encoded by cdtB). These genes are similarly 
transcribed and spaced as a result of the presence of 52 non-coding nucleotides between them 
in C. difficile (Perelle et al., 1997).   
CDT was observed to cause depolymerisation of microfilament. It induces through cellular 
protrusions in epithelial cells. Which lengthens between 5- less than 150µm. These actions 
occur at the same time with adp ribosylation of actin (Gerding et al., 2014). CDT binary toxin 
gene was identified in human C. difficile isolates in Brazil for the first time in a 2015 report 
(Silva et al., 2015)  
Goncalves et al., 2004, observed CDT in 6% of 369 strains analysed. These strains were 
isolated in Paris from AAD patients in healthcare facilities (Goncalves et al., 2004). Further 
research carried out by Stubbs et al., (2001) in the UK observed 59 strains out of 170 strains 
analysed which were positive for CDT. CdtR is a lytTR family response regulator, and was 
observed to be responsible for maximal production of CDT. The cdtR, cdtB & cdtA gene locus 
is referred to as Cdt loc (Carter et al., 2007). The role of CdtR, was questioned in another 
research on 078 ribotype, a mutation was observed in cdTR gene which should have prevented 
the secretion of the binary toxin but this was not the case (Metcalf & Wease, 2010).  
The role of CDT in causing disease has been suggested in some research. A report in Australia 
of a 15 year old hospitalised boy with diarrhoea and other health complications, showed a 
negative stool test for toxin A and toxin B using the Chek complete rapid membrane enzyme 
immunoassay kit (Androga et al., 2015). However, a second analysis was performed and C. 
difficile was isolated anaerobically and typed using PCR ribotyping. The strain of C. difficile 
was of ribotypes 033 and was confirmed to be toxin A- and toxin B- but was positive for the 
binary toxin. The presence of RT014/020 known to lack CDT but produce toxins A and B was 
later also detected using a different test. This findings insinuate that CDT in absence of toxin 
A&B might be able to cause CDI however this is yet to be confirmed (Androga et al., 2015).  
Also, in France toxinotype XI of zoonotic origin only possessing binary toxin genes has been 
observed in patients with apparent CDI. The presence of toxinotype XI is rare in humans but 
this could largely be due to it not being noticed since the routine test for C. difficile test is a test 
for toxin A and B. So Cdt+ only strains could have been classified as not toxigenic (Eckert et 
al., 2015). This study showed that infection of C. difficile strain, positive only to the binary 
toxin was pathogenic giving an inclination to the severity of the disease elicited by this toxin 
(Eckert et al., 2015)  
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Other factors contributing to the virulence of C. difficile   
1.73 Quorum sensing  
The production of toxin in C. difficile has also been observed to be facilitated and regulated by 
quorum sensing. The presence of antimicrobial therapy increases the presence of resistant C. 
difficile due to death of the intestinal microbial flora (Darkoh et al, 2015). Thus a thiolactone 
signal is synthesized by these C. difficile as the population increases, the thiolactone signal is 
a form of quorum sensing done by C. difficile to quantify its population in an environment 
before toxin production. Due to continuous cell increase the thiolactone signal reaches a break 
point which leads to the transcriptional activation of toxin gene as a result of the activation of 
a 2 component system Agr C2A2 (Darkoh et al, 2015).   
1.74 Colonisation Factors  
Surface layer proteins (SlpA) has been observed to be a major adherence factor in C. difficile 
to epithelial cells (Merrigan et al, 2013). An anaerobic quantitative assay was used to detect 
the level of attachment to host epithelial cells by vegetative cells of C. difficile strains. It was 
observed that the C. difficile isolates analysed which included isolates obtained during CDI 
outbreaks, have high adherence capability, partially as a result of the presence of SlpA 
(Merrigan et al., 2013). C. difficile surface associated protein Cwp84 protease, observed to be 
associated to S – layer proteins, was characterised and reported to be an inactive proprotein 
which can be expressed as an active form after a process of maturation as a result of trypsin 
action or the reducing environment within the colon (Janoir et al, 2007). Cwp84 was reported 
to be responsible for the degradation of vitronectin and laminin as well as the cleaving of 
fibronectin, thus aiding toxin diffusion (Janoir et al, 2007).  
1.75 Biofilm:   
Biofilms have been earlier reported to protect bacteria from adverse environments such as 
antibiotic environments due to therapy. Not much information is known with respect to 
biofilms produced by anaerobic bacteria, this could be as a result of challenges encountered in 
creating the required environment for in vitro formation of biofilms. C .difficile biofilms have 
also been proposed to have the potential to prevent the effect of cellular immune response 
during CDI thus contributing to pathogenesis and C. difficile recurrence (Dapa & Unnikrsihan 
2013). Additionally, biofilms may protect C. difficile vegetative cells and spores from 




Certain features have been observed to influence C. difficile biofilm formation, e.g. glucose 
was observed to increase biofilm formation in C. difficile 630 but not in R20291 (ribotype 027), 
thus the gut nutritional environment can impact on C. difficile biofilm formation. A well-
developed S layer was observed to be required for biofilm formation probably due to its role in 
early stage biofilm formation in holding proteins that aid surface binding. C. difficile motility 
was also observed to be an important factor in biofilm formation, since a flagellin knockout 
mutant, which is a major protein component of flagella, was observed to be defective in 
formation of biofilm in vitro (Dapa et al., 2013). The data obtained in the research also 
indicated the involvement of quorum sensing mediated by lux S in vitro. Dapa et al., 2013 also 
speculated that initiation of biofilm formation, sporulation and toxin production could be a role 
done by spoOA. 
Biofilms have been demonstrated to possess a gradient of nutrient availability and are often 
nutrient limited within microcolonies. Therefore, sporulation in C. difficile may be initiated 
within biofilms and several studies have demonstrated the presence of C. difficile spores in 
microtitre plate biofilms and in more complex fermentation vessel models (Dapa et al., 2013, 
Crowther et al., 2014). Sporulation in C. difficile is controlled by the master regulator of 
sporulation, SpoA, and this regulatory protein has been observed to be involved in biofilm 
formation. As Biofilm regions can be characterised by depletion in nutrients. SpoA has been 
observed in B. subtilis to influence biofilm matrix formation. Phosphorylated SpoA has been 
observed to activate biofilm matrix formation as well as sporulation dependent on the SpoA. 
Biofilm matrix is activated by SpoA-P action on SinI a depressor of matrix formation. This is 
done by sinI binding to sin R a repressor of matrix formation (Chai et al., 2011, Viamakis et 
al., 2013). Thus the switch from matrix formation to sporulation is dependent on SpoA-P levels 
which if high, turns off matrix and switches on sporulation. Thus this switch is also affected by 
the number of copies of Sin I – SinR complex in a cell (Viamakis et al, 2013).                                                                                 
1.76 Sporulation  
Stress conditions such as depletion of nutrients enhance the formation of the dormant form of 
C. difficile commonly referred to as spores (Awad et al., 2014). C. difficile sporulation ability 
enables this pathogen to withstand the stomach acidity and aerobic environment when not 
inside a host (Smith et al., 2016). Awad et al., 2014 also referred to it as an infectious particle 
necessary for transmission of the infection. The spore consist of inner and outer coat, with the 
outer coat made up of four layers approximately 75nm in width, surrounding the inner coat 
(Driks, 1999).  These coats enclose a core that contains the organisms entire genome copy 
(Awad et al., 2014). Clostridium difficile strains of hypervirulent ribotype 027 was observed to 
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have diverse sporulation features and also have similar sporulation rates to other ribotypes 
analysed (Burns et al., 2011).    
1.77 Membrane vesicles  
C. difficile was observed to secrete membrane vesicles (MVs) consisting of 262 proteins. In 
Caco-2- cells, these MVs stimulated the expression of proinflammatory cytokine genes, also 
surface associated proteins, flagellin and GroEL proteins were also observed using proteomic 
analysis. Cytotoxicity in cells of colonic epithelium were observed to be induced by C. difficile  
MVs. However the role of MVs in CDI is yet to be elucidated. (Nicholas et al., 2017)   
1.8 Epidemiology in C. difficile  
The epidemiology of C. difficile in Canada was carried out in 1997 and another in 2009. It 
detected the hospital acquired -CDI (HA-CDI) rates in Canada, these ranged from 20-167 cases 
/100,000 patient days. The rates were different in different Canadian regions and provinces 
(Gravel et al., 2009). The other provinces were more than 100% lower, in rate of HA-CDI 
occurrence compared to central Canada 2.8vs7.0 cases for every 1000 admissions in hospitals 
(Gravel et al., 2009). However there was not much increase in HA_CDI in this 2009 
surveillance compared to that in 1997 but increase in death rates were observed to be linked to 
HA-CDI four fold higher, than in 1997. These patients were above 60years of age. The 
limitation of this research though was highlighted to be unmonitored data allocation and specify 
research to teaching hospitals so not totally representing adult patients in all Canada hospitals 
(Gravel et al., 2009). Another research has quantified the CDI infections in Canada and cost, 
which totaled to 37900 CDI cases and cost CAD $281 million. More than 90% was due to 
rehospitalisation and increased stay in hospitals (Levy et al., 2015).   
CDI in US, was observed to increase from an approximate 30-40 cases for a population 100,000 
in the 1990’s to 61cases in 2003 (McDonald et al., 2006). However lower income areas had a 
decreased CDI rate in the US (Lucado et al., 2012).   
CDI in England was reported to have had an increase from 1990 up until 2007 which was the 
highest report and a decline was observed in 2008 almost a difference of 20,000 reports decline, 
which decreased steadily, approximately 10,000 reports were received in 2013 and 2014 
(public health England surveillance of C. difficile, 2014).  Hypervirulent ribotype 027 was 
observed to decline from April 2007 with over 60% incidence down to less than 10% in March 
2013. Emergence of 078, 002, 015, 014/020 and 005 were also observed during this period. 
Rate of C. difficile infection at 2014 was very similar in Male and Female but more prevalent 
in ages 65yrs and above having 50per 100,000 population with higher incidence observed in 
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85+ ages (>250 per 100,000 population (public health England surveillance of C. difficile, 
2014).  
  
1.9 Molecular Epidemiology of CDI  
Ribotyping is a taxonomic methodology that involves the use of rDNA restriction fragment 
sizes to differentiate bacterial species. Ribotyping specifically involves PCR amplification of 
16S-23S rDNA spacer regions which was observed to be of variable length which enabled 
differentiation between strains (Gurtler, 1993). Polymerase Chain Reaction (PCR) ribotyping 
is used for characterising C. difficile isolates (Huang, 2009).  
Ribotypes 027, 106 and 001 were reported to be the most prevalent in England in 2008, with 
prevalence rate 36%, 13% and 7% respectively however a 19% reduction was observed in 027 
prevalence between 2007 and 2008 (Freeman et al., 2010). As was reported earlier other 

















Table 1.1 Molecular epidemiology showing the distribution of C. difficile ribotypes in different 
countries 
Ribotype  Characteristics and Country of prevalence 
027  Hypervirulent, also known as North American pulsed field gel 
electrophoresis type1 (NAP1), and detected to be of a toxinotype III. 
 Most common PCR ribotype in the Unites States (Janezic et al., 2012) 
 027 was reported to be 75.2% of the isolates analysed from Montreal area 
Hospital (MacCannell et al., 2006) 
 A decline in 027 has been observed in the UK (Wilcox et al., 2012). 
 027 caused outbreak in Portugal (Oleastro et al., 2014) 
 027 was reported in 2 outbreaks in West and East Scotland (Kuijper et al 
2008) 
 72 Severe CDI cases in Hesse state in Germany reported 027 as the most 
prevalent ribotype  (Arvand et al., 2009) 
106   Ribotype 106 was identified in humans and dogs in Brazil (Silva et 
al; 2015).  
 Britain C. difficile surveillance program in 2007 identified ribotype 106 
as one of three major ribotypes to be responsible for 3/4 of the CD1 
(Brazier et al, 2007) 
 Ribotypes 106 was the third most prevalent ribotype with a prevalence of 
12.8% of the Irish clinical C. difficile isolates in 2011 (Solomon et al; 
2011). 
 In a Brazillian study, ribotype 106 was the second highest prevalent 
toxigenic C. difficile (Silva et al; 2015). 
010  Not toxigenic, that is it lacks the pathogenicity locus on which the genes 
responsible for toxin production are situated (Lee and Cohen 2013). 
 It has been identified in humans and the environment (Janezic et al., 2012) 
 010 was the first C. difficile ribotype to be isolated with reduced 
susceptibility to metronidazole in UK 
 An Italian study reported the predominant ribotype in dogs to be ribotype 








Ribotype  Characteristics and Country of prevalence 
017   Has also been observed in animals (Janezic et al., 2012). 
 Ribotype 017 was a dominant strain in Poland (Huang, 2009)  
 Most isolated in Asia (Collins et al., 2013) 
 Ribotype 017 in a Korean study was the second most predominant 
ribotype (Lee et al., 2014). 
001  In 2011, ribotype 001 was the third most prevalent ribotype in England 
and Northern Ireland. 
 In Korea C. difficile ribotyped 001 had the highest prevalence of 26.1% 
but a decline was observed from year 2000 (Lee et al., 2014) 
 Ribotype 001 (11%) was observed to be the second most predominant 
ribotype in Europe (study involved 19 countries) (Davies et al., 2016) 
014/020  One of the common ribotypes in a Korean study (Lee et al, 2014). 
 The most predominant toxigenic ribotype in a Brazilian study (Silva et al; 
2015) 
078  Cuts across species affecting both animals and humans (Debast, 2013) 
 The third highest prevalent ribotype in the North East Ireland in 2009 
(Brabazon et al; 2014) 
 A Brazilian report observed 078 only in foals (Silva et al; 2015). 
002  Current most prevalent ribotype in the UK and one of the 5 most prevalent 
ribotypes in Belgium (Dauby et al., 2017). 
 Though common in Europe ribotype 002 was not found to have a high 











1.91 C. difficile infection decline in UK  
C. difficile infection was observed from 2006 to have declined drastically (80%). Research was 
performed to identify the specific control measure that resulted in the decline (Dingle et al., 
2017). Two factors considered were limitations on the use of certain antibiotics and increase in 
infection control interventions performed in hospitals (Dingle et al., 2017). Data from 1998- 
2014 on antimicrobial prescription, CDI onsets, and 4045 whole genome sequences of C. 
difficile isolates were obtained (Dingle et al, 2017). It was detected that transmission factors 
were not affected but isolates resistant to fluoroquinolone was decreased thus antimicrobial 
stewardship had a high contributing impact to decline in C. difficile infection (Dingle et al., 
2017). Fluoroquinolone-resistant isolates were observed to no longer be present in Oxfordshire 
C. difficile population, thus eliminating the use of antibiotics might cause the resistant C. 
difficile to lose its prevalence (Dingle et al, 2017).   
 
 
1.92 C. difficile in Africa   
There is very little information available on the prevalence of C. difficile in sub–Saharan  
Africa. A recent study researched the prevalence of C. difficile in rural Ghana (Janssen et al;  
2016). This study was in a combination of symptomatic and non-symptomatic individuals 
(Janssen et al; 2016). The C. difficile prevalence was determined to be 5%, and mostly 
nontoxigenic strains were observed in C. difficile–positive diarrhoea patients, however, other 
pathogens causing diarrhoea were not investigated. Despite some patients being prescribed 
metronidazole 2 weeks prior to the study, susceptibility to metronidazole and vancomycin was 
observed (Janssen et al., 2016). Resistance was observed mainly to ciprofloxacin and 
erythromycin (Janssen et al., 2016). A significant correlation of p=0.042 between the 
occurrence of malaria and C. difficile was observed (Janssen et al., 2016). The most common 
ribotype isolated was ribotype 084 (Janssen et al., 2016), a ribotype previously observed in a 
pan-European survey under a clade that was majorly susceptible to metronidazole, 
vancomycin, and fidaxomicin (Debast et al., 2013). This was the first research to report the 
presence of C. difficile in symptomatic and asymptomatic individuals in Ghana (Janssen et al., 
2016).  
This study concluded that C. difficile was not a major cause of diarrhoea in the setting 
investigated but indicated the need for further research on the increased prevalence of 
nontoxigenic strains (Janssen et al., 2016). The low prevalence though was associated to the 
intake of antibiotics by some participants (Janssen et al., 2016). This could also be linked to 
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the fact that the prevalent ribotype was non-toxigenic as the use of non-toxigenic C. difficile 
strain, M3 (NTCD-M3) spores as a probiotic therapy has been earlier reported to limit the 
colonisation of toxigenic C. difficile reducing recurrence rates (Gerding et al., 2015).  
C. difficile has also been identified and reported for the first time in Tanzania. Of 141 diarrhoea 
patients C. difficile was detected in 6.4% which were mostly children. Participants without 
diarrhoea had no observed C. difficile (Seugendo et al., 2015). The occurrence of C. difficile 
was linked to HIV infection as well as exposure to antibiotic and long hospital stay. Ribotyping 
and susceptibility testing was performed for seven isolates, 3 of which were non toxigenic and 
2 toxigenic strains had unknown ribotype. The last 2 isolates were toxigenic of ribotype 045 
(Seugendo et al., 2015). Susceptibility to frontline antibiotics, metronidazole and vancomycin 
was observed in the 7 isolates (Seugendo et al., 2015).  
In Nigeria C. difficile was detected and screened in faecal sample of children as well as neonates 
(Emeruwa & Oguike, 1990). Cytotoxin production was also detected in 14.8% of isolates 
analysed (Emeruwa & Oguike, 1990). Children that were 12months and less were observed to 
have the highest cytotoxin titres of 16.7% (Emeruwa & Oguike, 1990).   There was a gradual 
reduction in percentage cytotoxin titres with increasing age, chidren from age 3-5 had no toxin 
titre detected (Emeruwa & Oguike, 1990). The quality of nutrient consumption was also 
assayed and it was detected that the lowest level of occurrence cytotoxin positive C. difficile 
isolates were with children given only breast milk (17.5%) (Emeruwa & Oguike, 1990). 
Nineteen percent of children fed with a mix of formula foods and breast milk were positive for 
C. difficile, while the highest occurrence (50%) was with children given only formula foods 
(Emeruwa & Oguike, 1990). Further studies have been performed in two hospitals in Nigeria. 
Adult HIV patients staying in the hospitals, had a CDI prevalence of 43%, while the prevalence 
among outpatients was 14%. No inclination of the prevalent ribotypes in this region of sub-
Saharan Africa was determined (Onwueme et al., 2011).  
A South African study characterised C. difficile in school children and hospital out patients 
detecting toxigenic profiles and correlation between various pathologic features. Prevalence 
was observed in out patients more than school children. Toxin negativity was also a 
characteristic feature in C. difficile isolates from school children while toxin positivity was 
detected for out-patients hospital isolates. Of the sample analysed 14% C. difficile prevalence 
was observed (Sammie et al, 2008). C. difficile prevalence were also observed in Zimbabwe 





1.10 Therapy   
1.10.1 Antimicrobial resistance in C. difficile   
  
C. difficile has been reported to possess resistance to a number of drugs. These resistant 
phenotypes could result from mutations on target sites, single nucleotide polymorphisms or 
transposons like TN5397 (Spigaglia, 2011). To chloramphenicol, C. difficile confers resistance 
using a catD gene carried by transposon TN4451/ Tn4453 group. This gene is responsible for 
inactivating the chloramphenicol. Also, Spigaglia et al., 2011, reported 51 of 82 multiresistant 
strains which showed resistance to rifampicin and moxifloxacin. This moxifloxacin resistance 
was observed to be mediated by a change in the amino acid of position 82 from threonine to 
ileucin in gyrA. Again, C. difficile may possess resistance to rifampicin with a genomic 
mutation occurring in the β-subunit of RNA polymerase (RpoB) at positions 488 and 548 
(Spigaglia, 2011). Resistance to clindamycin in C. difficile isolates has been observed (Feldman 
et al, 2005) and resistance to erythromycin has been seen in many C. difficile ribotypes 
including 001, 027, 017 and 078 ribotypes (Reil et al., 2012). Three hundred and sixteen C. 
difficile strains were analysed in 2011, belonging to eleven ribotypes; 148 were observed to be 
resistant to a minimum of one of the eight antibiotics used in the study. More than half of the 
resistant strains showed multidrug resistance (Spigaglia et al., 2011).  
 Metronidazole and vancomycin are first line antibiotics for Clostridium difficile infection 
(CDI). However increases in MICs of metronidazole have been detected and full resistance in 
some strains has been reported to metronidazole. The mechanism of resistance is yet to be 
determined (Spigaglia et al., 2011).   
 1.10.2 Metronidazole  
Mechanism of action  
Metronidazole has been used as a drug against microbial infections for over 45 years and can 
be used against Gram positive and Gram negative bacteria. Metronidazole has been observed 
to depend on the microbial metabolic pathways (Edwards and Mathison, 1970) for its activation 
which aids its selective toxicity as metronidazole reduction happens mainly in anaerobic cells 
(Land and Johnson, 1999).  
Metronidazole enters bacterial cells through the process of passive diffusion into the cytoplasm 
where it is reduced. The reduction of metronidazole intracellularly is by scavenging electrons 
that should have been accepted by ferredoxin. This is possible because the redox potential of 
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metronidazole is -0.56V and that of ferredoxin is -0.46V. Thus metronidazole would accept 
more electrons than ferredoxin since its redox potential is more negative (Edwards and 
Mathison 1970). The intracellular reduction further aids the diffusion of metronidazole into the 
cell, within the cell an electron is transferred to the nitrogroup of metronidazole converting it 
into a nitrosofree radical that is unstable; thus activating the drug (Lofmark 2010). The 
activated drug is cytotoxic and results in DNA degradation (Lofmark 2010). DNA damage has 
been reported not to be as a result of binding of nitroimidazole to the DNA, but nitroimidazole 
causes the oxidation of DNA by scavenging electron from it which results in breakage of DNA 
strands (Edwards, 1993)  
  
Figure 1. 6 Mechanism of activation of metronidazole (Leiros et al., 2004)  
Susceptibility to Metronidazole  
Despite the high activity of metronidazole against C. difficile, strains of C. difficile have been 
observed to show reduced susceptibility to metronidazole (Baines et al., 2008, Brazier et al., 
2001). Reduced susceptibility to metronidazole in C. difficile was first identified in 2001 by 
Brazier et al, it was identified to be a nontoxigenic ribotype 010, and the MIC obtained by Etest 
was 16mg/L (Brazier et a.l, 2001). Reduced susceptibility (MIC>2mg/L) has also been 
identified in ribotype 001 for 24.4% of the isolates tested (Baines et al, 2008).  
Resistance of metronidazole in B. fragilis was seen to be as a result of nitroimidazole resistance 
genes commonly known as the nim genes which confer resistance against nitroimidazole 
antimicrobial agents by encoding nitroimidazole reductase. These nim genes have been seen to 
confer resistance to metronidazole in H. pylori, but none except nimB (Chong et al, 2014) has 
been identified in C. difficile. A study testing both C. difficile isolates with reduced 
susceptibility and non-reduced susceptibility reported absence of nim genes in both groups 
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(Pelaez et al., 2008). Though it was suggested that the reduced susceptibility could be as a 
result of reduced uptake of metronidazole by C. difficile and reduced nitroreductase activity 
(Lofmark, 2005).  
High level mobility in clinical settings can be as a result of anaerobes causing diseases for 
example Bacteroides fragilis is a disease causing pathogen in the intestines. It has been 
observed that it has laterally transferred, amongst anaerobic bacteria, genes that are responsible 
for resistance to antibiotics for example clindamycin and metronidazole. Metronidazole which 
was used to eradicate most antibiotic resistant Bacteroides has now been seen to decline slowly 
in efficacy as there is an emergence of resistant species (Lofmark, 2005).The therapeutic 
breakpoint of metronidazole is 32mg/L and anything below is referred to as been susceptible 
(EUCAST, 2017)   
1.10.3. Vancomycin  
Mechanism of action  
Peptidoglycan synthesis involves more than five steps, the formation of D-alanyl-D-alanine (D-
ala-D-ala) being the second step. Vancomycin prevents the formation of peptidoglycan for 
bacteria cell walls by binding to the C- terminus of D-ala-D-ala thereby hindering the joining 
of the other precursors. Vancomycin also reacts with target bacteria after the late precursors 
are translocated to the exterior membrane surface since it does not penetrate the cytoplasm 
(Courvalin, 2006).  
 Figure 1.7 Mechanism of action of vancomycin (adapted from Courvalin et al., 2006) and structure 
of vancomycin (adapted from Vila et al, 2007).                     
 




Susceptibility to Vancomycin  
Vancomycin also is a first line antimicrobial agent used to treat C. difficile. The use of 
vancomycin has been observed to be more effective for chronic CDI compared to 
metronidazole, both antimicrobials can be used for treatment of mild CDI (Zar et al, 2007). 
However to limit the incidence of vancomycin resistant enterococci (VRE) selection, the use 
of vancomycin is being reduced newer therapies (e.g. fidaxomicin) are being developed and 
implemented in the treatment of CDI (Hierholzer et al, 1995).  
There has been one case of resistance in Poland in 1991 but other cases of reduced susceptibility 
have been observed, 13 isolates in Spain had high MIC from 8-16mg/l (references Poland and 
Spain).  Mechanism(s) causing these reduced susceptibility were not determined, but in 
Enterococcus spp, vancomycin acquired resistance was seen to be as a result of production of 
peptidoglycan precursors, which had decreased affinity for glycopeptide antibiotics. This was 
as a result of the presence of van A, van B, van D, van E, and van G genes (Huang, 2009), so 
the precursors produced for peptidoglycan synthesis are less susceptible to the action of 
vancomycin (Courvalin, 2006).  
In general the antimicrobial resistance mechanisms such as mutation and acquisition of resistant 
genetic information in C. difficile have been seen to be same in other Gram positive bacteria. 
As a result this can be applied to ascertain for mechanisms in vancomycin and metronidazole 
reduced susceptibility that is yet to be determined. An example can be seen in some tetracycline 
resistance cases are caused by tetM gene related to Tn916 whose elements have been seen in 
some C. difficile isolates and which is predominating in other Gram positive bacteria (Huang, 
2009).   
1.10.4 Other therapeutic measures:  
1.10.4.1 Fidaxomicin  
  
Fidaxomicin was prepared for CDI treatment in US and Europe in 2011. This bactericidal 
antibiotic has been observed to be more active than metronidazole and vancomycin with low  
MIC’s (Mullan, 2014, Goldstein et al., 2011).  
Its mechanism of action involves inhibiting RNA polymerase thus inhibiting protein synthesis 
(Artsimovitch et al, 2012) due to decrease in RNA synthesis. Its spectra of activity is higher 
towards clostridial RNA, though it is also effective against enterococci and staphylococci 
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(Finegold et al, 2004). Yeast are completely resistant to fidaxomicin as well as Gram negative 
organisms (Beidenbach et al, 2010). Therefore the narrow spectrum of activity of fidaxomicin 
is one of its main advantages, given that it will disrupt less the gut microflora and potentially 
reduce recurrent infections with C. difficile.   
Its administration twice daily post antibiotic effect range between 9.5hours -12.5hours and like 
vancomycin its faecal concentrations is above MIC of C .difficile due to its inability to diffuse 
from the gastrointestinal tract (Babakhani et al, 2011)  
An elderly CDI patient was unresponsive to intravenous metronidazole and vancomycin 
administered through a nasogastric tube (Arends; et al, 2016). After 10 days, the therapy was 
stopped and crushed fidaxomicin was given using a nasogastric tube (Arends; et al, 2016). This 
led to a resolution of the disease in one day and a further negative C. difficile stool sample. 
Diarrhoea continued till the tenth day and no recurrence was observed within the in – 
hospitalstay (Arends et al, 2016). Due to the efficacy demonstrated in this case, the use of this 
form of therapy for chronic cases requires further study (Arends et al, 2016).  
Clinical studies have demonstrated similar curative rates of CDI using either fidaxomicin-or 
vancomycin-treated patients (Louie et al, 2011). Also comparing fidaxomicin and vancomycin, 
the clinical trial identified a higher recurrence rate of the non-north American pulsed field type1 
strains with vancomycin compared to fidaxomicin previously named OPT 80 (Louie et al, 
2011). Exposure of CD toxigenic strains (110) from United States was made to 15 
antimicrobials these strains included 027 ribotype (n=6) also from Europe and Canada. Five 
antibiotics were observed to be most active, these were fidaxomicin, rifaximin nitazoxanide, 
tizoxanide and rifalazil, with MIC 90 ≤ 0.125 mg/L (Hecht et al, 2007). Fidaxomicin was also 
identified to actually eliminate the offending bacteria while vancomycin just hinders the 
bacteria growth (Babakhani et al, 2011).   
A C. difficile isolate was observed during disease recurrence to have a high MIC of 16mg/L to 
fidaxomicin following exposure to the antimicrobial, but no mechanism of resistance was 
determined (Goldstein et al., 2011). Reduced susceptibility to fidaxomicin was observed in 
isolates identified during a serial passage experiment and whole genome sequencing was used 
to characterise the genotype. Results showed mutation in the CD22120 or rpoB in the 
fidaxomicin reduced susceptible phenotype. The significance of these changes is yet to be fully 
elucidated (Leeds et al., 2014).   
1.10.4.2 Other CDI antimicrobial therapies  
Other therapeutic agents are also being developed and researched to increase the options for 
clinicians.  For example surotomycin is a lipopeptide that was observed in an in vitro gut model 
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to decrease the toxin levels and growth of C. difficile without the development of reduced 
susceptible strains (Chilton et al., 2014) Cadazolid is another therapeutic agent in development 
for treating CDI by inhibiting translation during protein synthesis (Locher et al., 2014), and 
clinical trial data for this antimicrobial when experimented on 64 healthy men, suggests that it 
was safe with low systemic exposure (Baldoni et al, 2013)  
Colectomy: Surgical removal of the colon is recommended in very severe cases showing toxic 
megacolon and pertoreal signs (Lamontagne et al., 2007). It was reported that patients that were 
immunocompetent and over 65years had improved health after colectomy (Lamontagne et al, 
2007).  
1.10.5 Biotherapy for CDI  
  
1.10.5.1 Faecal microbiota transplantation (FMT) 
Since CDI onset is as a result of the disruption of the colonic microflora of the patient. FMT is 
a method employed to reinstate the colonic microflora thus limiting the proliferation of C. 
difficile due to presence of competing healthy bacteria. FMT involves the introduction of a 
faecal suspension from a healthy personnel into a patient's gut. This can be done via enemas, a 
nasogastric tube and using oral capsules. A study was done involving 19 patients which failed 
other treatments options, but FMT showed disease resolution from 6 months up until 45years 
after which reinfection was reported (Rohlke et al, 2010)  
  
Amongst the methods of administration, colonoscopy was documented to be preferred by 
patients (Rohllke et al., 2010). FMT for recurrent CDI has also been reported using the 
nasogastric method. Ninety percent disease resolution has been published for 100 patients using 
FMT (Bakken, 2009).  
The efficacy of faecal transplantation was determined by administering it 2 days after a 2weeks 
oral vancomycin was stopped (Hota et al., 2017). It was examined compared to the standard 
oral vancomycin therapy to resolve CDI therapy. But no significant difference was observed. 
It should be noted that faecal administration in this study entailed a single administration and 
was done via enema (Hota et al., 2017).  
The use of faecal microbiota transplantation (FMT) was researched on using vancomycin 
simultaneously on severe and severe/complicated CDI cases. It was reported to have a high 




1.10.5.2 Intravenous immunoglobulin  
C. difficile toxins which are its major virulence factors may be neutralized using intravenous 
immunoglobulin (IVIG), thus preventing colitis. IVIG binds and neutralise toxin A as an 
antitoxin (Shah et al., 2014). A 2014 research study reported IVIG to have been used to 
successfully treat an elderly patient that was unresponsive to both metronidazole and 
vancomycin (Shah et al., 2014). This has also been successful administered in severe 
pseudomembranous colitis (Salcedo et al., 1997, Chandrasakar et al., 2008)  
  
1.10.5.3 Transcutaneous immunization   
C. difficile toxin A (CDA) was treated with formalin and administered to mice transcutaneously 
to induce immune response, alone or with cholera toxin (CT) an immunoadjuvant (Ghose et 
al., 2007). Anti CDA and Anti CT IgA were observed in stools while in serum, anti-CT 
immunoglobulin G (IgG), anti-CDA and anti IgA (Ghose et al., 2007). A cell culture assay was 
used to detect the neutralisation capacity of sera collected from immunized mice (Ghose et al, 
2007); thus showing the efficacy of transcutaneous immunization using CDA toxoid (Ghose et 
al, 2007). C. difficile toxoid vaccine for humans was researched on consisting of toxoids A and 
B inactivated with formalin. It was experimented on 30 healthy adults and was observed to be 
safe and immunogenic (Kotloff et al, 2001). Toxoid vaccine has also been observed to be useful 
in recurrent diarrhoea resolution as observed in 3 patients with recurrent CDAD, after the 
administration of the vaccine, no further recurrence was observed in these patients 
(Sougioultzis et al, 2005)  
  
1.10.5.4 Beta lactamase enzymes  
SYN-004, beta- lactamase enzymes was designed as an orally administered therapy to degrade 
residual β-lactam antibiotics in the gut (Kaleko et al., 2016) to stop further harm on the normal 
flora in the gut. It was observed to destroy ceftriaxone in the gut of pigs and dogs. SYN-004 
has been observed to be a safe therapeutic in a phase 1 trial and its capacity to prevent CDI is 
being researched in a Phase 2 clinical trial (Kaleko et al., 2016)  
  
1.10.5.5 Toxin binding  
An anionic polymer, tolevamer (GT160 -246), was evaluated for its capacity to neutralize C. 
difficile toxin A and B. GT160 -246 was reported to possess no antimicrobial activity thus may 
have no effect on the normal flora of the intestine. Additionally, invitro test also showed no 
interference with the other antibiotics (Kurtz et al; 2001). The use of this polymer had no 
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adverse effect with respect to inflammation, fluid accumulation or permeability it was observed 
to prevent inhibition of protein synthesis and cell rounding caused by toxins (Kurtz et al., 
2001). The affinity of GT160-246 to toxin A was suspected to be higher than in toxin B as was 
detected in vero cells (Kurtz et al; 2001). In vivo test was unable to give useful information as 
toxin B receptors is absent in rodents. The test was also done on hamsters as well using 
metronidazole and cholestyramine (Kurtz et al; 2001). Ten percent of animals survived after 
being administered cholestyramine 100% survived with metronidazole and 80% with GT160 -
246 however after 80% survivors after metronidazole withdrawal, died but no death was 
observed after the administration of GT160 -246 was stopped. GT160 -246 was involved in a 
phase 1 trial and observed to be of no significant risk to healthy individuals (Kurtz et al; 2001)  
However supporting phase III clinical studies (Lewis and Anderson, 2013), gut model 
experiments have shown that the cytotoxic effect of C. difficile was not affected despite 
exposure of high concentrations of tolevamer (Baines et al, 2009).   
  
1.10.5.6 Non toxigenic C. difficile (NTCD)  
NTCD has been reported in a number of researches to prevent colonisation of toxigenic C. 
difficile thus limiting the onset of CDI (Wilson et al; 1983, Natarajan et al, 2013). A study 
using the hamster model to study the protective capacity of NTCD against CDI onset was 
performed by Wilson and colleagues, and ninety three percent of animals first exposed to 
NTCD before toxigenic strains survived compared to the control (21% survival) (Wilson et al; 
1983). However, no protection was observed when the NTCD and toxigenic strains were given 
together. The safety profile of NTCD in humans has been investigated by giving healthy adults 
oral spore suspension of VP20621 strain M3. This NTCD was observed after vancomycin 
therapy to colonise gut and be tolerated (Viliano et al; 2012). The mechanism for this protection 
is yet to be elucidated, it could possible just be as a result of simply competing for nutrients or 
for mucosal niche (Natarajan et al, 2013).  NTCD has also been used to reduce CDI recurrence 
in patients (Gerding et al; 2015). NTCD –M3 spores were administered orally after treatment 
of CDI patients with metronidazole or vancomycin. Of the 43 patients that received placebo, 
30% demonstrated recurrence in CDI but of the 125 patients who received NTCD, only 11% 
demonstrated recurrent CDI (Gerding et al; 2015).  A non-toxigenic C. difficile strain (Z31, 
ribotypes 009) was sequenced and analysed in Brazil. An observation of the genome shows it 
relates to a toxigenic strain ATCC9689, its nontoxigenic characteristics makes it useful as a 
form of therapy to compete with other toxigenic strains thus preventing the onset of CDI 
(Pereira et al., 2016). However analysing its sequence was important to detect if it had other 
features that would enable a successful competition with other toxigenic Clostridium strains 
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(Pereira et al., 2016). Other virulence earlier reported to be necessary for intestinal colonisation 
such as surface layer protein SlpA and genes coding for flagellar proteins FliC and FliD were 
also observed. Spo0A necessary for sporulation of these Z31 was also identified as well as 
cotA, cotB, cotC, cotD and sodA genes coding for the proteins forming the spore coat. 
Importantly, none of the genes for toxin A, toxin B and the binary toxin were found (Pereira et 
al., 2016).  
1.10.5.7 Monoclonal Antibodies  
Bezlotoxumab and actoxumab are monoclonal human antibodies targeted against toxin A and 
B for neutralisation of these major C. difficile virulence factors. These form of passive 
immunity were observed for their efficacy in preventing C. difficile recurrent infection in 2655 
CDI patients (Wilcox et al, 2015). While no beneficial use was observed when actoxumab was 
added to therapy, Bezlotoxumab was detected to prevent recurrence at a higher rate compared 
to the therapy using placebo, and 38% higher than the use of just the standard of care therapy 
and no health hazard was observed. More than quarter of the recurrent cases were observed 
after the standard effective treatment duration of 4 weeks. Twelve weeks duration of recurrent 
prevention was observed with bezlotoxumab showing its efficacy when administered with 
standard of care therapy antibiotic (Wilcox et al, 2015)  
  
1.10.5.1 Probiotics  
  
Living microbes known to improve the health of another living organism on administration to 
the later are referred to as probiotics (FA0/WHO, 2002). CDI being an antibiotic associated 
disease usually correlates with an imbalance of the gut microflora so the use of probiotics has 
been researched. Most cases of antibiotic-associated diarrhoea result from an osmotic 
imbalance in the colon, leading to excess luminal carbohydrate and loss of water across the 
mucosa by osmosis and resultant diarrhoea. Probiotics have been proposed to carry out their 
mechanism of action by not just replacing the protective coverage of intestinal mucosa but also 
aiding fermentation of carbohydrate (Hickson 2011) which would hinder diarrhoea 
downstream. Pilal and Nelson (2008) stated that there is not enough information to base the 
single use of probiotics in the treatment of CDI (Pillai and Nelson, 2008).  
One of the in vitro characteristics observed to enable the probiotic effect of an organism is its 
ability to attach to the intestinal wall, its pH tolerance and the capacity to prevent the 
proliferation of pathogenic bacteria (Jacobsen, et al; 1999). L. reuteri DSM12246 was 
observed to show this antimicrobial feature though did not affect normal flora of the intestine 
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(Jacobsen, et al; 1999). However these features appeared not to be enough to sustain long term 
colonisation of the lactobacilli strains been examined in the gut (Jacobsen, et al; 1999). A 
2016 systematic review was reported where probiotics in adults between the ages of 18 and 
64 years old having AAD, as well as older people. In subjects less than 65 years old, probiotics 
was observed to have a positive impact in the prevention of AAD but this was not same with 
those over 65 years old (Jafarnejad et al; 2016).  The use of probiotics in prevention of CDI 
was ascertained in another systematic literature review article. These article analysed 7957 
patients in 26 randomised control trials. Slightly over 60% reduction in CDI was observed on 
administration of probiotics. Over 50% of adult and children AAD patients had a positive 
response to probiotics (Lau and Chamberlain; 2016). The decrease in CDAD (over 55% 
reduction) was effective with the use of probiotics such as Lactobacillus, Saccharomyces (Lau 
and Chamberlain; 2016).  
Live Lactobacillus casei Shirota (LcS) contained in a commercially produced drink was 
examined for its ability to prevent AAD and CDI in spinal cord injury patients. LcS 
administration was performed during and one week after antibiotic therapy which led to 
reduced AAD onset (Wong et al, 2014)  
 In summary the onset of C. difficile infection can be treated by first ending the medications the 
patient has been exposed to. All personnel in contact with the patient would be required to make 
use of disposable medical equipment and practice basic hygiene especially hand washing with 
soap and water which is the preferred choice above use of sanitizers due to the ability of C. 
difficile to sporulate (Goldstein et al, 2015)  
As was earlier mentioned metronidazole and vancomycin are the first line medications for 
treating CDI. In addition the administration of these first line antibiotics is dependent on the 
severity of the disease and response of patients. Moderate/mild CDI would require oral 
intravenous metronidazole 500mgq.i.d for 10-14 days (Carmo et al, 2015), and 125mg q.i.d of 
vancomycin administered orally could also be used for this level of severity. A standard 
vancomycin dose is required if the patient response is not positive after 5-7 days metronidazole 
use. For severe CDI, 125mg q.i.d- 500mg q.i.d of vancomycin is required. With respect to ileus, 
megacolon and colonic diversion, vancomycin can be given as a retention enema (Cohen et al, 
2010). For ileus this can be done in conjunction with intravenous metronidazole (Carmo et al, 
2015, Ofosu 2016). Fidaxomicin can also be used instead of vancomycin as curative levels 
have been recorded to be higher in fidaxomicin in comparison to vancomycin (Cornely et al, 




Determination of the characteristics of less susceptible C. difficile strains and clear mechanism 
by which this bacterium becomes less susceptible to metronidazole would enhance research 
works, thus limiting development of resistance.  
 
1.11 Aims of project  
This project aims to characterise reduced metronidazole susceptibility in UK C. difficile 
isolates.  
1.12 Main objectives  
To isolate current clinical C. difficile isolates with reduced susceptibility to metronidazole. 
To characterise the reduced susceptibility phenotype using population analysis profiling and 
antimicrobial susceptibility testing.  
To assess the stability, and the potential of further increases in minimum inhibitory 
concentrations (MICs), of the reduced susceptibility phenotype using serial passaging studies.  
To assess the uptake and activation of metronidazole in C. difficile strains with reduced 
susceptibility to metronidazole using antimicrobial bioassay techniques.  
To assess nutritional factors (e.g. iron availability) that may contribute to the reduced 
susceptibility phenotype in C. difficile using antimicrobial susceptibility testing techniques.  
To determine genetic mechanism(s) of reduced susceptibility to metronidazole.  
 1.13 Laboratory experiments   
This research was focused on strains of three UK C. difficile ribotypes: 027, 001 and 106. In 
total, 37 C. difficile strains with metronidazole MICs of ≥4mg/L were studied. These C. difficile 
strains are characterized as C. difficile with reduced susceptibility to metronidazole (CDRM) 
based on comparism to epidemiological cut-off (ECOFF) values for the drug. These CDRM 
strains were compared to 11 C. difficile strains of the same ribotypes which were susceptible 
to metronidazole (CDSM). Additionally, two experimental control C. difficile strains, E4 and 
ATCC 700057 were also studied. C. difficile E4 was the first C. difficile strain (non-toxigenic, 
ribotypes 010 coded as 110) reported with the CDRM phenotype (Brazier et al, 2001), while 
ATCC 700057 is a commercially available C. difficile strain (ribotype 038 coded as 111) and 
is a CDSM strain. C. difficile strains in this study are identified using their corresponding 




2.0 Antimicrobial Susceptibility Testing of UK C. difficile ribotypes 027, 001, 001/072, 106  
2.1 INTRODUCTION  
 
Antimicrobial susceptibility testing (AST) is an experiment designed to detect the level of 
resistance of a certain microbe to an antimicrobial agent. AST is employed in a clinical setting 
to select the drugs that best combat an offending pathogen. This test could be performed 
manually for example using agar incorporation methods, gradient agar plate methods, or disc 
diffusion methods; or it can be achieved with the use of automated instruments (Jorgensen & 
Ferraro, 2009).  
Though disc diffusion tests are not costly and can be used for routine clinical tests, the Clinical 
Laboratory Standard Institute (CLSI) suggests an agar dilution method as the preferable method 
for antimicrobial susceptibility testing of Clostridium difficile. Agar incorporation methods are 
convenient for minimum inhibitory concentration (MIC) surveillance and assessment of new 
antibiotics and also are reproducible (Erikstrup et al., 2012).  
Research evaluating the antimicrobial susceptibilities of nine Clostridium difficile ribotypes 
against metronidazole using several methods including: E-test, agar dilution method (ADM), 
an agar incorporation method (AIM) was performed (Moura et al., 2012). It was observed that 
the ability of AIM to detect reduced metronidazole susceptibility in the test strains transcended 
that of the other two methods (Moura et al., 2012). Similar research at the University of Leeds 
in the United Kingdom also demonstrated that AIM was a superior method in detecting reduced 
metronidazole susceptibilities in C. difficile and that both the choice of agar base and the broth 
ingredients used to raise the inoculum influenced the metronidazole MICs (Baines et al., 2008).  
2.11 Antimicrobial Susceptibility in Clostridium difficile isolates.  
The first line treatments for mild/moderate Clostridium difficile infection include 
metronidazole and vancomycin, therefore routine surveillance of antimicrobial susceptibilities 
in C. difficile is recommended given the few efficacious alternatives that are available. 
Experiments have been performed to detect susceptibility levels of Clostridium difficile to these 
antibiotics using different methods. Baines et al., (2008) carried out a study with metronidazole 
whereby MICs were ascertained for different strains using spiral gradient endpoint analysis, 
Etesting, and AIM. It was also stated that C. difficile growth on supplemented Brucella agar 
and other agars were observed to be a lot less than the reproducible growth observed on Wilkins 
Chalgren agar during susceptibility testing (Baines et al., 2008). Ribotypes 106 and 027 were 
susceptible to metronidazole as well as a large quantity of ribotypes 001 strains tested, however 
reduced susceptibility (Minimum inhibitory concentrrations (MIC) >2mg/L) was observed in 
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24.4% of ribotype 001 C. difficile isolates with the use of agar incorporation method (Baines 
et al., 2008).  Clostridium difficile susceptibilities to metronidazole, vancomycin and 
oritavancin have also been compared using agar incorporation methods and broth 
macrodilution methods. The use of an agar incorporation method resulted in metronidazole 
being the most potent antibiotic of the three antibiotics tested against C. difficile (O’Connor et 
al., 2008). Another research tested one hundred and eighty eight C. difficile ribotypes for their 
levels of antimicrobial susceptibility to 30 antibiotics by the use of a broth macrodilution 
method. The result showed that ribotypes 027 along with 8 other polymerase chain reaction 
(PCR) ribotypes were multiresistant to the antibiotics tested (Pirs et al., 2013).  
The metronidazole MIC range for 415 strains of C. difficile in a 7 year study was recorded to 
be from 0.016-32µg/ml, while the MIC50 was 0.5µg/ml and MIC90 was 4µg/ml. However, 26 
strains out of the 415 strains were metronidazole resistant having MIC ≥32 µg/ml and the 
clinical breakpoint (CLSI) was 16µg/ml (Pelaez et al, 2002). The same numbers of strains were 
tested against vancomycin and the MIC range was 0.016 to 16µg/ml, MIC90 was 2 µg/ml and 
MIC50 was 1µg/ml. Reduced susceptibility to vancomycin was observed in 3.1% of the tested 
strains but there were no resistant strains (Pelaez et al, 2002). The MIC range for 9 C. difficile  
ribotypes were also obtained amongst which 027 ribotype had a range of 0.125-0.5 mg/L, 078 
had a range 0.125-0.25 mg/L, 001 was 0.064-1 mg/L, 010 was 0.125-32 mg/L using agar 
dilution method (ADM). Of the nine ribotypes 2 strains belonging to the PCR ribotype 001 had 
reduced susceptibility to metronidazole which resulted to 4mg/L when tested with ADM. 
Ribotypes 027, 078, 001,010 were reported to be metronidazole susceptible and heterogeneous 
that is the colonies from each ribotype had varying MIC (Moura et al, 2012). A pan European 
study, detected the antibiotic susceptibility levels of common ribotypes of C. difficile (Freeman 
et al, 2015). Susceptibility to metronidazole and vancomycin as well as 7 other antimicrobial 
agents were determined for 953 C. difficile strains obtained from 22 countries. Out of the 99 
recognized ribotypes identified 027 and 001 were among the four prevalent ribotypes (Freeman 
et al, 2015). Though resistance was observed to some antibiotics like moxifloxacin and 
clindamycin, no resistance was observed to metronidazole and vancomycin, reduced 
susceptibility rates detected was low, as MIC90 = 2mg/L for both metronidazole and 






2.12 Aims  
To determine the antimicrobial susceptibilities of a panel of UK C. difficile isolates, some of 
which have previously shown reduced metronidazole susceptibility.   
2.13 Objectives  
To use an agar incorporation MIC method to compare the activity of the metronidazole and 



















2.2 METHOD  
2.21 C. difficile isolates   
Thirty seven strains of C. difficile from three PCR ribotypes: 027, 001, and 106 were evaluated 
in this study. These strains were selected because they had earlier been identified with reduced 
susceptibility to metronidazole (CDRM), with MICs >2mg/L which is the European committee 
on antimicrobial suscepitibility testing (EUCAST) epidemiological cut-off (ECOFF) for 
metronidazole (EUCAST, 2017). These 37 strains were compared with 11 C. difficile strains 
of the same ribotypes which were previously demonstrated to be susceptible to metronidazole 
(CDSM strains) in addition to two control strains, E4 (Brazier et al., 2001) of ribotypes 010 (an 
environmental isolate, CDRM coded as 110) and ATCC 700057 of ribotype 038 (CDSM strain 
coded as 111). The clinical strains were all isolated in the United Kingdom and were obtained 
from Professor Mark Wilcox (Leeds Teaching Hospitals NHS Trust and the University of 
Leeds). The strains were stored as spores in 50% ethanol which could germinate spontaneously 
in presence of germinants (e.g. bile salts) contained within the selective agar used 
2.22 Agar incorporation MIC testing  
The agar incorporation MIC method used in this study was based upon that described by Baines 
and colleagues (2008), given that this method has been demonstrated previously to be able to 
detect reduced susceptibility to metronidazole in C. difficile. Twenty microliters of spore 
preparation of each strain was inoculated and streaked out on Brazier’s agar (LAB160, Neogen 
Europe Ltd, Ayr,  UK) plate supplemented with 2% (v/v) lysed horse blood (SR0050, Oxoid, 
Basingstoke, UK) to grow overnight in the anaerobic cabinet (N2:H2:CO2, 80:10:10) (Don 
Whitley Scientific, UK). Three to four colony forming units of these strains were than swabbed 
individually using a sterile cotton swab into respective test tubes containing sterile pre-reduced  
Schaedler’s broth (CM0497 Oxoid, Basingstoke, UK) and incubated overnight anaerobically 
at 37oC.  
Four hundred microliters of overnight cultures (approximately 1 x 107 cfu/mL) was applied to 
the surface of pre-dried Wilkins Chalgren agar (CM0619 Oxoid, Basingstoke, UK) plates 
containing doubling dilutions of antibiotics (metronidazole (M3671, Sigma-Aldrich, Poole 
UK) and vancomycin (101489773, Sigma-Aldrich, Poole UK)) ranging from 0.03mg/L to 
128mg/L using a multipoint inoculator (UriDot, Mast Group Ltd., Bootle, UK).  The pins of 
the multipoint inoculator are manufactured to deliver 1μL of the bacterial inoculum onto the 
surface of the agar plate (approximately 104 cfu), which is in line with the recommended 
inoculum (CLSI) for anaerobic bacteria when performing AIM susceptibility testing.  
Metronidazole and vancomycin solutions were prepared, filter sterilized using syringe filters 
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and diluted to different concentrations using sterile water. Antimicrobial solutions were 
prepared at ten-fold higher concentrations, then diluted 1:10 in molten (50°C) Wilkin’s 
Chalgren Anaerobe agar and all MICs were determined in duplicate. The susceptibility was 
confirmed by determining the minimum inhibitory concentrations (MIC) of these antibiotics 
for the C. difficile strains. Geometric mean MIC values were determined for C. difficile PCR 
ribotypes along with MIC50 and MIC90 values. MIC50 is the MIC that inhibited 50% of the C. 
difficile strains studied while MIC90 is the MIC that inhibited 90% of the C. difficile strains 
studied. Geomean is a type of mean, it represents all the MIC values of the strains analysed. 
After inoculation the agar plates were incubated anaerobically at 37°C overnight. Aerobic and 
anaerobic control plates lacking antibiotics were also inoculated and incubated in the 
appropriate atmosphere to assess for contamination and as a growth control respectively. The 
plates were then removed from the anaerobic cabinet and MIC values recorded. The lowest 
concentration of antimicrobial agent that elicited a mark reduction in visible growth/no growth 
when compared to anaerobic growth control agar plate was deduced to be the MIC (CLSI) and 
MIC concentrations for metronidazole greater than 2 mg/L was reported to have reduced 
susceptibility.  Kruskal -Wallis significance testing was performed to detect significance in 
metronidazole MIC differences between CDRM strains of the ribotypes analysed. Post hoc 
testing using Dunn’s multiple comparism test was also done 
2.23 Statistical analysis  
 Kruskal -Wallis significance testing was performed to detect significance in metronidazole 
MIC differences between CDRM strains of the ribotypes analysed. Post hoc testing using 











2.3 RESULTS  
Metronidazole overall geometric mean MICs for C. difficile ribotype 001, 027 and 106 were 
3.76, 2.72 and 3.18mg/L, respectively (table 1), with ribotype 001 being the highest. The 
metronidazole MIC range for ribotype 001 was observed to be wider than the other ribotypes 
analysed. The geometric mean vancomycin MIC for C. difficile ribotype 001, 027 and 106 were  




Table 2. 1 Antimicrobial susceptibilities of CDRM strains (mg/L) using AIM with Oxoid Wilkin’sChalgren 
agar, with inocula raised in Oxoid Schaedler’s anaerobe broth  
Antibiotics   PCR  
Ribotype  
No of strains 













Metronidazole  001  22  0.125-8  4  8  3.76  
027  9  2-4  2  4  2.72  
106  6  2-4  4  4  3.18  
              
Vancomycin  001  22  0.25-2  0.5  1  0.57  
027  9  0.5  0.5  0.5  0.5  
106  6  0.5  0.5  0.5  0.5  
       
  
Kruskal -Wallis significance testing was performed to detect significance in metronidazole 
MIC differences between CDRM strains of ribotypes 001,027, 106. The P value was 0.0187 
which was significant and post hoc testing- Dunn’s multiple comparism test showed significant 
difference was between 001 vs 027. However, for vancomycin the MIC differences between 
ribotypes were not significant as the P-value was 0.944.  
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The MIC50 for metronidazole against all C. difficile ribotypes analysed was ≤4mg/L while 
MIC50 for vancomycin against all test C. difficile ribotypes analysed were 0.5mg/L (Figure 2.1 
and table 2.1). The MIC90 of metronidazole for CDRM strains of ribotypes 001 was 8mg/L and 
in CDRM strains from ribotypes 027 and 106 were 4mg/L, while MIC90s for vancomycin for 
all C. difficile ribotypes analysed were ≤1mg/L (Figure 2.2 and table 1).  
The MIC of the control C. difficile strains were within the standard range for each strain, e.g. 
for E4 the metronidazole MIC range expected was 4-16mg/L and for ATCC 700057 was from 
0.125- 0.5mg/L (CLSI, 2007). The MIC values of the CDRM strains for metronidazole 
confirmed most of the strains had the reduced susceptibility phenotype. Amongst the 22 strains 
of ribotype 001 tested, 20 strains showed reduced susceptibility to metronidazole. While for 
ribotypes 027 and 106 4 strains of each ribotype were susceptible to metronidazole, out of the 
9 and 6 strains respectively that were tested, as indicated in table 2.1.  
  
Table 2.  2 Antimicrobial susceptibilities of CDSM (mg/L) strains using AIM with Oxoid Wilkin’s Chalgren 
agar, with inocula raised in Oxoid Schaedler’s anaerobe broth.  
Anitbiotics  Ribotype  Range of MIC 
detected(mg/L)  




Geomean   
METRONIDAZOLE  001  0.25 -0.5  0.5  0.5  0.42  
027  1-2  1  2  0.6  
106  0.125-2  1  1  0.63  
            
VANCOMYCIN  001  0.5-2  0.5  2  1  
027  0.5-1  0.5  0.5  0.5  
106  0.5-1  0.5  0.5  0.63  
  
No significant difference was observed within ribotypes for both metronidazole and 




Figure 2. 1 MIC50 (mg/L) for metronidazole and vancomycin against C. difficile. The ribotypes with the 
lighter bars indicate the metronidazole susceptible C. difficile strains (CDSM) used to compare 
metronidazole reduced susceptible C. difficile strains (CDRM). 
.  
 
Figure 2. 2 MIC90 (mg/L) for metronidazole and vancomycin against C. difficile. The ribotypes with the 
lighter bars indicate the metronidazole susceptible C. difficile strains (CDSM) used to compare 
metronidazole reduced susceptible C. difficile strains (CDRM). 
 
  
All reported CDSM strains were confirmed as susceptible to metronidazole with MIC90 ≤2mg/L 
in this experiment. The difference in susceptibility of CDRM and CDSM strains at MIC90 was 
two or more dilutions for metronidazole except 027 with one dilution.   
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2.4 DISCUSSION  
There was a major difference in MIC90 between the CDRM and CDSM strains of the 001 
ribotype to metronidazole. MIC50 of CDRM strains showed that majority the strains of 
ribotypes 106 and 001 showed reduced susceptibility to metronidazole. But for vancomycin all 
CDRM and CDSM strains showed same susceptibility level at MIC50 = 0.5mg/L. More than 
90% of the total strains tested were susceptible to vancomycin at an MIC of less than 2mg/L.  
Ribotypes 106 and 027 showed a higher level of susceptibility to metronidazole and 
vancomycin compared to 001 ribotype. The MIC50 and MIC90 results were very similar which 
indicates that within each ribotype the strains had similar response to the antibiotics tested.  
Similarly, the past research work by Baines et al., (2008) reported a geometric mean 
metronidazole MIC for all strains of PCR ribotype 001 (n= 22) to be 5.94mg/L, thus it is in line 
with this research which observed reduced susceptibility in 20 isolates of the PCR ribotype 001 
strains. Ribotype 001 has also been observed to be the most predominant ribotype showing 
multidrug-resistance to 11 multidrug resistant ribotypes observed in a study that analysed 316 
isolates from 14 countries in Europe (Spigaglia et al, 2011). These C. difficile isolates were 
obtained from patients in hospitals and 82 of the isolates were identified to be resistant to more 
than one antibiotic (Spigaglia et al, 2011). Though metronidazole and vancomycin were 
amongst the antibiotics analysed, no reduced susceptibility was observed to metronidazole and 
vancomycin, but this could be as a result of the Etest method being used (Spigaglia et al, 2011). 
It is worthy of note that detecting MIC is method dependent, using agar incorporation method 
is the gold standard which has been employed in the present research and the use of Schaedlers 
broth and Wilkins Chalgren agar for MIC detection maximised the chances of detecting a 
reduced susceptible phenotype. The therapeutic breakpoint for vancomycin activity on 
Clostridium difficile is 2mg/L and the results for vancomycin showed MICs against the 
majority of C. difficile strains were less than 2mg/L, except 3 strains of C. difficile PCR ribotype 
001 which were at the breakpoint 2mg/L and one strain of same ribotype that was resistant at 
an MIC of 4mg/L. This indicates that the strains investigated in this research were susceptible 
to vancomycin, which is in line with an earlier report which stated that C. difficile strains were 
mostly susceptible to vancomycin and resistance was rare (Freeman et al, 2005). Though at 
low levels, reduced susceptibility to metronidazole and vancomycin has previously been 
reported in C. difficile isolates from a pan European study (Freeman et al, 2015). The MIC 
range being from ≤ 0.125-8 for metronidazole having MIC90 =2mg/L and ≤ 0.125-16 for 
vancomycin having MIC90 =2mg/L (Freeman et al, 2014). Susceptibility to vancomycin was 
also observed in previously reported CDRM strains of ribotype 001 which displayed a 
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geometric mean MIC of 2.14mg/L (Baines et al., 2008). The MIC of vancomycin in this 
research also correlated with the results from a 2002 research that reported a total absence of 
resistance in the C. difficile strains tested to vancomycin (Pelaez et al., 2002).  
This research is in line with an additional research, where 330 strains of C. difficile were 
analysed and no strains resistant to vancomycin was observed (Pituch et al., 2011). The 
difference observed in metronidazole and vancomycin MIC in this research emphasizes the 
variation in antibiotic activity which has been earlier argued to be same. Based on the MIC90 
results of each ribotype analysed one can infer that the rate of reduced susceptibility occurrence                         
to metronidazole is more in 001 compared with other ribotypes analysed.    
Though reduced susceptibility was observed in this experiment, other than the control strain 
the highest MIC obtained was 8mg/L it was observed to be slightly lower than metronidazole 
faecal concentrations which is approximately 9mg/L, while the faecal concentrations of 
vancomycin is 1000mg/L (Baines and Wilcox, 2015). Though the MIC of these strains might 
not necessarily reflect the features obtained inside the human gut as MIC testing is an 
approximation of the likely effects of an antimicrobial on a bacterium, but in vivo conditions 
would be very different: the inoculum density (higher or lower ) of C. difficile would be 
different which would affect MIC, spores would be present which would not be affected 
directly by the antimicrobials so would survive until antimicrobial levels in the gut declined to 
sub-MIC then they could outgrow. MICs were done in pure culture rather than it being a mixed 
culture with the gut microflora as it would be in vivo so this again might affect C. difficile 
response. Then growth and the levels of the antimicrobial, the growth phase of C. difficile might 
be different in vivo, again, this would affect the effects of the antimicrobials (MICs use late 
log-phase cultures normally which may not reflect CD growth in vivo).  
Conclusion and future work 
 This research identified 29 CDRM strains to have reduced susceptibility to metronidazole and 
one C. difficile strains not susceptible to vancomycin. Replicates in these experiments yielded 
similar results and all control organism MICs were within the appropriate MIC ranges, 
therefore the MICs can be assumed to be accurate. The reduced susceptibility could be as a 
result of selection of isolates with reduced susceptibility that used to be heterogeneous by 
continuous exposure to metronidazole or vancomycin (Baines et al., 2008). It could also be as 
a result of acquisition/inducing of features causing resistance like nim genes for metronidazole 
and van A-G genes for vancomycin (Carlier et al., 1997, Huang, 2009, Chong et al., 2014). All 
strains including CDRM strains that showed susceptibility to metronidazole will be further 
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analysed to detect MIC heterogeneity and mechanisms of reduced susceptibility will be 
assessed. The clinical significance of CDR strains (metronidazole and vancomycin) remains to 
be definitively demonstrated. This could be achieved by assessing the clinical notes of patients 
infected with CDRM strains and looking at their clinical outcomes following treatment 
compared to patients infected with the same ribotypes, at the same time, in the same 
geographical location. Although this work is beyond the scope of the present study, it would 
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3.0 Heterogeneity in susceptibility to Metronidazole and Vancomycin in UK C. difficile 
isolates.  
3.1 INTRODUCTION  
Within any microbial strain it has been identified that there can be physiological variation 
amongst cells (Lidstrum and Konopka, 2010).These differences might influence the responses 
of the divergent microbial cells to environmental stimuli such as nutrient availability and 
antimicrobial compounds. The term heterogeneity indicates differences within a group, 
therefore within a particular bacterial strain, some colonies might have different minimum 
inhibitory concentrations (MICs).   
Heterogeneity in antimicrobial agent MICs has been observed in some facultatively anaerobic 
organisms such as Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) and 
additionally in microaerophilic pathogens such as Helicobacter pylori (H. pylori), where 
heterogeneity in metronidazole MICs was previously identified (Weel et al., 1996).Ten percent 
of the H. pylori heterogeneous populations also reflected genetic variation (Weel et al., 1996).  
C. difficile is the most prevalent infectious cause of antibiotic associated diarrhoea (Mutlu et 
al., 2007, Lynch et al., 2013, Debast et al., 2013) and is usually treated with metronidazole, 
vancomycin, or fidaxomicin, depending on the severity of infection and the status of the patient 
with regard to recurrent infection. However, not only has C. difficile been reported to have 
reduced susceptibility to metronidazole and vancomycin, heterogeneous MICs to these 
therapeutic agents have also been reported. Toxigenic C. difficile that previously demonstrated 
resistance to metronidazole were evaluated for metronidazole heteroresistance by Pelaez and 
colleagues (2008).  The authors reported heteroresistance to metronidazole, with MIC ranges 
in distinct clones (e.g. colony forming units) ranging between 16mg/L - 64mg/L, however all 
metronidazole-susceptible strains were homogeneous in their MICs to metronidazole (Pelaez 
et al, 2008). Moura et al (2012) also reported MIC heterogeneity for metronidazole against C. 
difficile ribotypes 001 and 010 and identified that these ribotypes were more heterogeneous 
with agar dilution method than with agar incorporation method (Moura et al., 2012). The 
presence of microbial heterogeneity in susceptibility to antimicrobial agents may lead to 
incorrect interpretation of susceptibilities, and potentially could impact treatment of infection, 
if a single colony forming unit was evaluated and was assumed to be representative of the 
whole bacterial population (Weel et al., 1996). Reduced efficacy of administered antibiotics 
may also be due to MIC heterogeneity in the offending microbial population (Moura et al., 
2013). Thus the need for evaluating the heterogeneity in susceptibilities of UK C. difficile 




3.11 Aims  
This research aims to screen for heterogeneity in metronidazole and vancomycin MICs in each 
of the 48 C. difficile strains analyzed.  
3.12 Objectives  
The objective of this experiment is to purify multiple distinct clones (i.e. colony forming units) 
of each C. difficile strain and determine the MICs of metronidazole and vancomycin using an 




















3.2 METHOD  
The heterogeneity test was carried out by determining the MICs for 13-17 single colony forming units 
per C. difficile strain. Numbers of colony forming units (CFU) evaluated differed between strains due 
to differences in the size and separation of the colonies. Thirty seven metronidazole reduced 
susceptible C. difficile strains (CDRM) belonging to PCR ribotypes 001, 106 and 027 were tested 
along with two control strains: ATCC 700057and E4 (see 1.14 for details of control strains). The 
CDRM strains were compared with 11 metronidazole susceptible C. difficile strains (CDSM) of 
ribotypes 001, 106, and 027. The minimum inhibitory concentration (MIC) was detected using an 
agar incorporation method (refer 2.2) with Wilkins Chalgren agar (WCA) and inocula raised in 
Schaedler’s anaerobe broth (Baines et al., 2008).  
Twenty microliters of spore preparation of each strain was inoculated and streaked out on a 
Braziers agar (LAB160, Neogen Europe Ltd, Ayr,  UK) plate supplemented with 2% (v/v) 
lysed horse blood (SR0050, Oxoid, Basingstoke, UK) to grow overnight in the anaerobic 
cabinet (N2:H2:CO2, 80:10:10) (Don Whitley Scientific, UK) at 37
oC. A range of 13-17 colony 
forming units were individually removed from the Brazier’s agar plates with a sterile cotton 
swab and inoculated into test tubes containing pre-reduced Schaedler’s anaerobe broth and 
incubated overnight anaerobically at 37oC.  
Four hundred microliters of each overnight culture was inoculated into the sterile sample block 
of the multipoint inoculator and 1µL of each culture was applied to the surface of pre-dried 
Wilkin’s-Chalgren agar (WCA) plates containing doubling dilutions of antibiotics 
(metronidazole and vancomycin) using a multipoint inoculator (see 2.22). Inoculated agar 
plated were incubated for 48 hours at 37oC under anaerobic conditions, alongside anaerobic 
growth control plates and aerobic contamination control plates (no antimicrobial agents were 
in these control plates). MIC endpoints were determined as in 2.22. Strains were referred to as 
homogeneous when all clones isolated from that strain had the same MIC. Strains were referred 
to as heterogeneous when some clones had a different MIC compared to other clones isolated 








3.3 RESULTS  
The three metronidazole reduced susceptible C. difficile strains (CDRM) ribotype groups 
individual clones from single colonies demonstrated metronidazole MICs ranging from 0.125- 
32mg/L (Table 3.1). CDRM from ribotypes 001 demonstrated the broadest metronidazole MIC 
range. Vancomycin MICs overall ranged from 0.25-4mg/L for CDRM strains, with the broadest 
range in MICs noted for the PCR ribotypes 106 (0.5-4mg/L) as can be seen in table 3.1. For all 
ribotypes it was observed that some metronidazole susceptible C. difficile strains (CDSM) had 
clones that were reduced susceptible to metronidazole at MIC ≥4mg/L (Table 3.1). The range 
of MIC observed in ribotype 106 antibiotics between CDSM and CDRM were similar with a 
±1 dilution. More than other ribotypes, ribotype 027 had a wider metronidazole MIC range in 
the CDSM strains compared to CDRM.  
Table 3.  1 Metronidazole and vancomycin MIC (mg/L) ranges for 3 C. difficile ribotypes isolates’ colonies 
tested individual purified colony forming units (13-17 cfu).  
C. difficile ribotype  Antibiotics  Range (CDRM)  Range(CDSM)  
Ribotype 001  Metronidazole  0.125 – 32mg/L  0.5-4 mg/L  
Vancomycin  1-4mg/L  0.5-4 mg/L  
        
Ribotype 027  Metronidazole  0.5 – 4mg/L  1-16 mg/L  
Vancomycin  0.5 – 2mg/L  0.5-2 mg/L  
        
Ribotype 106  Metronidazole  0.25 – 4mg/L  0.25-4 mg/L  
Vancomycin  0.5 – 4mg/L  0.5-2 mg/L  
  
Fifty percent of ribotype 001 CDRM strains showed heterogeneity in their susceptibility to 
metronidazole (Figure 3.1). While 75% of the C. difficile PCR ribotype 001 CDSM strains 
showed heterogeneity in their susceptibility to metronidazole. One clone of CDRM tested 
showed full resistance to metronidazole with an MIC of 32mg/L (Figure 3.1). Amongst the 
heterogeneous strains of ribotype 001, C. difficile, strain 114 (CDSM strain) showed the most 
heterogeneity, with a total of four MICs observed for the 16 CFU tested (range 0.5-4 mg/L). In 
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general, C. difficile strains that demonstrated heterogeneity in metronidazole MICs elicited two 
MICs, with the majority of isolates of a particular strain demonstrating one MIC.  
  
 
Figure 3. 1 Metronidazole MICs (mg/L) of ribotype 001 showing heterogeneity. Metronidazole reduced 
susceptible C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains 
(CDSM) (orange bars) of individual clones/colony forming units determined using an agar 




Figure 3. 2 Vancomycin MICs (mg/L) of ribotype 001 showing hetereogeneity. Metronidazole reduced 
susceptible C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains 
(CDSM) (orange bars) of individual clones/colony forming units determined using an agar incorporation 
MIC method.  The numbers in the bars show the number of colonies having the MIC value.  
Forty five percent of CDRM 001 ribotype strains showed heterogeneity to vancomycin, while 
50% of the susceptible strains also showed heterogeneity to vancomycin. Amongst the 
heterogeneous strains, MICs from one up to a maximum of four different MICs were observed 
for one isolate.   
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 Four homogenous CDRM strains (strains 76, 84, 89 and 85), showed susceptibility to 
metronidazole, though earlier in chapter 2 all four strains showed reduced susceptibility to 
metronidazole at MIC ≥2mg/L with the exception of strain 84 MIC= 0.125mg/L for 
susceptibility testing. Strain 84 had the lowest metronidazole MIC of the 001 ribotype strains 
(Figure 3.1). Most strains were susceptible to vancomycin unlike metronidazole; only three 
strains had colonies that showed reduced susceptibility to vancomycin, i.e. 2 CDRM strains 
and 1 CDSM strain (76, 92 and 114 respectively). CDSM strain 114 had 11 colonies with 
reduced susceptibility to vancomycin. Strain76 a CDRM strain was homogeneous and showed 
reduced susceptibility to vancomycin but this strain was shown to be susceptible to 




Figure 3. 3 Metronidazole MICs (mg/L) of ribotype 027 showing heterogeneity. Metronidazole reduced 
susceptible C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains 
(CDSM) (orange bars) of individual clones/colony forming units determined using an agar 
incorporation MIC method. The numbers in the bars show the number of colonies having that MIC  
  
Fifty six percent of 027 C. difficile ribotype CDRM strains showed heterogeneity in their 
susceptibility to metronidazole. While the CDSM strains compared with it had 50% 
heterogeneity in their susceptibility to metronidazole. A wider range of heterogeneity was 
observed amongst the CDSM strains, strain 41 (1-4mg/L) and strain 35 (4-16mg/L) than the 
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Figure 3. 4 Vancomycin MICs (mg/L) of ribotype 027 showing heterogeneity. Metronidazole susceptible 
C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains (CDSM) (orange 
bars) of individual clones/colony forming units determined using an agar incorporation MIC method. The 
numbers in the bars show the number of colonies having that MIC.  
  
Fifty six percent of ribotype 027 CDRM showed heterogeneity in their susceptibility to 
vancomycin. Correspondingly, CDSM strains demonstrated 75% heterogeneity in their 
susceptibility to vancomycin. Strain 41 (CDSM) was the most heterogeneous of all ribotype 
027 strains tested (Figure 3.4).   
Strains 98 & 102 were homogenous and susceptible to metronidazole. Strain 95 was 
homogenous but had reduced susceptibility to metronidazole MIC =4mg/L (Figure 3.3). 
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Heterogeneous CDRM strains 97, 98 and 103 had some susceptible colonies and others with 
reduced susceptibility to metronidazole (Figure 3.3). All strains both CDRM and CDSM 
showed susceptibility to vancomycin with MICs ≤2mg/L. The heterogeneity observed, showed 
distribution of most of the colonies were at 0.5mg/L or a dilution higher with the exception of 
strain 99 that had 11 colonies with MICs at 2mg/L (Figure 3.4).  Strain 96 is equally susceptible 
to metronidazole and vancomycin. CDSM strains 41 and 37 had similar response in 




Figure 3. 5 Metronidazole MICs (mg/L) of ribotype 106 showing heterogeneity. Metronidazole reduced 
susceptible C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains 
(CDSM) (orange bars) of individual clones/colony forming units determined using an agar 
incorporation MIC method. The numbers in the bars show the number of colonies having that MIC.  
  
Sixty seven percent of the CDRM strains of C. difficile ribotype 106 showed heterogeneity to 
metronidazole compared with 100% heterogeneity observed in CDSM strains. C. difficile strain 
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Figure 3. 6 Vancomycin MICs (mg/L) of ribotype 106 showing heterogeneity. Metronidazole reduced 
susceptible C. difficile strains (CDRM) (blue bars) and metronidazole susceptible C. difficile strains 
(CDSM) (orange bars) of individual clones/colony forming units determined using an agar incorporation 
MIC method. The numbers in the bars show the number of colonies having that MIC  
Sixty seven percent of both CDRM and CDSM strains of ribotype 106 showed heterogeneity 
to vancomycin. C. difficile strain 108 (CDRM) was most heterogeneous to vancomycin and 
demonstrated three MIC values.  
C. difficile ribotype 106 strains all demonstrated MICs ≤4mg/L to metronidazole. Two strains 
of purported CDRM ribotype 106 appeared as CDSM, with MICs of 0.5 mg/L (strains 105 & 
109) showed susceptibility to metronidazole (Figure 3.5). Strain 118 & 119 of purported CDSM 
strains demonstrated colonies that showed reduced susceptibility to metronidazole. Strains 109 
and 119 were the most heterogeneous to metronidazole of C. difficile ribotype 106 (Figure 3.5), 
with three MICs evident in these experiments.  
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All strains of ribotype 106 were susceptible to vancomycin with MICs ≤2mg/L, except strain 
108, which demonstrated some of its colonies were with apparent reduced susceptibility to 
vancomycin (MICs 4mg/L). Strain 108 was also the most heterogeneous of the ribotype 106 
strains to vancomycin.   
Ribotype 106 was the most heterogeneous with regards to metronidazole MICs amongst the 3 
ribotype groups tested in this study for CDRM strains alone with 67% heterogeneity. On 
considering the total CDRM and CDSM strains analyzed ribotype 106 was also the most 
heterogeneous of the 3 ribotypes with 78% heterogeneity.  
  
  
Table 3.2 Number of C. difficile strains (CDRM and CDSM separated) heterogeneous in susceptibility 
to metronidazole and vancomycin  
Ribotype   Phenotype  Number of strains 
heterogeneous to 
metronidazole  
(%)   
Number of strains 
heterogeneous to 
vancomycin (%)   
Total number of 
strains analyzed  
001  CDRM  11 (50%)  11 (50%)  22  
  CDSM  3 (75%)  2 (50%)  4  
          
027  CDRM  5 (56%)  5 (56%)  9  
  CDSM  2 (50%)  3 (75%)  4  
          
106  CDRM  4 (67%)  4 (67%)  6  









Table 3.3 Number of C. difficile strains (combination of CDRM and CDSM) heterogeneous in 
susceptibility to metronidazole and vancomycin.  
  
Ribotypes  Number of strains 
heterogeneous to 
metronidazole (%)  
Number  of  
Heterogeneous 
vancomycin (%)  
strains 
to  
Total number of  
strains analyzed  
001  14(54)  13(50)   26  
027  7(54)  8(62)   13  
106  7(78)  6(67)   9  
Total  28(58)  27(56)   48  
  
 The number of heterogeneous C. difficile strains to both antibiotics were almost same, 28 and 
27 to metronidazole and vancomycin respectively (Table 3.3). Also for both antibiotics the 
number of heterogeneous strains compared to non-heterogeneous strains was more than 50%.  
Ribotype 106 has the highest level of heterogeneity with 78% and 67% heterogeneity to 
metronidazole and vancomycin respectively. It was observed in the hetereogeneity results 
obtained separately for CDRM only, that for all ribotypes, the same percentage of strains 
heterogenous to metronidazole was heteregenous to vancomycin (Table 3.2). Ribotype 106 was 
still the highest in hetereogeneity to metronidazole when CDSM and CDRM were analysed 











Table 3.4 Total number of strains analysed (including CDSM strains) in this research highlighting 
those with heterogeneity MIC distribution across two MICs or more in their susceptibility to 
metronidazole and vancomycin.  
Ribotypes  Number of strains 
heterogeneous to 
metronidazole (%)  
Number of strains 
heterogeneous to 
vancomycin (%)  
Total number of  
strains analysed  
001  3(12)  2 (8)  26  
027  2 (15)  1 (8)  13  
106  2 (22)  1 (11)  9  
Total  7 (15)  4 (8)  48  
  
The percentage number of strains with heterogeneity result of MIC distribution across two 
MICs or more, was ≤ 15% for both antibiotics, with ribotype 106 demonstrating the highest 
percentage of heterogeneous isolates, with 22% and 11% of isolates being heterogeneous for 














3.4 DISCUSSION  
The presence of reduced susceptible clones amongst CDSM strains at MIC≥4mg/L as observed 
in this hetereogeneity experiment shows the possibility of it reverting into a CDRM strain. In 
comparism with the susceptibility range obtained in chapter 2, ribotype 027 and 106 reflected 
that there were more susceptible colonies as observed in the heterogeneity assay within the 
CDRM strains. But CDRM ribotype 001 showed clones with metronidazole reduced 
susceptibility higher than the range obtained in chapter 2. Though after individual strain 
analysis it was observed that the 2 fold increase in range was from 3 CDRM strains not 
necessarily the bulk of the strains analysed for ribotype 001.  
The range of MIC observed per ribotype, due to the heterogeneity of the colonies taken from 
strains tested to metronidazole and vancomycin was moderate, mostly spanning between two 
to five MIC’s however the widest was observed in ribotype 001 to metronidazole from 0.125 - 
32mg/L (CDRM). Amongst the 3 ribotypes CDRM strains tested, C. difficile ribotype 106 had 
the highest heterogeneity to metronidazole and vancomycin. While amongst the CDSM strains 
ribotype 106 also showed a higher heterogeneity to vancomycin than that observed in ribotypes 
027 and 001.   
Susceptible strains for C. difficile ribotype 106 showed a higher degree of heterogeneity to 
metronidazole and vancomycin compared to the CDRM strains. There was a similar 
observation in the C. difficile ribotype 001 group to metronidazole. C. difficile ribotype 027 
CDRM strains showed a higher heterogeneity to metronidazole compared to susceptible strains 
but the reverse was observed to vancomycin. Therefore, the heterogeneity rates of CDRM 
versus CDSM was different with different ribotypes and antibiotics.   
As was mentioned above, an average of 16 colonies for a total of 48 strains (CDRM and CDSM 
strains) were tested for heterogeneity in MICs to metronidazole and vancomycin. On analysing 
the total number of strains in this research irrespective of ribotypes, it was showed that with an 
almost negligible difference the number of heterogeneous strains were more with 
metronidazole than vancomycin.  
The heterogeneity in metronidazole MICs observed among the CDSM strains, explained earlier 
was not reflective of the data from an earlier report that reported susceptible C. difficile strains 
were homogeneous to metronidazole (Peleaz et al., 2008). However, the ribotype(s) evaluated 
in those experiments were not stated, so it could be that different ribotypes were studied (Peláez  
et al., 2008). In the present study, the heterogeneity in MICs of ribotype 001 strains 
corresponded with the observations of a previously published study, where three strains of 
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ribotype 001 were analysed with agar incorporation and agar dilution methods, and on all four 
strains showed heterogeneity in metronidazole MICs and elicited between two to five MICs 
(Moura et al., 2012).   
The summary of MIC results for all strains in this study for both antibiotics indicated that the 
number of heterogeneous strains compared to non-heterogeneous strains was more than 50%. 
This is concerning and could contribute to uncertainty in the analysis and interpretation of 
clinical MIC data, if scientists do not select a mixture of colony forming units to test; 
experimentation involving just one colony would not represent the whole population (Weel et 
al., 1996). It could also be a concern clinically as a decrease in the efficiency of administered 
antibiotics may also be due to heterogeneity in the offending microbial population (Moura et 
al., 2012). Under a metronidazole selection pressure in the human colon, given the low faecal 
concentrations of metronidazole that may be observed in humans following oral dosing it may 
be that a proportion of the C. difficile population is not inhibited by metronidazole. For 
example, faecal concentrations of metronidazole have been demonstrated to be on average 9.3 
mg/L (Bolton & Culshaw, 1986), therefore some CDRM clones in the present study would 
have been inhibited, whereas others from the same strain would not have been inhibited; 
allowing potential clonal expansion while the selection pressure existed and compromising 
treatment. Given the much higher concentrations of vancomycin observed in faecal contents 
following oral administration, i.e. 1350 mg/L (Abujamel et al, 2013), any heterogeneity in 
MICs would likely be insignificant in its effect on C. difficile infection (CDI) treatment with 
the drug, since MICs up to the maximum observed in this study would be several hundred times 
lower than the faecal concentration. Most of the heterogeneity observed in the present study 
may not be of great impact since the accepted error in agar incorporation MIC methods is one 
doubling dilution, but the notable heterogeneity observed in this study was ≤ 15% of the total 
number of strains analysed, as the hetereogeneity was ≥2 doubling dilutions.   
Researchers should be aware that heterogeneity in MICs can be observed readily in C. difficile 
with respect to both vancomycin and metronidazole across a range of PCR ribotypes. Several 
colony forming units must be inoculated into antimicrobial susceptibility tests in order that a 
full assessment of susceptibilities can be made. Although only vancomycin and metronidazole 
were evaluated in the present study, it seems probable that for other antimicrobials, whether 
treatment agents for CDI or antimicrobials that may initiate CDI in susceptible demographic 
groups, heterogeneity in MICs will be observed which could potentially have implications for 




Conclusion and Future work 
Heterogeneity in the MIC of frontline antibiotics for CDI therapy as observed in this research 
may also pose clinical problems and this research maybe reflection of the ungoing status of 
CDI in hospitals as these strains are clinical isolates. The presence of heteroresistance in C. 
difficile has been earlier linked to therapy failure (Peleaz et al, 2008), which emphasizes the 
need for continuous surveillance 
Further research is warranted to gain a fuller understanding of the response of C. difficile to 
antimicrobial agents both in the absence and presence of an antimicrobial agent selection 



















4.0 Population analysis profiling  
4.1 INTRODUCTION  
Population analysis profiling (PAP) is a method used to determine resistant features of a 
microbial population (Berger-Bachi et al, 1986). PAP has also been used to detect three strains 
of S. aureus, resistant to methicillin (MRSA), determining its level of susceptibility to 
vancomycin (Hiramatsu et al, 1997). Though PAP has been used as a reference method in past 
experiments particularly in detection of vancomycin resistance in S. aureus, it has also been 
described in literature to be a labour intensive procedure (Satola et al, 2010). PAP was 
previously used to identify vancomycin hetero-resistant S. aureus (HVRSA) and vancomycin 
resistant S. aureus (VRSA) amongst 100 methicillin resistant S. aureus (MRSA) collected over 
a period of 16 years, in an effort to determine the prevalence of HVRSA and VRSA in clinical 
centres in the United Kingdom (Wootton et al, 2000). PAP, Hiramatsu’s screening method, an 
agar incorporation method (AIM) and antibiotic gradient plates were methods employed in the 
study done by Wootton and colleagues (2000). Though all methods had varying results, PAP 
was reported to accurately identify HVRSA in S. aureus strain MU3 and none in the hundred 
MRSA analysed (Wootton et al, 2000). Additionally, it was also previously reported in an 
experiment to evaluate the specificity and sensitivity of seven methods, that PAP was used as 
a reference method to determine the effectiveness of these seven methods used to detect S 
.aureus strains with reduced susceptibilities to vancomycin (SRSV) (Walsh et al, 2001). 
Furthermore, there have been reports on anaerobic organisms like B. fragilis where PAP was 
used to determine heterogeneity in resistance to cefoxitin (Soki et al, 2011). This method was 
also used to determine the colony forming units (CFU) of B. fragilis and E. cloacae in relation 
to antibiotic MIC’s, on exposure to different concentrations of piperacillin-tazobactam, 
ceftizoime and piperacillin, in an experiment to detect the resistant strains and antibacterial 
activity of the samples (Stearne et al, 2004). However, there are no published reports of PAP 
use with C. difficile in relation to either therapeutic agents used to treat C. difficile infection 
(CDI) or antimicrobials with a propensity to induce CDI.  
4.11 Aims  
To perform population analysis profiling of C. difficile for vancomycin and metronidazole.  
4.12 Objective  
To use agar incorporation of antimicrobial agents alongside total viable counting of 
metronidazole reduced susceptible C. difficile (CDRM) and metronidazole susceptible C. 
difficile (CDSM) strains to inform on the susceptibility of C. difficile to metronidazole and 
vancomycin at the population level.  
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4.2 METHOD  
4.21 C. difficile isolates   
Two CDRM strains and one CDSM strain was selected from UK isolates of ribotype 001, 106 
and 027 along with a control 110 strain of ribotype 010 for this experiment. The CDRM strains 
selected had metronidazole MIC in antimicrobial susceptibility test/ heterogeneity test ≥4mg/L. 
Except strain 95 after the heterogeneity test was homogenously 4mg/L.  
Table 4.1 Selected strains based on metronidazole susceptibility profile and their respective MICs 
detected in chapter 2, to be used for PAP test  
RIBOTYPE   STRAIN  MIC (mg/L)  
001 CDRM  80  8  
  86  8  
001 CDSM  114  0.5  
      
027 CDRM  95  2  
  99  4  
027 CDSM  12  1  
      
106 CDRM  108  4  
  109  4  








4.22 Population analysis profiling (PAP) test  
Each of the selected C. difficile strains was cultured on Braziers agar (LAB160, Neogen Europe 
Ltd, Ayr,  UK) plate supplemented with 2% (v/v) lysed horse blood (SR0050, Oxoid, 
Basingstoke, UK) to grow overnight in the anaerobic cabinet (N2:H2:CO2, 80:10:10) (Don 
Whitley Scientific, UK). A sterile swab was then used to transfer the C. difficile colonies from 
the agar plate to a 7ml Schaedler’s anaerobe broth (CM0497, Oxoid, Basingstoke, UK) and 
anaerobically incubated overnight. The OD600 of the overnight cultures was determined and 
used to create standardised inocula of OD600 of 0.1 in Schaedler’s anaerobe broth in duplicate. 
The C. difficile cultures were then allowed to grow until reaching the required start optical 
density (OD) (detected from a preliminary experiment that was done as an effort towards 
starting all strains at a similar range of CFU count). Then serial 10-fold dilutions of C. difficile 
cultures in peptone water (CM0009, Oxoid, Basingstoke, UK) to 10-7 were performed, then 
each dilution (20µL) was plated in duplicate onto Brazier’s agar containing antibiotics 
(metronidazole and vancomycin (Sigma-Aldrich, UK)) in doubling concentrations from 0.03–
8mg/L alongside control plates without antibiotics. Colony counts were recorded after 
anaerobic incubation (24hrs, 37oC). Total viable counts were determined from the colony 
counts, where ideally 20-200 colony forming units (cfu) were counted and colony counts were 
multiplied by the appropriate dilution factor and expressed as log10-cfu/ml, this value was 
deducted from the control (without antibiotics) log10cfu/mL. The decline obtained was 
incorporated in a graph, plotted against the respective antibiotic concentrations. This PAP test 
was designed following experiment by Wootton et al (2000). The area under the curve (AUC) 
was calculated for C. difficile strains in order to assess the population susceptibility to 









4.3 RESULTS   
CDRM strains 80 and 86 of ribotype 001 were largely unaffected by all concentrations of 
metronidazole used in this study and viable counts remained constant up until 8mg/L of drug, 
despite prior MICs of 8mg/L being observed. As shown in figure 4.1 the population decline of 
CDRM strains of ribotype 001 when exposed to antibiotics, from the control plate without 
antibiotic exposure, was negligible. Conversely, CDSM strain 114 viable counts had a rapid 
decline at 1mg/L of metronidazole (Figure 4.1).  
 
  
Figure 4. 1 Population analysis profiling (PAP) of two CDRM (80 and 86) and one CDSM (114) 




Figure 4. 2 Population analysis profiling (PAP) of two CDRM (95 and 99) and one CDSM (12) ribotype 
027 strains using doubling concentrations of metronidazole (mg/L) in Oxoid Wilkin’s Chalgren agar.  
  
Ribotype 027 viable counts of CDSM strain 12 and CDRM strain 95 showed a rapid viable 
population decline only after exposure to 2mg/L. Viable counts of CDRM strain 99 were 
unchanged until exposure to 4 mg/L metronidazole (Figure 4.2)  
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Figure 4. 3 Population analysis profiling (PAP) of two CDRM (108 and 109) and one CDSM (120) 
ribotype 106 strains using doubling concentrations of metronidazole (mg/L) in Oxoid Wilkin’sChalgren 
agar.  
Rapid decline in viable counts of CDRM strain 108 was not observed until 2mg/L 
metronidazole CDRM strain 109 was inhibited at one dilution higher of metronidazole. 
Interestingly, CDSM strain was inhibited by a very low concentration of metronidazole 
(0.25mg/L), but a pronounced reduction in antimicrobial activity of metronidazole was 
observed at a higher concentration (Figure 4.3).  
 
  
Figure 4. 4 Population analysis profiling (PAP) of C. difficile control strain E4 (ribotype 010) strains using 
doubling concentrations of metronidazole and vancomycin (mg/L) in Oxoid Wilkin’s Chalgren agar.  
  
Control C. difficile strain E4 coded as 110 (Figure 4.4) was inhibited by 8mg/L metronidazole 
and viable counts were constant at lower concentrations of the drug. For vancomycin, C. 
difficile strain E4 was inhibited to below the limit of detection by 0.5mg/L. The AUC for 
metronidazole and vancomycin were calculated to be 16.14 and 59.69 respectively for this C. 
difficile strain.   
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Figure 4. 5 Population analysis profiling (PAP) of two CDRM (80 and 86) and one CDSM (114) 
ribotype 001 strains using doubling concentrations of vancomycin (mg/L) in Oxoid Wilkin’s Chalgren 
agar.  
  
 Ribotype 001 CDRM strains 80 and 86 behaved similarly in this experiment with vancomycin and 
were both inhibited to below the limit of detection at 1mg/L of drug (Figure 4.5). CDSM strain 114 
appeared less susceptible to vancomycin and required exposure to 4mg/L of drug before viable counts 
declined below the limits of detection.  
 
Figure 4. 6 Population analysis profiling (PAP) of two CDRM (95 and 99) and one CDSM (12) ribotype 
027 strains using doubling concentrations of vancomycin (mg/L) in Oxoid Wilkin’sChalgren agar.  








Vancomycin concentration (mg/L) 
  













Figure 4. 7 Population analysis profiling (PAP) of two CDRM (108 and 109) and one CDSM (120) 
ribotype 106 strains using doubling concentrations of vancomycin (mg/L) in Oxoid Wilkin’sChalgren 
agar.  
  
All the three strains tested of ribotypes 027 and 106 were inhibited by low concentrations of 
vancomycin and viable counts were below the limit of detection following exposure to  
1mg/L vancomycin for all ribotype 027 and 106 strains (Figure 4.6 and Figure 4.7)  
 
Table 4. 2 Area under the curve (AUC) data for the 3 C. difficile ribotypes analysed for PAP test, for 
metronidazole and vancomycin  
 
  













The AUC data was directly proportional to susceptibility of the organism thus increased AUC 
equals increase in susceptibility to the inciting antibiotics (Table 4.2) (Note: this is as a result 
of the graph used to detect the AUC Fig 4.1-4.7).  CDSM strains were observed to have higher 
AUC compared to CDRM strains when exposed to metronidazole (Table 4.2). All strains had 
higher AUC on exposure to vancomycin, however ribotype 001 and 027 CDSM strains had 
lower AUC compared to CDRM strains of the same ribotypes on exposure to vancomycin. The 





























4.4 DISCUSSION  
Heteroresistance is of unknown significance in CDI in terms of its contribution to the efficacy 
of treatments and also the induction of CDI, but for S. aureus, heteroresistant methicillin 
resistant S. aureus (MRSA) are a complication for treating infections. This study was carried 
out to examine in greater depth the effects of metronidazole and vancomycin on CDRM and 
CDSM of UK origin using a PAP method which has been employed previously as a reference 
method in detecting antimicrobial heteroresistance in bacteria. Due to the laborious nature of 
PAP methods, only a selection of C. difficile strains were analysed, i.e two CDRM and one 
CDSM per ribotype, in addition to a control strain (E4, CDRM coded as 110).  
It is important to note that the viable counts of the cultures used in the present studies were 
more variable than those that were used in standard MIC testing experiments (see 2.22). This 
is due to the nature of PAP and the fact that mid-log phase cultures are preferable for these 
experiments in comparison to the overnight cultures used in standard MIC testing which are 
likely to be late-log phase or early stationary phase. Also, there is substantial variability 
between the viable counts that result from different C. difficile cultures of different strains with 
the same apparent OD600 (data not shown). Despite these experimental challenges, the present 
study results are interesting and are additive to the data generated in previous chapters. C. 
difficile strain E4 which was used as the control in the present study (ribotype 010) was 
inhibited in the present study at 8mg/L metronidazole, which reflected the expected MIC range 
of 4-16 mg/L for this strain.  Furthermore, the data generated following exposure to 
vancomycin also correlated with the expected MIC to this drug of 0.5mg/L.  
All ribotypes with the exception of strain 114 of ribotype 001 showed a higher susceptibility to 
vancomycin than metronidazole in this PAP study. Strain 114 amongst all the susceptible 
strains showed reduced susceptibility to vancomycin in this PAP study. Though the 
susceptibility test in chapter 1 showed an MIC of 2mg/L, the reduced susceptible phenotype 
observed in this PAP test has earlier been detected in the hetereogeneity test, where 11 clones 
had a vancomycin MIC of 4mg/L of the 17 clones, of strain 114 analysed.  The mechanism of 
action of vancomycin targets the peptidoglycan precursors during cell wall synthesis and 
previous research of Staphylococcus strains resistant to vancomycin identified that the reason 
could be the hardening of the cell wall (Hiramatsu et al., 1997). There are no published 
explanations for reduced susceptibility to vancomycin in C. difficile, and this phenomenon has 
been reported in previous studies (Freeman et al., 2015). This PAP test showed that ribotype  
001 CDRM strains were reduced susceptible to metronidazole and increases in metronidazole 
concentrations up to 8mg/L had little or no effect on the viable counts of the CDRM strains 
tested. The maximum concentration of 8mg/L was selected based on the previous MIC data 
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generated for the strains in this PAP study from Chapter 2. All ribotype 027 strains showed 
reduced susceptibility to metronidazole including the CDSM which was expected to be 
susceptible to metronidazole. The reason for this CDSM strain persisting in the presence of 
metronidazole at concentrations higher than the apparent MIC is interesting and may be 
explained by a slightly higher inoculum used in the present study, or perhaps it may be evidence 
that persistence/tolerance may be possible for C. difficile strains. The CDRM strains of 106 like 
the other 2 ribotypes were not susceptible to metronidazole however decline in CFU for strain 
109 and 108 started on exposure to a metronidazole concentration of more than 2mg/L and 
4mg/L respectively. Though it has been mentioned repeatedly in literature that PAP is one of 
the most reliable of the susceptibility test available, there has been no mention of PAP with 
relation to C. difficile in earlier research.  
Ribotype 106, strain 109 that had reduced susceptibility in antimicrobial test and was observed 
to be susceptible in heterogeneity test was however confirmed to be reduced susceptible to 
metronidazole in PAP. While strain 108 of ribotype 106 strain showed reduced susceptibility 
to metronidazole in the three methods however the heterogeneity test revealed that its colonies 
were a mix of susceptible colonies and colonies with reduced susceptibility to metronidazole 
such cases could have adverse therapeutic implications.  
The reliability of PAP as seen in this research confirmed earlier works which also observed 
susceptibility to vancomycin amongst 330 C. difficile strains (Pituch et al., 2011). The 
susceptibility in 001 ribotype to vancomycin has also been observed in earlier research using 
agar incorporation and Etest (Baines et al., 2008).  
The AUC data reflected the results obtained in the figures in more detail. The lowest AUC was 
observed in ribotype 001 CDRM strains which depicted a high level of reduced susceptibility 
in comparison with the other ribotypes this was observed in chapter 2 where 001 ribotype was 
observed to have the highest level of reduced susceptibility. The AUC also observed the 
susceptibility of CDSM strains to metronidazole in comparison with CDRM strains. As well 
as the susceptibility of all strains to vancomycin in a higher level compared to metronidazole 
(except CDSM strain 114 as previously described) thus the population analysis profile confirms 
susceptibility results obtained in chapter 2 and 3.    
The reliability of the method used was also observed in ribotype 001 and 106 with the reduced 
susceptibility seen in strain 12 showing susceptibility at 4mg/L and rebounce of strain 120, 
both strains earlier observed to be susceptible to metronidazole. The rebounce of strain 120 
could be as a result of presence of subpopulations with reduced susceptibility to metronidazole 
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which was selected and able to undergo clonal expansion due to the clearance of majority of 
strain 120 populations susceptible to metronidazole (Baines et al, 2008).  
Conclusion and future work 
This PAP test confirmed most of the susceptibility profile observed in chapter 2 and 3. The 
detection of the AUC of a standard C. difficile heterogeneous strain, would have aided more 
information, to be obtained with respect to heterogeneity. This could be a further work as the 























5.0 Stability and mutability of C. difficile with reduced susceptibility to metronidazole   
5.1 INTRODUCTION  
In the clinical environment, bacteria exposed to antimicrobial agents are exerted to a selection 
pressure, which depending on the antimicrobial agent, its concentration and mechanism of 
action, may facilitate the development of single nucleotide polymorphisms (SNPs) within the 
genome of the bacterium.  
Serial passage experiments in the presence and absence of antimicrobial agent selective 
pressures are employed mainly in research settings to assess the stability and mutability of 
microorganisms that are of wild-type, or mutated genotypes/phenotypes. Cell expansion is 
required to generate sufficient results from laboratory experiments such as antibiotics 
susceptibility and resistance, growth rates studies etc, hence the practice of serial passage 
(Stothard, 1998). Though not all diagnosis require cell expansion, these information generated 
from laboratory experiments might be applied clinically which could be affected by lack of 
monitoring the serial passage procedure.  
Serial passage studies involve the sequential repetition of cell expansion without constant 
contact with the original cells and the cells grown in each step are a source of inoculum for the 
next step (Leeds et al., 2013). Serial passage experiments with antimicrobial agents can be 
carried out with elevated drug concentration (Leeds et al., 2013).  
Though a useful technique serial passage has been observed in several cases to result to or 
select for mutant cell strains (Gilbert et al., 2001) irrespective of cell type. However, the 
development of mutants is strain dependent and depends on the condition of growth (Gilbert et 
al., 2001).  
5.1.2 Development of resistant mutant microorganisms on continuous exposure to antibiotics.  
 
Serial passage experiments have been used to study the likelihood and stability of developing 
antimicrobial resistance in a range of pathogens. Gilbert and colleagues (2001) studied 123 
microbes including Serratia marcescens, Pseudomonas aeruginosa, methicillin susceptible 
and methicillin resistant strains Staphylococcus aureus, Enterobacter cloacae and Escherichia 
coli were exposed to three fluoroquinolones and serially passaged 10 times. Before the serial 
passage, the minimum inhibitory concentration (MIC) that inhibited 50% of the C. difficile 
strains studied (MIC50) for all microbes analysed and for all fluoroquinolones was within the 
range 0.004 – 0.5µg/ml, after serial passaging the MIC50 was within the range 0.25-256 µg/ml. 
Though there was variation in the onset of resistant bacteria with respect to the bacteria and 
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the drug used, the research deduced that the use of serial passage could select for bacteria 
resistant to fluoroquinolone (Gilbert et al., 2001).  
Furthermore, Drago et al. (2005) carried out a research working with nosocomial isolates of 
Acinetobacter spp and Pseudomonas aeruginosa exposed to 2 fluoroquinolones individually 
as well as in combination with amikacin and four β-lactams. Five serial passages were 
performed individually with the seven antimicrobials used and then five serial passages with a 
combination of antimicrobials (Drago et al., 2005). It was observed that after the first passage, 
all strains of P. aeruginosa had significantly elevated (minimum inhibitory concentrations) 
MICs, when passaged with individual antibiotics. All strains that were initially susceptible to 
imipenem and amikacin became resistant after the first passage, and most P. aeruginosa strains 
had become resistant after the fifth passage (Drago et al., 2005).  
    
After the first serial passage involving the addition of amikacin or β lactams to 
fluoroquinolones, there was a fourfold increase in MIC for all except one antibiotic 
combination in at least one strain. Also onset of resistant P. aeruginosa strains were greatly 
reduced even after the fifth passage compared to the single antibiotics administration, where  
≥ 3 strains developed resistance for each antibiotic tested, except for imipenem that had no 
resistant strain (Drago et al., 2005).  
Acinetobacter was more susceptible to the single antibiotics than P. aeruginosa however 
resistant strain was observed after the final passage to all antibiotics except imipenem. 
Significant elevated MIC and resistant strains was also observed after last serial passage when 
serial passage was done with combinations of antibiotics but at a reduced rate compared to 
single antibiotics (Drago et al., 2005).  
  
Interestingly serial passage has also been observed to affect metabolic activity in bacteria, as 
reported in a six week serial passage study of Staphylococcus aureus. Production of the citric 
acid cycle enzyme aconitase, which has previously been observed to affect the production of 
virulence factors in S. aureus, was assessed. A decrease in aconitase activity was observed after 
the first week of serial passage experiments compared to parent strain and a 38% (P<0.001) 
decrease in aconitase activity was then observed after the sixth week. Conversely, a 12% 
increase in growth yield was observed in S. aureus derived from the sixth week of serial passage 
experiments (Somerville et al., 2001). Therefore, these data suggest that it is important to 
consider the physiological changes that may occur in bacteria during serial passage 
experiments, independent of exposure to sub-inhibitory concentrations of antimicrobial agents, 
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and that these changes may indirectly affect a microorganism to influence growth and/or 
antimicrobial susceptibilities.  
5.1.3 Development of resistant anaerobes on exposure to antibiotics  
 
Many strains of anaerobic bacteria have been assessed for their propensity to mutate following 
exposure to sub-inhibitory concentrations of metronidazole. Larson and Fiehn (1997) studied 
metronidazole resistance development in strains of: Actinobacillus, Fusobacteroium, 
Peptostreptococcus, Porphyromonas, and Prevotella and these researchers detected resistance 
development to metronidazole (Larsen and Fiehn, 1997). MICs of most strains for 
metronidazole were ≤ 0.5mg/L, whereas serial passage experiments in the presence of sub-
inhibitory concentrations of metronidazole increased metronidazole MICs 1-32 fold (Larsen 
and Fiehn, 1997). Serial passage in the absence of antimicrobial agents, and therefore in the 
absence of a selection pressure, may result in MICs declining and a reversion of a wildtype 
genotype/phenotype. Gal and Brazier (2004) reported that a decrease in MIC was observed in 
several metronidazole-resistant Bacteriodes fragilis strains, serially passaged seven times in 
the absence of metronidazole (Gal and Brazier 2004). Conversely, in a study of a 
fluoroquinolone-resistant Bacteriodes fragilis strain, the strain mutated following exposure to 
the fluoroquinolone sparfloxacin. Serial passage for 10 days and monitoring of MICs using 
broth microdilution, demonstrated stability in the resistant phenotype (Peterson et al., 1999). 
Therefore, the likelihood of resistance development following serial passage experiments and 
the stability of the resistance phenotype/genotype may be species and/or antimicrobial agent 
dependent.  
  
5.1. 4 Serial passage experiments with Clostridium difficile  
 
Serial passage studies with Clostridium difficile have been performed previously, and have 
predominantly examined novel or existing antimicrobial agents for the treatment of CDI. Leeds 
and colleagues (2013) performed ten serial passages on four C. difficile strains, strains 
(ATCC43255, and 3 other clinical isolates REA type AA, REA type J, and an untyped isolate) 
using three antimicrobial agents to provide a selective pressure, i.e. vancomycin, LFF571 (a 
novel therapeutic in development), and fidaxomicin. Two of the strains showed ≥ 8-fold decline 
in susceptibility to vancomycin and fidaxomicin at different points during the serial passage 
experimental time series. REA type AA demonstrated less than a 2-fold change in MIC to 
fidaxomicin and vancomycin, whereas REA type J susceptibility to fidaxomicin after 10 
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passages yielded a 4-fold shift. These susceptibility changes were however not observed to the 
novel antimicrobial agent LFF571 after employing serial passage technique. Whole genome 
sequencing was performed and mutations in strains with reduced susceptible phenotypes were 
analysed. Change in susceptibilities was linked with many pathways including mutations in the 
proteins MarR (fidaxomicin-exposed C. difficile) and MurG (vancomycin), which are 
implicated in the activation of antibiotic resistance/oxidative stress responses and 
peptidoglycan precursor transfer during cell wall synthesis in bacteria. The authors of this study 
concluded that continuous serial passage overtime predisposes to genetic mutation (Leeds et 
al., 2013).   
Surotomycin is an orally administered bactericidal cyclic lipopeptide antimicrobial that is in  
Phase III clinical trials for the treatment of CDI (Lee et al., 2016; Biox et al, 2017) C. difficile, 
Enterococcus faecalis and Enterococcus faecum were exposed to an oral lipopeptide antibiotic 
CB 183,315 also known as surotomycin (Mascio et al., 2014). Serial passage experiment was 
done under selective pressure to detect multistep resistance and with the exception of one 
strain, no change was observed by the 15th day (Mascio et al., 2014). Also SMT19969, one of 
the novel agents used for therapy in C. difficile infection (CDI) cases was observed for stability 
in susceptibility as C. difficile strains were serially passaged for more than 14 days within 
subinhibitory concentrations of the drug. Amongst all the isolates tested 31 were of 027, 001 
and 106 ribotype. No change in MIC of SMT19969 was observed (Vickers et al., 2011).  
C. difficile strains have also previously been exposed to cadazolid in serial passage 
experiments; this antimicrobial is a novel oxazolidinone-fluoroquinolone hybrid antimicrobial 
currently in phase III clinical trials for treating CDI, acts by preventing protein synthesis and 
is, at an higher concentration, involved in DNA synthesis inhibition (Locher et al., 2014). The 
experiment involved 13 passages which resulted in MIC increases after about 3 steps on 
exposure to linezolid and cadazolid (Locher et al., 2014). However, the increase cadazolid 
MICs observed were reported to be insignificant, whereas 16-fold MIC increases were 
observed against moxifloxacin (Locher et al., 2014).  
Development of resistance to antibiotic can occur in vivo following exposure to antimicrobial 
agents in the clinical setting. In the laboratory, scientists can mimic the exposure of 
microorganisms to antimicrobial agents using serial passaging experiments with sub-MIC of 
antimicrobials, in order to assess the propensity of antimicrobial agents to select for resistant 
clones. Additionally, the stability of a resistant (or reduced susceptible) genotype/phenotype 
can be studied in vitro to assess the likelihood of reversion of the phenotype/genotype to the 
wild-type distribution in the absence of the antimicrobial agent selection pressure.  
Metronidazole is one of the frontline antibiotics for treating CDI, therefore if selection of 
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resistant mutants occurred at a high mutation frequency then this would impact on the use of 
this antimicrobial agent in the clinical setting.   
  
5.1.5 Aim  
Assessment of the stability of the Metronidazole Reduced susceptible C. difficile strains 
(CDRM) phenotype and the propensity to elevate metronidazole MICs in C. difficile.   
  
5.1.6 Objectives  
To assess the stability of the CDRM and Metronidazole susceptible C. difficile strains (CDSM) 
phenotype using serial passage experiments in drug-free medium and monitor any changes in 
metronidazole and vancomycin MICs using an agar incorporation MIC method.  
 To use serial passage experiments with vancomycin and metronidazole. 
 To expose CDRM and CDSM strains to sub-inhibitory concentrations of antimicrobials and 



















5.2 METHOD  
5.21 C .difficile strains  
Thirty seven strains of CDRM from three PCR ribotypes: 027, 001, and 106 were evaluated in 
this study, compared with 11 CDSM strains of the same ribotypes, in addition to two control 
strains E4 and ATCC700057 (ribotypes 110 and 111 respectively). The susceptibilities to 
metronidazole and vancomycin were confirmed by determining the minimum inhibitory 
concentrations (MIC) of these antibiotics using the same method as described previously in 
2.22.   
  
5.22 Serial passage without antibiotic exposure in drug free medium  
C. difficile strains were grown on Columbia blood agar (PB0122, Oxoid, Basingstoke, UK), 
then sterile pre-reduced Schaedler’s anaerobe broth (CM0497, Oxoid, Basingstoke, UK) was 
inoculated and incubated anaerobically overnight at 37oC MIC was determined using agar 
incorporation method on Wilkins Chalgren agar as described in section 2.21.   
The strains were then retrieved from individual blood agar plates and re-cultured on fresh blood 
agar, then Schaedler’s anaerobe broth was inoculated and MICs were then determined. The 
transfer of strains to fresh blood agar from the previous step was repeated continuously until 
the 6th fresh blood agar plate was inoculated and MIC was determined at every step.  
MIC determination was perfomed for metronidazole and vancomycin.  
.  
5.23 Serial passage with sub inhibitory concentration of metronidazole  
5.23.1 C .difficile strains  
Twenty eight strains of C. difficile were selected from previous MIC testing and heterogeneity 
in MIC experiments carried out in this research reported in section 2 and 3, the selected strains 
were those with colonies showing MIC of ≥2mg/L. Thirteen strains belonged to C. difficile 
ribotype 001, eight were from ribotype 027, and seven were from ribotype 106. In addition to 
the CDRM strains evaluated, two CDSM strains for each ribotype were also assessed in this 
experiment, along with the C. difficile E4 control (CDRM) strain.    
  
5.23.2 Serial passage  
C .difficile strains were cultured anaerobically from spore stocks at 37oC on Columbia blood 
agar, then were transferred into sterile pre-reduced Schaedler’s anaerobe broth for overnight 
incubation. MICs were determined using agar incorporation method on Wilkins Chalgren agar 
as described in section 2.22.  
78  
  
Where possible, the C. difficile strains were then retrieved from the Wilkins Chalgren agar 
containing subinhibitory concentrations of metronidazole which was mostly 2 dilutions below 
the MIC, except the colonies on that dilution was low then that strain will be retrieved from 3 
dilutions less than the MIC. The retrieved strains were resuspended in 150µl of saline. Then 
110µl of saline with respective C .difficile strains were transferred into the multipoint 
inoculator block, anaerobically. The strains were then inoculated on Wilkins Chalgen agar 
containing doubling concentrations of metronidazole from 0.03mg/L – 128 mg/L using a 36-
pin multipoint inoculator. The inoculated Wilkins Chalgren agar plates were incubated in the 
anaerobic cabinet for 48 hours. Then MIC was determined and the strains were re-cultured 
from the new MIC plates 2 dilutions below the MIC, this process was done 6 times and the 


























5.3 RESULTS  
 
The results obtained from serial passage experiment without antibiotics, differed amongst 
strains with respect to the antibiotic tested.  
  
5.3.1. Serial passage without antibiotic exposure in drug-free medium  
CDRM strains serially were passaged 5 times and MIC of metronidazole were detected at each 
passage. MIC decline was observed at the final passage compared to the initial MIC detected. 
This observation was same for all ribotypes analysed, as shown in table 1, ribotype 001 shifted 
from an initial MIC range of 0.5-16mg/L with an MIC50 of 4mg/L to 0.1252mg/L with an 
MIC50 of 0.5mg/L.  All except one CDRM strain of ribotype 001 had MIC of  
≥2mg/L at the first detection of MIC but after last passage all had MIC ≤2mg/L. Of the 22 
CDRM strains of ribotype 001 tested only 3 strains had an MIC of 2mg/L after the last passage.  
  

















   
Table 5.1. MICs of metronidazole and vancomycin against clinical C. difficile from ribotypes 027,  
106, and 001 before serial passage and after five serial passages in drug-free Oxoid Schaedler’s anaerobe 
broth.  
  Passage  
RT (N) Antibiotic 0* 1st 2nd 3rd 4th 5th 
001 CDRM  MTZ range 0.5 -16 0.25-16 0.25-8 0.125-8 0.25-2 0.125-2 
MIC50 4 4 4 2 2 0.5 
VAN range 0.5-4 1-4 0.5-4 0.5-4 0.5-4 0.06-4 
MIC50 1 2 1 1 1 1 
001 CDSM  MTZ range 0.5-2 0.25-0.5 0.25-0.5 0.25-0.5 0.25-1 0.25-0.5 
MIC50 1 0.5 0.5 0.5 0.5 0.5 
VAN range 1-4 1-4 1-4 1-2 1-2 1-4 
MIC50 1 1 1 1 1 1 
027 CDRM  MTZ range 2-8 2-4 1-2 2 1-2 0.5-1 
MIC50 2 2 2 2 2 1 
VAN range 1-2 2-4 1-2 1-2 1-2 1-2 
MIC50 1 2 2 2 2 1 
027 CDSM  MTZ range 4 2-4 1-2 1-2 2 1-2 
MIC50 4 2 1 2 2 1 
VAN range 2-4 1-2 1 1 1 1 
MIC50 2 1 1 1 1 1 
106 CDRM  MTZ range 1-4 2-8 1-4 1-4 1-2 0.5-1 
MIC50 2 4 4 2 2 1 
VAN range 0.5-1 2-4 0.5-2 1-2 1-4 0.5-2 
MIC50 1 2 1 2 1 1 
106 CDSM  MTZ range 0.5-4 0.25-2 0.25-1 0.25-1 0.25-2 0.25-1 
MIC50 0.5 0.25 0.25 0.25 0.25 0.25 
Van range 1-2 1-2 1-2 1 1-2 1-2 
MIC50 1 1 1 1 1 1 
 
Most ribotype 027 CDRM strains, showed stability with the usual strain variability of ±1 
dilution. Except strain 95 & 98 that showed a decrease of ≥2 dilutions in Metronidazole MIC. 
The CDSM ribotype 027 strains initial metronidazole MICs (passage 0) were higher than 
expected (MIC50 4 mg/L), but a gradual decline in MICs was observed as the number of serial 
passages increased, finally with MIC50 of 1mg/L after 5 passages (Table 5.1). Most of ribotype 
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106 CDRM strains increased in MIC on the first serial passage (1 doubling dilution) and then 
a general decrease in metronidazole MICs was observed but CDSM strains did not demonstrate 
any notable change in metronidazole MICs.  In contrast to metronidazole MICs, vancomycin 
MICs of all CDRM and CDSM ribotypes were stable table 5.1.  
  
Figure 5. 1. MICs of metronidazole against control C. difficile strain E4 (ribotype 010 coded as 110) before 
and after five serial passages (110sp) & 110CTL, MIC determined from spore stocks without serial 
passaging  
 
The metronidazole and vancomycin MICs observed from the serially passaged C. difficile E4 
(Figure 5.1, 5.2) (110 sp) and the control E4 strain were very similar all through the experiment 
with very little variation. There was a 2-fold reduction in MICs by the end of the experiment, 
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Figure 5. 2 MICs of vancomycin against control C. difficile strain E4 (ribotype 010 coded as 110) before 
and after five serial passages in drug-free medium and control (CTL) 110, MIC determined from spore 
stocks without serial passaging.  
  





Figure 5. 3 Geometric mean MICs of CDRM ribotype 001 strains exposed to sub-inhibitory MICs of 
metronidazole during five serial passages  
   
Statistical analysis of the figure above was done using one way Analysis of variance  
(ANOVA), demonstrated that there was statistical significance between MIC values  
(P=0.0087) as P < 0.05. Post hoc testing was done using Bonferroni’s Multiple Comparison 








0 1 2 3 4 5 
Serial passaged strain 110sp control strain MIC at each serial  










CDRM strains of ribotype 027 unfortunately died on subculture, therefore this data is lacking 




Figure 5. 4 Geometric mean MICs of CDRM ribotype 106 strains exposed to sub-inhibitory MICs of 
metronidazole during five serial passages  
Statistical analysis of the Figure 5.4 above was done using Kruskal – Wallis test and P value  
=0.1084 thus non-significant. Post hoc testing was done using Dunn's Multiple Comparison 























5.4 DISCUSSION  
The effects of serial passage without antibiotic exposure were observed to result in declines in 
metronidazole MICs of CDRM strains. As observed in table 5.1. Reduced susceptible strains 
of ribotype 001 had MIC50 shift from an initial metronidazole MIC50 of 4mg/L to 0.5 mg/L at 
the fifth passage. This decline was however not as much in other two ribotype groups of CDRM 
strains.  Conversely, vancomycin MICs were predominantly stable irrespective of C. difficile 
ribotype or the susceptibility phenotype of the strain. Therefore, serial passage was observed 
to affect the MICs of metronidazole but had no substantial effect on vancomycin MICs and it 
had a higher effect on CDRM phenotype strains of ribotype 001 than other ribotypes.   Though 
Leeds et al, 2013 have reported a decline in vancomycin MIC in 2 C. difficile strains as a result 
of serial passage but it is useful to note that the experiment reported, entailed a selection 
pressure (Leeds et al, 2013). 
Serial passage without selective pressure had little or no effect on the C. difficile control strains 
E4 for both vancomycin and metronidazole.  The CDRM control strain E4 did not lose its 
reduced susceptible phenotype despite continuous exposure to a non-antibiotic pressured 
environment as was observed in an earlier research that reported a metronidazole resistant strain 
in a patient who had not had metronidazole therapy (Schapiro et al., 2004).   
With exposure to subinhibitory antibiotic concentrations, the effect of serial passage was 
minimal irrespective of ribotype. It was however noted that most 027 strains could not be 
recovered on the first passage after the initial MIC was obtained, this was also observed for the 
027 CDSM strains after the first passage. The other 2 ribotypes CDRM strains showed MIC 
stability between passages when strains were exposed to sub inhibitory antibiotic 
concentration.  
It was also observed that the CDSM strains did not stably select for resistant phenotype at the 
end of passage for all ribotypes. Thus this test has shown that serial passage effect on 
metronidazole MIC is more when the passage environment has no antibiotic pressure. Thus the 
CDRM strains tend not to retain the reduced susceptible phenotype if passaged in the absence 
of antibiotics. However, this phenotype is stable if experimental conditions of serial passage is 
performed under an antibiotic selection pressure. This finding was not in line with a previous 
research on serial passage experiments involving strains of peptostreptococcus, an increase in 
metronidazole MIC from 1-32 fold was observed (Larsen and Fiehn, 1997) though the disparity 
could be as a result of differences in microbes analysed.  
As was earlier mentioned both condition have been observed in previous literature with the 
serial passaging practice. The MIC stability observed under selective antibiotic pressure in this 
85  
  
research was also reported in a serial passage experiment with surotomycin and SMT19969 on 
C. difficile (Mascio et al., 2014; Vickers et al., 2011) 
Conclusion and future work 
In conclusion, serial passage is a technique that enable the accumulation of mutations through 
several generations (Leeds et al 2013).  The data derived in this experiment suggests that serial 
passaging of UK C. difficile under selective antibiotic pressure does not affect its susceptibility 
phenotype to metronidazole. Thus this technique under selective antibiotic pressure may not 
contribute to the development of a resistance phenotype to metronidazole but could give false 
susceptibility profile if practiced without selective pressure. Thus depicting the CDRM 
phenotype may be an unstable phenotype. These passaging could occur invivo not only in 
laboratory practice, this research has shown that it could rarely lead to a resistant phenotype. 
The instability of the CDRM phenotype could pose a problem in detecting underlying 
mechanisms that could be responsible for the CDRM phenotype. Thus the practice of this serial 
passage technique has to be limited both in research and clinically. Future work could be done 
involving more passages as well as carrying out one step passage experiments using super-
inhibitory concentrations of metronidazole as opposed to multiple step passage with sub 



















6.0 Nitroreductase assay   
6.1 INTRODUCTION    
Nitroreductase are enzymes that has been observed to reduce nitrocompounds to nonmutagenic 
compounds and to activate prodrugs (Bryant et al, 1981). Nitroreductases have been applied to 
detect chemicals in the environment as a biosensor for pollutants as well as: in the identification 
of vapours from explosives (Gwenin et al. nd). Nitroreductases could be involved in 
bioremediation e.g pnrA is a gene that encodes a nitroreductase observed to increase 
phytoremediation after it was introduced into a transgenic aspen used for phytoremediation of 
2, 4, 6 trinitrotoluene an environmental pollutant (Van Dillewijn et al, 2008).  
Nitrocompounds have been observed to be mutagenic to bacteria, as was confirmed in a 
research study involving 2,4 dinitrotoluene and 2,6 dinitrotoluene, which were shown to be 
mutagenic to Salmonella typhimurium (Padda et al, 2003). However, incidence of mutagenic 
stimulation may be lower than expected because of the conversion of nitrocompounds into their 
metabolites which are less harmful (Rafii et al, 1991). One bacterial genus observed to play a 
significant role in the conversions of nitro-compounds is Clostridium (Rafii et al, 1991). It was 
confirmed in an earlier research study which exposed faecal microbial flora of human origin to 
1-nitropyrene, that organisms with clear zones around areas of microbial growth were isolated 
and identified. Though the experiment was limited in that the faecal material was from one 
human source, it served as platform for more research (Raffii et al, 1991). The organisms that 
metabolized 1-nitropyrene as identified by the clear zones were Clostridium clostridioforme, 
Clostridium paraputrificum, Clostridium leptum, Clostridium sp and Eubacterium sp.  
The presence of nitroreductase enzymes in microrganisms has been useful clinically in 
activation of prodrugs:, e.g. 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) is a therapeutic 
agent against tumour cells has been observed to be reduced by NfsA and NfsB, which are E. 
coli nitroreductase enzymes (Knox et al, 1988, Anlezark et al, 1992, Vass et al, 2009). 
Additionally, benznidazole is a prodrug that becomes active against Trypanosomal cruzi 
following its reduction initiated by a nitroreductase (Hall and Wilkinson, 2012).   
  
6.11 Nitroreductase in anaerobic organisms  
Some nitroreductase genes have been isolated whose activation or inactivation has been 
associated with resistance to metronidazole. Metronidazole is a nitroimmidazole and a prodrug 
that requires the action of nitroreductases for its activation. Anaerobic bacteria such as 
Helicobacter pylori the cause of peptic ulcer, Bacteroides fragilis and Clostridium species 
which are normal colonic flora, that also could be pathogens, are sometimes being treated by 
antimicrobials requiring the activation by nitroreductase enzymes. As a result the activation 
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and inactivation of the genes encoding these nitroreductase enzymes, could have an effect on 
efficacy of antimicrobial therapy.  
Nitroreductase activity is naturally occurring within microorganisms, thus it does not require 
an external influence for its activity (Raffii et al, 1998) this is because it is involved in the 
normal cellular processes, e.g glucose metabolism. Nitroreductase involvement in normal 
metabolic processes was also reported in previous research by Britz and Wilkinson (1979), 
where the products of glucose metabolism in metronidazole resistant B. fragilis were compared 
with a metronidazole susceptible parent strain. It was observed that the increase in resistance 
to metronidazole was associated with a concurrent decrease in pyruvate dehydrogenase 
activity. The difference in production of other metabolic end products in the resistant B .fragilis 
strain relative to the wild type correlated to the decrease in pyruvate dehydrogenase activity 
(Britz and Wilkinson 1979).   
  
The resistant mutants were of two levels of resistance at 25µg/ml MIC & highly resistant B 
.fragilis at 100µg/ml MIC (Britz and Wilkinson 1979). A quarter of the normal dehydrogenase 
level was produced in the lower level resistant strain; and pyruvate accumulation and increases 
in lactate concentrations were also observed. There was almost no dehydrogenase activity 
observed for the highly resistant B. fragilis strain and increased levels of CO2 lactate and 
ethanol were produced. The results observed in the Britz and Wilkinson (1979) study suggested 
that resistant Bacteroides fragilis strains show lower energy yields obtained from glucose. 
When compared with normal B. fragilis, a decline in growth rates were observed in some 
resistant B. fragilis. The accumulation of pyruvate in the moderately resistant B. fragilis 
showed that it was unable to metabolize pyruvate via other pathways unlike the highly resistant 
B. fragilis.  
However, conflicting data were reported by Tabeqchali et al (1983), where pyruvate 
dehydrogenase activity was observed to be active in metronidazole reduced susceptible B. 
fragilis, (MICs of 2-8mg/L) and also in highly resistant B. fragilis strain (MIC of 64mg/L) as 
well as metronidazole – susceptible B. fragilis strains with MIC 0.5mg/L). These observations 
question the indication that pyruvate dehydrogenase activity could be associated with reduction 
in susceptibility to metronidazole (Tabeqchali et al, 1983).   
  
Nitroreductase activity is probably not the single cause of resistance to nitroimidazole, papers 
have also identified decreased uptake of antibiotics (Lacey et al, 1993). During therapy against 
Bacteriodes fragilis using metronidazole, Enterococcus faecalis has been observed to inhibit 
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the susceptibility of Bacteriodes fragilis to metronidazole by inactivating metronidazole. Thus 
the resistance of Bacteriodes fragilis to metronidazole could also be influenced by other 
microbes in the environment. (Nagy and Foldes, 1991). Metronidazole resistance in 
Bacteriodes fragilis has also been observed to be conveyed by nim genes (Gal and Brazier, 
2004).  
As was stated earlier the bacteria frequently reported for metabolising nitrocompounds that 
could be detrimental to the human health was isolated and identified to be of Clostridium genus. 
Clostridia were identified to metabolise -1- nitropyrene and associated compounds to amine 
derivatives (Rafii et al, 1991). This conversion was carried out by a nitroreductase which was 
confirmed using a nitroreductase assay. The nitroreductase enzyme was further characterised 
to be extracellular, requiring anaerobiosis for its activity as well as an optimal pH of 8 (Rafii 
et al, 1991). The isolates comprising of Eubacterium sp, Clostridium leptum, Clostridium 
clostridioforme, Clostridium paraputrificum and Clostridium sp all showed nitroreductase 
activity without the addition of FAD except Clostridium sp. One distinct nitroreductase was 
identified per isolate (Rafii et al, 1991). The redox potential necessary for the reduction of 
metronidazole is -450mV (Edwards, 1980). The reduction of metronidazole not only activates 
the bactericidal effect of the drug but also increases its concentration intracellularly (Edwards., 
1980)  
Sisson et al., 2002 determined the specificity of a range of nitroreductase enzymes e.g Pyruvate 
oxidoreductase (POR), RdxA, FrxA in activating of certain nitrocompounds:  
Metronidazole nitrofurans and nitazoxanide. It was elucidated that POR reduced nitrofurans 
but not to the same extent as FrxA, all three nitroreductases reduced nitazoxanide. The only 
nitroreductase that reduced metronidazole in Helicobacter pylori (H. pylori) was observed to 
be RdxA (Sisson et al., 2002). This paper not only identified the nitroreductase specific for 
metronidazole but also showed that some nitroreductase enzymes can activate multiple 
substrates. The rdxA gene encodes an oxygen insensitive NADH nitroreductase activity and 
was also identified as a potent contributor to metronidazole resistance as a functional rdxA 
gene from H. pylori was transformed into normally metronidazole resistant E. coli and H. pylori 
and both strains became susceptible to metronidazole (Goodwin et al, 1998). Goodwin et al, 
(1998) paper also proposed that mutations in rdxA causing resistance could be as a result of 
continuous use of the drug and this supports Jenks et al, (1999) who worked on mice and found 
rdxA to be stable when not exposed to metronidazole. Resistance to metronidazole was linked 
to mutation in rdxA following exposure to metronidazole (Jenks et al., 1999). However, the 
resistant phenotype was observed to be stable despite consecutive subcultures in the absence 
of metronidazole (Jenks et al., 1999). Not all resistant H. pylori had a mutation in the rdxA 
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gene, thus showing the involvement of other factors in conferring resistance in H. pylori (Jenks 
et al., 1999).  
Another nitroreductase that has been implicated in metronidazole resistance is frxA, which 
encodes an oxygen insensitive NAD(P)H - flavin nitroreductase (Sisson et al., 2002).  
Comparison of the gene sequence of 9 pairs of rdxA and frxA susceptible and resistant in H. 
pylori, identified mutations linked to either of these genes in 8 of the pairs however one pair 
had no obvious mutation in rdxA, frxA and recA a gene for DNA repair in bacteria (Marais et 
al, 2003). RecA of H. pylori was identified to also contribute to metronidazole sensitivity by 
identifying the effects of mutant recA in H. pylori this as well affected DNA repair and 
transformations (Marais et al, 2003).   
On frxA it was identified that frxA without mutation on rdxA gene can confer resistance to 
metronidazole in H .pylori as one of the 8 metronidazole resistant strains had mutation only in 
frxA gene not in rdxA. The role of frxA was further emphasized in a transformation experiment 
using frxA from a H. pylori susceptible to metronidazole, which was inserted into a 
metronidazole resistant E. coli which became susceptible. Thus it was suggested that frxA by 
itself could affect susceptibility metronidazole (Marais et al, 2003).  
 A similar experiment was performed by Kwon et al, (2000) transferring frxA from a 
metronidazole resistant H. pylori cloned gene into metronidazole sensitive H. pylori (minimum 
inhibitory concentrations (MIC) = 0.5-1 mg/L) yielded moderate level resistance to 
metronidazole (MIC =32mg/L). Metronidazole sensitive H. pylori strains had increased level 
of MIC (32mg/L) when their rdxA genes were inactivated (Kwon et al, 2000)   also one strain 
was reported to have Metronidazole MIC increase to 128mg/L, thus showing the possibility of 
the inactivation of rdxA being involved in metronidazole resistance (Kwon et al, 2000).   
  
Nitroreductase assay was carried out on Clostridium species resistant to nitrofurantoin. The cell 
free supernatant of the isolates mutants or wild type also metabolised nitrofurantoin which was 
detected by the disappearance of the nitrofurantoin peak using high performance liquid 
chromatography (HPLC). The use of cell free supernatant further indicates that nitroreductases 
are extracellular, and confirmation of nitroreductase presence was detected by the conversion 
4- nitrobenzoic acid to 4 aminobenzoic acid (a known role of nitroreductases (Rafii et al., 
1991). Using a Nitrofurantoin susceptible bacillus a bioassay was used to detect that 
nitrofurantoin was converted to a non-bactericidal substance by 2 of the mutants. This research 
confirms that both susceptible and resistant Clostridium species could produce nitroreductase 
but would convert substrate to different metabolites (Rafii and Hansen, 1998). This same 
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characteristics was observed in Enterococcus casseliflavus and Enterococcus gallinarum (Rafii 
et al, 2003).  
Nitroreductase activity can be assayed for by measuring the conversion of 4- nitrobenzoic acid 
(PNBA) to 4-amino benzoic acid (PABA) which is an action carried out by the enzyme (Rafii 
et al., 1991) the concentration of PABA is quantified by the production of a purple azo dye that 
occurs after a series of reaction that ends with addition of N-(1-Naphthyl) ethylenediamine 
dihydrochloride (NEDD) to produce the azo dye that is measured using spectrophotometer.   
 
6. 1.2 Aim  
To analyse metronidazole reduced susceptible C. difficile strains (CDRM) from each ribotypes 
001, 106 and 027 were selected along with metronidazole susceptible C. difficile strains 
(CDSM) strains and for nitroreductase activity.  
6.1.3. Objectives  
Use of a spectrophotometry-based nitroreductase assay for the conversion of 4-nitrobenzoic 
acid (PNBA) to 4-aminobenzoic acid (PABA) in Metronidazole reduced susceptible C. difficile 













6.2 METHOD  
6.21 Clostridium strains  
CDRM strains from ribotypes 001 (n=4), 106 (n=2), and 027 (n=5) were analysed in this 
experiment alongside CDSM strains 001 (n=2), 027 (n=1). Control strains 110 (E4) and 
111(ATCC 70057) were incorporated into these experiments alongside Clostridium 
prefringens (Rafil et al, 1991) which was previously reported as a nitroreductase positive 
control (Rafil et al, 1991).  
6.22 Nitoreductase assay                                    
Overnight culture of Clostridium difficile strains in BHI broth (CM1135, Oxoid, Basingstoke, 
UK) were standardized to OD600 = 0.1 in sterile BHI broth. Then 500µg/ml of 4-nitrobenzoic 
acid (PNBA) (101553376 Sigma Aldrich, Poole UK) was added in a 1:10 dilution to new 
culture anaerobically and allowed to incubate for two hours. The culture mixture was then 
centrifuged for 30 mins at 4000rpm. Subsequently, the 4-aminobenzoic acid (PABA) (Sigma 
Aldrich, Poole UK) concentration in supernatant was detected by adding the following 
chemicals at 1 in 10 dilution as was described in Rafii et al., 1991.  
Trichloroacetic acid (0.21% w/v) (11964921 Fisher Scientific, Loughborough, UK) thereafter, 
sodium nitrite (0.007%w/v) (563218, Sigma Aldrich, Poole, UK) was added and incubated at 
room temperature for 20 minutes. Next ammonium sulfamate (0.04%w/v) (51512, Sigma 
Aldrich, Poole, UK) was added to neutralize the sodium nitrite following a 3min incubation 
period at room temperature. After NEDD N-(1- Naphthyl) ethylenediamine dichloride (NEDD 
0.35%w/v) (1001844308, Sigma Aldrich Poole, UK) was added to a mixture to yield a purple 
dye. The PABA concentration was then determined using a Spectrophotometer (Cecil 
instruments, Cambridge, England) set to an absorbance of 540nm (Rafil et al, 1991)., one unit 









6.3 RESULTS  
Table 6. 1 Nitroreductase (Nit) activity demonstrated by Clostridium difficile strains from ribotypes 001, 
027, 106 using a spectrophotometry based PNBA reduction assay at 540nm.  
  
   
C. difficile ribotype  Number of CDRM strains 
nitroreductase positive (%)  
Number of CDSM  
strains nitroreductase 
positive (%)  
001  
   
1(25)  0(0)  
027  0(0)  
   
0(0)  
106  2(100)  
   
No strains analysed  
 The strains with positive enzyme activity were all approximately one enzyme unit which was very 
low. Variability was also observed in this assay. 
  
C. perfringens ATCC 3626 demonstrated nitroreductase activity in the assay but the two 
internal C. difficile control strains did not. Only a low proportion of CDRM strains 
demonstrated nitoreductase activity. None of the CDSM strains analysed showed detectable 










6.4 DISCUSSION  
This research has shown that majority of C. difficile strains were nitroreductase negative with 
the exception of three strains using the method of detection described by Rafii et al., 1991 
where Clostridium species actually showed positive nitroreductase activity. Although the 
nitroreductase assay used in this experiment yielded positive nitroreductase data for the C. 
perfringens strain used as a positive control, there was inconsistency in the data generated from 
C. difficile strains, both clinical CDRM isolates and CDSM isolates and in the internal control 
strains used.  
  
Rafii et al., 1991 stated that the nitroreductase activity was extracellular and constitutive 
however metronidazole activation has been reported to occur intracellularly (Edwards and 
Mathison 1970). It has also been stated previously that nitroreductase enzymes are substrate 
specific (Sisson et al, 2002) thus there is a possibility that the nitroreductase enzyme 
responsible for conversion of PNBA to PABA is extracellular and that of metronidazole is 
intracellular. The method used in the present study was following the method reported for the 
detection of nitroreductase activity in wild type bacteria and nitrofurantoin resistant mutants 
(Raffii et al, 1998). Nitrofurantoin is a nitrofuran antimicrobial agent and this group of nitro 
compounds has been identified to have redox potentials ranging from -250mV to -270mV, 
nitazoxanide has a redox potential of -360mV while that of metronidazole is -485mV (Sisson 
et al., 2002). The substrate specificity was observed to be largely linked to the redox potential 
requirement of each substrate. Therefore, in Helicobacter pylori, POR was more active to 
reduce nitazoxanide, RdxA reduced metronidazole and FrxA reduced nitrofurans, while both 
RdxA and FrxA were also observed to reduce nitazoxanide (Sisson et al., 2002). Furthermore, 
Raffii et al., (2003), has observed nitroreductase activity in metronidazole resistant 
Enterococcus species, which metabolised metronidazole to a non-bactericidal metabolite and 
the nitroreductase activity was detected by measuring PABA production. It was also elucidated 
that PNBA conversion was not affected by the presence of metronidazole thus there was no 
substrate competition which should not be the case when PNBA was converted and 
metronidazole metabolised (Raffii et al., 2003), this further emphasizes the likelihood of 
different reductase enzymes involved in the nitroreduction in bacteria.  Thus indicating that 
perhaps the conversion of PNBA to PABA might be performed by specific nitroreductases, 
distinct from those responsible for the activation of metronidazole, or perhaps this conversion 
could occur by a wide range of nitroreductases. This present research and previously published 
literature have shown that due to the substrate specificity of different nitroreductase enzymes, 
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any experiment with the aim of detecting nitroreductase activity has to be modified with respect 
to the substrate and potentially the microorganism under study.   
Conclusion and future work 
In conclusion the method employed was not efficient to detect the nitroreductase enzyme 
reduction of metronidazole, since the method detects extracellular nitroreductase. Devising a 
method using radio labelled metronidazole (Tally et al., 1978) and monitoring the decline in 
the radiolabel signal, which is proportional to the level of nitroreduction, may be a more useful 
method in correlating nitroreductase activity to the CDRM phenotype. This approach may also 
provide an insight into the level and rate of activity of reductases. Thus would likely be more 
sensitive in the detection of nitroreductase activity. 
There is yet to be a nitroreductase enzyme associated with Clostridium difficile with respect to 
metronidazole activation but as a frontline therapy for CDI, this warrants further investigations. 
Future work on the identification of nitroreductases, both intracellularly and extracellularly 
expressed are warranted in Clostridium difficile in order to more fully understand the process 
of nitroreduction in Clostridium difficile. Whole genome sequencing in C. difficile would 
identify putative nitroreductases, potential mutations (SNPs or deletions), and mutagenesis 
experiments and gene knockouts (Jeong et al, 2000, Jeong et al, 2001) targeted at the 
nitroreductases would yield valuable data on the role of these enzymes in C. difficile physiology 











7.0 Nim Genes: A Potential Mechanism of Reduced Susceptibility to Metronidazole in C. 
difficile  
7.1 INTRODUCTION  
Nitroimmidazole resistance genes (nim genes) encode for nitroreductases that aid the reduction 
of metronidazole to non-antimicrobial compounds (Schapiro et al, 2004). The contribution of 
nim proteins to reduced susceptibility to nitroimmidazoles has been reported following a 
comparative study of nim positive and nim negative Bacteroides fragilis strains. Both strains 
were exposed to a dimetronidazole, which is a 5-nitroimidazole compound. The nim negative 
strain reduced dimetronidazole to a nitroso radical anion then to 5, 5’ –azobis-(1,2-
dimethylimidazole) but the nim positive strain reduced it to 5 amino-1, 2, dimethylimidazole 
which was nontoxic to Bacteroides fragilis (Carlier et al, 1997). Thus elucidating that the nim 
positive strains code for an enzyme that reduces metronidazole to a less harmful derivative 
compared to the nim negative strains (Carlier et al, 1997). Land and Johnson (1999) correlated 
the features associated with metronidazole decreased activity, in varying organisms including 
anaerobic bacteria, parasitic anaerobic protists as well as microaerophilic bacteria. It was 
concluded that metronidazole resistance was multifactorial, but a common link was observed 
to be due to metronidazole activation which is metronidazole inactivation or lack of activation 
(Land and Johnson, 1999). The above findings from Carlier et al, 1997 showing the roles of 
nim genes have supported these statements.  
  
Mostly, nim genes have been observed in Bacteroides fragilis but there has been some 
controversy in their presence causing reduced susceptibility to metronidazole. Gal and Brazier 
(2004) analysed the susceptibilities of the Bacteriodes spp. sent to the Anaerobe Reference 
Laboratory (ARL, Cardiff, UK) and correlated susceptibility with the presence of specific nim 
genes. The total Bacteriodes species analysed were 206 isolates of human origin of which 142 
were Bacteriodes fragilis. Fifty of these isolates were observed to be nim positive out of which 
nimA was more frequently observed (Gal and Brazier, 2004). The high occurrence of the nimA 
gene in nim positive strains analysed was also observed in a 2005 research, where of 30 nim 
positive Bacteroides fragilis strains the most common was nimA gene which was more than 
half of the population (Lofmark et al, 2005).  
Another study by Schaumann et al (2005) examined metronidazole reduced susceptible, 
resistant and susceptible Bacteroides fragilis strains for the presence of nim genes. Some of 
these strains were reference strains of known nim activity. Those with reduced susceptibility 
were nim positive and those with susceptibility were nim negative. However, after serial 
passaging B. fragilis with the sub-inhibitory concentrations of metronidazole, all strains 
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demonstrate increased MICs up to >256mg/L irrespective of the nim status (positive or 
negative).This was therefore suggestive of the need for further research in elucidating 
metronidazole reduced susceptibility mechanisms in B. fragilis without ruling out the 
association of nim genes. The decreased metronidazole susceptibility is likely to be a 
multifactorial process (Schaumann et al, 2005). Consequently, it could be that increase in 
metronidazole concentrations observed in patients following antimicrobial therapy has a way 
of switching on/off genes linked either to the activation, uptake, extrusion or inactivation of 
metronidazole (Schaumann et al, 2005).   
The frequency of Bacteroides fragilis with decreased susceptibility to metronidazole was 
relatively low when the published literature in this area were analysed (Lofmark et al, 2005).  
Further to this, the frequency of  nim positive strains has also been shown to be low, as observed 
in Lofmark et al,  (2005) which showed only 30 strains out of 1502 Bacteroides fragilis strains 
analysed, were nim positive (2%) (Lofmark et al, 2005). It was also observed that nim positive 
strains had a higher propensity to show further decreases in their susceptibility when exposed 
to metronidazole in vitro compared to strains without nim genes. The stability of the 
mechanism(s) responsible for these further elevations in metronidazole MICs was 
questionable, given that less than 20% of the strains that showed elevated MIC where 
irreversibly induced. The controversy on the role of nim genes in metronidazole reduced 
susceptibility/resistance was questioned in a study where 21 nim positive anaerobe strains were 
observed to be susceptible to metronidazole (Theron et al, 2004).  
7.1.1 Presence of Nim Genes in Other Microorganisms  
Nim genes have also been identified in anaerobic Gram positive cocci, mostly of 
Peptostreptococcus species, most of which were nimB positive. However, metronidazole 
susceptibility was also observed in these nimB positive strains (Theron et al, 2004) except for 
two strains of F. magna which were resistant to metronidazole with a MIC of >128mg/L.   
A South African study identified the presence of nimA in a strain of Clostridium bifermentans 
following the analysis of 64 anaerobes, and reported the presence of nim genes in 35 anaerobes, 
including some strains of Bacteriodes fragilis and Prevotella spp and Actinomyces species 
(Lubbe et al, 1999)  
The nim gene primers were designed by Trinh and Resset in their 1996 research article. They 
designed two polymerase chain reaction (PCR) primers (nim3 and nim5) which were observed 
to lead to the amplification of a product consisting of 458bp irrespective of gene location 
(plasmid or chromosome). These primers were also identified to be specific for nim genes due 
to the absence of cross reactivity with other regions of bacterial genomes. However, the 
97  
  
sensitivity of the PCR assay was dependent on specificity and copy number of the nim target 
(Trinh and Reysset, 1996). The common nim genes identified in previous published research 
are nimA - nimF, however other nim genes have also been discovered including; nimG, nimH, 
nimJ, and nimI. NimI genes have been isolated in Prevotella species and not to be associated 
with previously identified nim-linked IS elements and were located on the chromosome 
(Alauzet et al., 2010). NimG genes were observed in Bacteriodes spp (Gal and Brazier, 2004) 
and nimJ was identified in Bacteriodes fragilis strains with a different sequence that could not 
be amplified from previously designed primers. Due to SNPs in the nucleotides encoding nimJ, 
the PCR was unsuccessful, however the amino acid sequences encoding nimJ were identical 
(Husain et al., 2013). Nagy and foldes (1991) screened Enterococcus faecalis known for the 
inactivation of metronidazole for the presence of nim genes but these facultative anaerobes 
were found to be lacking nim (Trinh and Reysset, 1997). It may have been that enterococcal 
mediated metronidazole inactivation was not due to presence of nim genes, or the universal nim 
primers cannot amplify the sequences of the nim genes of Enterococcus faecalis.  
As a result of the numerous associations of nim genes with resistance to metronidazole in 
Bacteroides fragilis, researchers have evaluated their presence in metronidazole resistant 
Clostridium difficile. However, there is yet to be a research study that has positively identified 
nim genes in Clostridium difficile with a resistant or reduced susceptible phenotype to 
metronidazole though some efforts have been made at genomic level. The first Clostridium 
difficile strain identified in UK to show reduced susceptibility to metronidazole was reported 
to show a negative result to assay for nim gene (Brazier et al., 2001). This C. difficile strain (C. 
difficile E4, ribotype 010) was isolated in a care home in Leeds and the strain possessed a 
metronidazole MIC of 16mg/L when susceptibility to metronidazole was carried out with use 
of E-test (Brazier et al., 2001). NimB is the only nim gene that has been associated with C. 
difficile in a proteomic assay (Chong et al., 2014).  
7.1.2 Aim  
To evaluate CDRM strains for the presence of nim genes. NimA –E was screened for in 3 
ribotypes, ribotype 001, 027 and 106. Susceptible and reduced susceptible strains will be 
compared.  
7.1.3 Objectives  
Polymerase chain reaction experiments will be performed to analyse CDRM strains from 
ribotypes 001, 027 and 106 for the presence of nimA – nimE as the universal primers for these 




7.2 METHOD  
7.21 Clostridium difficile strains   
Twenty eight Clostridium difficile strains were selected from previous MIC and heterogeneity 
experiments carried out earlier in this research (see Figure 3.1, 3.2 and 3.6 ) the selected strains 
were those demonstrating metronidazole MICs of ≥2mg/L. Thirteen, eight and seven strains 
were selected of ribotypes 001, 027 and 106. These strains were inclusive of two C. difficile 
strains known to have being susceptible to metronidazole (CDSM strains) for each ribotype.  
Two control strains where also involved E4 and ATCC 700057 of ribotype 010 and 038 
respectively, as well as the positive control for nimB which was Bacteroides fragilis strain BF8 
(Soki et al., 2006).  
7.22 Nim gene detection   
A suspension of C .difficile colonies for each strain was made in sterile water (100µl) (Eitel et 
al., 2013). The suspension was incubated for 15mins in 95oC then it was centrifuged at 14000 
rpm for 2mins to obtain the DNA template. This was performed for all sample strains as well 
as the positive control for nimB which was BF8 (Soki et al., 2006). PCR mixture contained  
1µl of DNA template, 1µl of primers (Primers NIM3 (5′-ATG TTC AGA GAA ATG CGG  
CGT AAG CG-3′) NIM5 (5′-GCT TCC TTG CCT GTC ATG TGC TC-3′)), 12.5µl of  
Amplitaq GoldTM PCR mastermix (10289234, Applied BiosystemsTM, Thermo Fisher 
Scientific, Loughborough UK) and 9.5-10µl of sterile distilled water. The primers used were 
the universal primers NIM-3 and NIM-5 known to be used for the amplification of nimA nimE.  
The nim genes PCR cycling conditions used were 35 cycles of: 94oC for 15seconds, 62oC for  
30secs, and 72oC for 30 seconds. The cycle was done (Eitel et al, 2013) in a thermal cycler 
(Biocompare, sanFrancisco, California, US). Then each PCR product was mixed with 2.5µl of 
loading dye and loaded in a tris boris EDTA gel, for gel electrophoresis alongside a 100bp 
ladder (1002389655, Sigma Aldrich, Poole, UK). Gel red (Biotium, Hayward, California, US) 
was incorporated in the agarose gel to enable detection of PCR products following exposure to 






7.3 RESULTS  
The nim gene PCR amplification was only observed in the nim positive control strain BF8 
(about 400 bp). All samples tested including ribotype 001 (appendix1) 027 and 106 CDSM and 
CDRM strains showed no nim PCR product (Figure 7.1)  
  
Figure 7. 1 PCR amplification of C. difficile strains and nimB positive control BF8.The first well contained 
100 base pair ladder, other wells contained C. difficile strains except the last 2 wells that contained the 













7.4 DISCUSSION  
Nim genes, as earlier mentioned, have been implicated in previous reports as being involved in 
contributing to decreased susceptibility to metronidazole in anaerobic organism such as 
Bacteroides fragilis. In the present study C. difficile PCR ribotypes 001, 027 and 106 were 
screened for the presence of nimA-E genes. Most of the strains screened were strains observed 
to be CDRM and the study also included CDSM for each of the ribotypes analysed. This 
research confirmed the absence of nim genes in C. difficile UK ribotypes irrespective of 
metronidazole susceptibility patterns. As shown in Figure 7.1, no nim genes were amplified in 
any of the ribotypes irrespective of susceptibility of the strains analysed. PCR amplification of 
putative nim was only observed in the nim positive control strain of Bacteriodes fragilis (BF8). 
Bacteriodes fragilis (BF8) as was earlier mentioned is nimB positive, positive control strains 
for the remaining nim genes could not be sourced as part of this study however, given that these 
cycling conditions have successfully amplified other nim genes previously (Eitel et al, 2013), 
had these nim genes been present then the PCR process would have successfully amplified 
them, as the primers used were universal primers for nimA-E. It is interesting that nimB was 
absent in the C. difficile strains evaluated, since research by Chong and colleagues (2014) 
suggested that nimB was present in both metronidazole susceptible and resistant ribotype 027 
variants of C. difficile.  
As earlier stated there has been some controversy correlating nim to decrease in metronidazole 
activity.  This controversy is further confirmed in an earlier research where 2% of Bacteriodes 
spp. from Hungary where reported to have reduced susceptibility to metronidazole. However 
just 5% of these decreased susceptibility strains were nim positive with the nimA and nimB 
genes (Urban et al, 2002). The present study is also in line with a previous research that 
involved observing twenty four isolates of Clostridium difficile for the presence of nim genes. 
Fourteen out of these isolates were identified to be metronidazole resistant, however nim genes 
were not found in the isolates (Pelaez et al, 2008). Whole genome sequencing was used also to 
analyse three C. difficile strains of ribotype 010 originally from Spain, one of the strains was 
reduced susceptible to metronidazole, the other metronidazole resistant, as well as susceptible 
strain. Nim genes were not observed in the genomic analysis of these C. difficile isolates (Moura 
et al, 2014).   
Conversely, a proteomic assay was carried out on three 027 ribotype strains which were 
metronidazole susceptible, reduced susceptible and resistant to metronidazole. NimB was 
detected and NimB expression was observed to be 3-fold higher in the reduced susceptible and 
metronidazole resistant strain compared to the susceptible strain (Chong et al., 2014). However, 
101  
  
these same strains had been earlier sequenced using next generation sequencing and nim genes 
were absent (Lynch et al, 2013). The possibility of nimB gene is further emphasized in the 
reclassification of C. difficile into the family of Peptostreptococcacaee that led to its renaming 
as Peptoclostridium difficile (Yutin & Galperin, 2013). The Peptostreptococci have previously 
been reported to possess nimB genes (Theron et al, 2004).  
 The present study has confirmed earlier findings showing the absence of nim in C. difficile, 
thus indicating that metronidazole reduced susceptibility may be due to factors other than the 
conversion of metronidazole into a less harmful derivative as facilitated by nim genes. It also, 
along with observations in published literature depicts the potential inability of the nim 
universal primers to identify nim sequences in all bacterial species. This issue was previously 
encountered in Bacteriodes fragilis, where the universal primers could not amplify nimJ 
because it had a different nucleotide sequence even though the proteins where same with the 
universal primers. Therefore, this would have given a false nim negative result if the research 
had been limited to PCR amplification using the universal primers (Hussain et al, 2013).   
Conclusion and Future work  
In conclusion this research has shown inability to amplify nim gene using the universal primers. 
Though, the present study did not assess at the proteomic level for the presence of Nim as in 
the study of Chong et al (2014), therefore the presence of Nim in the C. difficile proteome of 
strains in the present study cannot be ruled out. The proteomic assay which demonstrated nimB 
expression that was not identified at genomic level (Lynch et al., 2013 and Chong et al 2014) 
indicates a different gene sequence that could have similar proteins as nimB. Thus this could 
be an aspect for future research as genomic assays is yet to identify nim presence in Clostridium 
difficile.  
The submission of the C. difficile Nim protein sequence to Phyre Protein Fold recognition 
server could also aid in the comparison with other nim protein structures using Dali server 
(Hussain et al, 2013).  As well as converting the C. difficile Nim protein sequence it to its gene 
sequence, which would aid identification of genetic differences with other nimB sequences in 
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8.0 Metronidazole Uptake as a factor contributing to reduced susceptibility  
 
8.1 INTRODUCTION   
The rate or magnitude of accumulation of an antimicrobial agent in a microbe can affect the 
efficacy of the antimicrobial and ultimately the susceptibility levels of the microorganisms, as 
has been researched and reported previously for the protozoal pathogen, Trichomonads 
vaginalis (Muller and Gorell, 1983)  
Metronidazole uptake in anaerobic bacteria has been observed to be dependent on the low redox 
potential present within the anaerobes, which enables metronidazole reduction to its active 
form that causes DNA degradation and then the resultant antimicrobial effect. The reduction 
of metronidazole to its active form has been observed to aid its uptake, as the intracellular 
metronidazole concentrations decline due to activation, thus enabling further extracellular 
metronidazole to diffuse passively into cell due to the concentration gradient (Edwards et al, 
1993). However, it is notable to emphasize that antimicrobial susceptibility related to drug 
uptake could be influenced by oxygen in the environment thus reducing the redox potential, as 
well as other metronidazole uptaking microorganisms such as E. coli and E. faecalis in the 
environment that could lead to decrease in concentrations below therapeutic levels (Edward, 
1980).   
Activity of metronidazole is not solely governed by the rate or magnitude of metronidazole 
uptake or accumulation within microbes Tally et al., 1978 studied 14C-metronidazole uptake 
by E.coli and Bacteroides spp drug uptake was successful in both susceptible and resistant 
samples bacteria, however the differences in metronidazole susceptibility was due to the ability 
to metabolise metronidazole (Tally et al., 1978). Metronidazole uptake in Helicobacter pylori 
has also been previously studied (Lacey et al., 1993), where H. pylori cultures were exposed 
to metronidazole (10mg/L) and uptake was assessed indirectly using a HPLC assay to 
determine residual metronidazole left in the broth cultures. The authors cross referenced 
metronidazole uptake to the total viable count of H. pylori. It was observed that with decrease 
in metronidazole concentration in broth there was a parallel increase in Total viable counts 
(Lacey et al., 1993).  
8.1.1 Aim   
To study metronidazole uptake in C. difficile as a possible mechanism of developing reduced 




8.1.2 Objectives   
To expose metronidazole reduced susceptible C. difficile strains (CDRM) and metronidazole 
susceptible C. difficile strains (CDSM) to a fixed concentration of metronidazole and assess directly 
and indirectly the uptake of metronidazole.  
  
8.2 METHOD  
8.2.1 C .difficile strains  
CDRM strains from three PCR ribotypes: 027 (n=6), 001 (n=9), and 106 (n= 3) were evaluated 
in this study, and compared with CDSM strains of ribotypes 027 (n=2), 001 (n=1), in addition 
to two control C. difficile strains E4 coded as 110 and ATCC 700057 coded as 111 (ribotype 
010 and 038 respectively).   
8.2.2 Sample preparation  
C. difficile overnight broth cultures were used to inoculate fresh Brain heart infusion (BHI) 
broth (CM1135, Oxoid, Basingstoke, UK) standardised to 0.1OD600, and cultures were 
monitored until they reached mid –log phase of approximately 0.55OD600. Metronidazole 
(M3671, Sigma- Aldrich, Poole, UK) was then added to C. difficile cultures in duplicate at a 
final concentration of 10mg/L, alongside control cultures were anaerobically incubated 
overnight at 37oC. OD readings were obtained after overnight exposure to metronidazole and 
total viable counts were determined. The procedure for determining total viable counts 
involved serial 10-fold dilution of cultures in pre-reduced peptone water (CM0009, Oxoid, 
Basingstoke, UK) to 10-7. Next twenty microliters of cultures were inoculated in duplicate onto 
Brazier’s agar under anaerobic conditions and plates were incubated anaerobically at 37oC. 
Between 20-200 colony forming units were counted and on each replicate and total viable  
counts were determined after calculation using the dilution factor and sample volume 
inoculated onto the agar plates, with total counts expressed as log10 cfu/ml. Calibrators were 
prepared to create a standard curve to detect metronidazole concentration.  
8.2.3 Uptake assay  
A microbiological bioassay was carried out using the susceptible control C. difficile ATCC 
700057 strain as the indicator organism, to detect the presence of residual metronidazole in the 
cell free broth. An overnight broth culture of this susceptible strain in BHI broth was 
incorporated in molten Wilkins Chalgren agar before pouring into square (100mm) Petri dishes 
(11349273, SterilinTM, Fisher Scientific, Loughborough, UK). On drying, wells (10mm) were 
cut into the agar with a sterilised cork borer and 20µL of samples, controls, as well as calibrators 
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were assigned wells. The plates were then incubated anaerobically overnight, the zone of 
inhibition (mm) around calibrator and cell – free cultures of C. difficile were determined. The 
standard with known metronidazole concentration were used to plot a line graph from which 
the metronidazole concentrations of the samples solution were extrapolated.  
8.2.4 Determination of Intracellular concentration of metronidazole  
C. difficile exposed to metronidazole and controls were centrifuged to pellet cells, this cells 
were washed with sterile water to remove broth that contained metronidazole. The cells were 
then resuspended in sterile water and added to ready to use 2ml lysing matrix tubes containing 
specialised beads (Mpbiomedicals LLC, UK) which was spun to shear cells in a FastPrep -
24sample preparation system (Mpbiomedicals, California, USA) an effort to release 
metronidazole uptaken into the cells which was then used to carry out a bioassay as reported in 
section 8.2.3  















8.3 RESULTS  
  
Spectrophotometric readings were obtained as well as total viable count, after cultures were 
exposed to 10mg/L metronidazole in duplicates. The spectrophotometric readings showed as 
observed in the Figure 8.1 below, a decrease in OD600 compared to the control that was not 
exposed to metronidazole for all strains analysed except for strain 82 that had higher OD600 
higher with test samples than control samples.   
 
 Figure 8. 1 Decline in OD600 of C. difficile strains exposed to metronidazole (10mg/L) in an uptake 
assay. Showing ribotype 001 (striped bars) 027 ribotype (crossed bars), Ribotype 106 (dotted bars). 
Clear bars are control strain E4 (110) (CDRM) and ATCC 700057 (111) (CDSM). CDSM strains were 
coloured brown  
  
  
Decline in OD600 was observed to be ≤0.3 for all strains analysed, metronidazole susceptible 
C. difficile strains (CDSM) control strain ATCC700057 (111) had a higher OD decline 
compared to metronidazole Reduced susceptible C. difficile strains (CDRM) control strain E4 
(110).  
This difference was not reflected in the samples analysed between CDSM and CDRM strains. 
Ribotype 027 CDSM strains had similar values to the CDRM strains. While 001 CDSM strain 




Clostridium difficile strains 
  
  
Figure 8. 2 Decline in total viable counts (log10-cfu/mL) of C. difficile strains exposed to metronidazole 
(10mg/L) in an uptake assay. Showing ribotype 001 (striped bars) 027 ribotype (crossed bars), Ribotype 
106 (dotted bars).Clear bars are control strain E4 (110) (CDRM) and ATCC 70057 (CDSM), CDSM 
strains were coloured brown. CDSM strain 12 bar too minute to be coloured.   
  
Decline in TVC was varied with strains and was not dependent on susceptibility phenotype as 














Table 8. 1 Mean metronidazole (MTZ) concentrations detected in cell-free cultures of C. difficile strains 
exposed to MTZ (10 mg/L); using a microbiological bioassay. *only one replicate demonstrated 




MTZ (mg/L)  Ribotype  
027 strain 
code  
MTZ (mg/L)  Ribotype  
106 strain 
code  
MTZ (mg/L)  
73  0  95  0  106    
3.05*  
  
79  0  97  2.09*  107  0  
80  0  98  0  108  0  
86  1.36*  99  3.75      
82  0  100  0      
92  0  103  0      
94  0  37(CDSM)  8.4      










8.4 DISCUSSION  
Metronidazole has been reported to demonstrate bactericidal activity against C. perfringens and 
B. fragilis in vitro (Ralph & Kirby, 1975) and is generally considered a bactericidal 
antimicrobial (Nemeth, Oesch, & Kuster, 2014); which results in a 1000- fold decline in viable 
counts of bacteria. The results from the present study indicated that exposure of C. difficile 
(CDRM and CDSM) to 10mg/L metronidazole resulted in bactericidal activity in 7/19 C. 
difficile strains. Metronidazole susceptibility status did not correlate strongly with whether 
bactericidal activity was observed. The activity of antimicrobial agents against bacteria is 
known to vary with the medium composition, antimicrobial concentration, and also whether a 
solid medium or liquid medium is employed for MIC testing (O’Connor et al., 2008). 
Therefore, the limited activity of metronidazole against some C. difficile strains in the present 
study may reflect the fact that in this assay a liquid medium was used to engage C. difficile 
vegetative cells and metronidazole, which is a different interaction than used in previous 
experiments (See Chapters 2 and 3) where a liquid culture was inoculated onto a solid medium 
containing metronidazole. It is possible that, although the C. difficile cultures were standardised 
to log-phase (approx. 0.55 OD600), some C. difficile strains might have been early-log 
phase/late-log phase depending on their growth rate and maximum biomass yield which were 
not analysed in this study and might have affected the antimicrobial effect of metronidazole. 
The concentration of metronidazole might also affect the Pharmacodynamics of metronidazole, 
and 10 mg/L was selected in order to reflect the study of Lacey and colleagues (1993), but this 
is also a concentration of metronidazole that is reflective of the magnitude of drug seen in the 
faeces of patients and volunteers following oral therapy (Bolton & Culshaw, 1986). Regardless 
of these experimental variables, the study of Lacey and colleagues (1983) clearly demonstrated 
in B. fragilis, exposure of bacterial cultures to 10mg/L of metronidazole resulted in loss of free 
drug from cell-free culture supernatants, and the data observed from the present study reflected 
these findings regardless of metronidazole susceptibility status in the C. difficile strains 
evaluated.  With respect to metronidazole susceptibility in anaerobes, it remains a possibility 
that reduced uptake of drug might contribute to metronidazole reduced susceptibility or 
resistance. When considering the CDRM and CDSM strains evaluated in the present study, 
there is little evidence that metronidazole uptake was attenuated in CDRM strains. In most C. 
difficile culture supernatants there was no recoverable metronidazole detected. Only six C. 
difficile cultures yielded recoverable metronidazole, one ribotype 001(CDRM), four ribotype 
027 (2 for CDRM, 2 for CDSM), and one ribotype 106 (CDRM)  
The growth changes in strains exposed to metronidazole compared with their control 
counterparts having no metronidazole did not correlate with their susceptibility profile. As was 
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observed using the OD readings the difference in growth as a result of exposure to 
metronidazole varied between strains and ribotypes. C. difficile strain E4 (Brazier et al., 2001) 
was less affected by 10mg/L in comparison to ATCC 700057 which was substantially 
adversely affected, the results correlated with their MIC of 16mg/L and 0.5mg/L respectively.   
Interestingly, Tally et al, (1978) also reported that metronidazole uptake was observed both in 
susceptible and resistant bacteria which confirms the bioassay data in this research however in 
their research only the susceptible anaerobic bacteria metabolised the drug which was not in 
line with observation made in the present research.   
 All C. difficile strains exposed to metronidazole and their unexposed counterparts were also lysed in 
order to measure the intracellular concentrations of metronidazole using the bioassay technique but 
no metronidazole was observed in any samples. The data from this present experiment, suggest that 
the intracellular activated metronidazole concentrations does not play a role in CDRM phenotype.  
Metronidazole reportedly enters bacterial cells by passive diffusion, influenced in a positive loop by 
the intracellular reduction of metronidazole (Edwards et al, 1980). Thus the undetectable intracellular 
metronidazole observed in the present research indicates its reduction which facilitated the maximal 
uptake from the broth and correlated with an earlier report that the toxic radical formed from 
metronidazole is very short-lived and it disintegrates further into tiny nontoxic particles rapidly 
(Edwards et al, 1980).   
Conclusion and future work 
This study had shown that uptake of metronidazole is not a factor that is likely to contribute to 
metronidazole phenotype. In consideration of the above data discussed, future work in the 
determination of mechanism of development of reduced susceptibility in C. difficile, should be 
directed more towards the downstream processes involved in the mechanism of action of 
metronidazole. This might encompass the targets of the redox radical as suggested by Muller 
and Gorrell, 1983.  It also useful to note that this research has observed that metronidazole 
reduction and uptake is taking place irrespective of the level of susceptibility. As activation of 
metronidazole increases the pressure diffusions of metronidazole into the cell. However, there 
is a possibility that a different mechanisms of metronidazole reduction take place for the 
CDRM strains compared to CDSM strains. This present research cannot also rule the possibility 





9.0 Effect of Hemin on The Susceptibility Level of C. difficile Strains to Metronidazole.  
 
9.1 INTRODUCTION  
Heme has been described as the split portion in haemoglobin that contains iron (Das, 2012) it 
is also referred to as the iron protoporphyrin section of haemoglobin that is insoluble (Saunders, 
2003) and hemin is the chloride form of heme. In anaerobic bacterial growth, heme synthesis, 
which produces the cytochrome system is needed for nitrate reduction. Jacobs and colleagues 
demonstrated the importance of adding exogenous hemin to growth media containing nitrate, 
in order to stimulate growth under anaerobic conditions when studying six strains of 
Staphylococcus spp. (Jacobs et al, 1964). Microorganisms like all other living organisms 
require nutrient to grow and multiply, as well as transition elements like iron to aid metabolic 
processes (Awad et al, 2016). Iron levels in living organisms have been stated to be of 
importance as lowered levels decrease bacteria growth and excess iron cause chronic oxidative 
stress. Published data also suggest that directly or indirectly iron or iron related metabolites are 
associated to decrease in metronidazole susceptibility (Veeranagouda et al, 2014).  
Metronidazole resistant mutants of Bacteroides fragilis (number of strains =32) were observed 
to have a mutated FeoAB gene (Veeranagouda et al, 2014). The minimum inhibitory 
concentration (MIC) reverted back to that of the parent strain when the growth medium was 
supplemented with iron. FeoAB is a protein linked to iron uptake in bacteria, thus reducing iron 
uptake may be linked to reduced susceptibility to metronidazole (Veeranagouda et al, 2014).  It 
is possible that the metronidazole activation process linked to Pyruvate ferredoxin 
oxidoreductase (PFOR) is iron dependent. The importance of FeoB in growth and expression 
of virulence factors was reported in a C. perfringens strain with a mutated FeoB strain which 
demonstrated growth defects, reduced manganese uptake, reduced gas production, and reduced 
toxin production that were later resolved by adding iron supplements to the growth medium 
(Awad et al, 2016). The research noted FeoB a subunit of FeoAB was more prevalent of the 13 
iron uptake systems identified using bioinformatics tools on C. perfringens (Awad et al, 2016). 
Another iron related protein linked to metronidazole susceptibility in bacteria is the ferric 
uptake regulator (Fur). Analysis of Fur, a bacterial regulator of iron homeostasis in bacteria, 
demonstrated increased Fur expression in metronidazole reduced susceptible C. difficile strains 
(CDRM) and fully-resistant ribotype 027 strains of C. difficile compared to a susceptible 
phenotype (Chong et al., 2014). This result indicates Fur expression, and correspondingly iron 
bioavailability in bacteria, is associated with the decline in metronidazole susceptibility in C. 
difficile (Chong et al, 2014). Consequently, the present study was undertaken to evaluate if iron 




 9.2 METHOD 
Agar incorporation MICs were performed as described previously (see 2.22) but with the 
following alterations. Overnight Schaedler’s broth cultures of Clostridium difficile were 
exposed to doubling dilutions of metronidazole (0.03- 64mg/L) on Wilkins-Chalgren agar, 
Wilkins-Chalgren agar supplemented with 5mg/L hemin (51280, Sigma Aldrich, Poole, UK), 
Brucella agar  and Brucella agar supplemented with 5mg/L hemin. The CDRM strains studied 
were of three ribotypes 001 (N=7), 027 (N=5), and 106 (N=5), along with CDSM strains of 
ribotypes 001 (N=2), 027 (N=2). The ATCC 700057 metronidazole susceptible strain was used 
as an experiment control. Brucella agar was made from Brucella medium base (CM0169, Oxoid 
Basingstoke, UK) by adding 1.5% Bacteriological agar (LP0011, Oxoid Basingstoke, UK) 
supplemented with 10µL/L Vitamin K1 (V3501, Sigma Aldrich, Poole, UK) and 5% (v/v) 
defibrinated horse blood (SR0050, Oxoid, Basingstoke, UK). The inoculated MIC plates were 
then incubated anaerobically at 37oC for 48 hours and MIC endpoints determined as previously 
described (see 2.22).     
Statistical analysis was performed using Graphpad Prism 7.0, geometric mean MICs for 
antimicrobial agents’ activity against the individual ribotype groups were calculated along with 
95% confidence intervals.  
A Mann Whitney test was used to test for statistical significance of MIC differences between 
groups and a P-value of >0.05 was considered statistically significant.  













9.3 RESULT  
On Wilkins Chalgren agar, MICs were consistent with or without supplementation of additional 
hemin (Figure 9.1) with exception of four Metronidazole reduced susceptible C. difficile strains 
(CDRM) strains (106 ribotype N=3, and 001 ribotype N=1) which had +/- 1 dilution difference 
in MIC. MIC was between 4-8mg/L (Figure 9.1) for CDRM strains. Metronidazole susceptible 
C. difficile strains (CDSM) 027 ribotype strains were observed to be 2mg/L MIC.  
On Brucella Agar, MIC with Hemin ranged between 2-8mg/L for CDRM strains and MIC 
without hemin ranged between 2-4mg/L (Figure 9.2). Ribotype 027 CDSM strains MICs were 
observed to be 1mg/L without hemin and 2mg/L with hemin. MIC increase with hemin was 
observed in 56% of the total strains and approximately 63% of the CDRM strains when tested 
in Brucella agar.  
  
 Tests for significance demonstrated that there were no significant differences in metronidazole 




Figure 9. 1 Geometric mean metronidazole (MET) MICs (mg/L, ±SE) against Clostridium difficile with 
reduced susceptibility to metronidazole from PCR ribotypes 001 (N=7), 027 (N=5), and 106 (N=4) on 








Figure 9. 2 Geometric mean metronidazole (MET) MICs (mg/L, ±SE) against Clostridium difficile with 
reduced susceptibility to metronidazole from PCR ribotypes 001 (N=7), 027 (N=5), and 106 (N=4) on 
Brucella blood agar ±5 mg/L additional hemin.  
For CDRM strains on Brucella blood agar, tests for statistical significance demonstrated for 
ribotype 001, that addition of hemin significantly increased MICs (P=0.021, Figure 9.2) as was 
also the case for ribotype 027 (P = 0.048); however, for ribotypes 106 addition of hemin did 
not significantly affect metronidazole MICs.   
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 9.4 DISCUSSION  
C. difficile strains with reduced susceptibility to metronidazole have been reported previously 
and the mechanism and clinical significance of this reduced susceptibility remains to be 
determined (Baines et al., 2008). Baines and colleagues (2008) demonstrated that the CDRM 
phenotype was method dependent and Wilkin’s-Chalgren agar was able to detect CDRM, 
whereas the Clinical & laboratory standards institute (CLSI) recommended method for the 
susceptibility testing of anaerobes using Brucella blood agar (no hemin) was not.  In the present 
study of CDRM these elevated minimum inhibitory concentrations (MICs) on Wilkin’s 
Chalgren agar were again demonstrated, although supplementation of Wilkins Chalgren agar 
with additional hemin did not further increase the MICs. Interestingly, the effect of hemin 
supplementation using Brucella blood agar clearly demonstrated significantly elevated MICs 
for CDRM from ribotypes 001 and 027, but not for ribotype 106. This raises the possibility that 
there may be a differential mechanism in metronidazole reduced susceptibility in C. difficile 
ribotypes. One possibility also is that the addition of hemin to Brucella agar increased the 
growth of the C. difficile inoculum on the agar, therefore an elevated inoculm might have 
produced an ‘inoculum effect’ and increased the MIC as has been observed in H. pylori for 
metronidazole (Hartzen et al., 1997). Iron, a secondary product of hemin though has been 
observed to affect growth and metronidazole susceptibility in C. perfringens deficient of iron 
(Awad et al, 2016), hemin effect on growth was also observed in six staphylococci strains that 
were facultative anaerobes as well as in Bacillus subtilis an obligate aerobe (Jacobs et al, 1964). 
However, data from Awad et al, 2016 earlier mentioned, conflict with the observations of Wu 
and Hurdle (2015), where iron containing molecules (10 µM FeCl3, FeSO4) were not observed 
to affect metronidazole MICs. Wu and Hurdle (2015a) reported the effect of hemin 
supplementation on unstable metronidazole reduced susceptibility in C. difficile. Also, this 
present study observed that in Brucella agar 100% decline in MIC was observed without hemin 
for CDRM strains of ribotype 027, thus confirming the results reported on the effect of hemin 
on ribotype 027 strains (Wu and Hurdle, 2015a). Interestingly, Wu and Hurdle (2015a) showed 
that CDRM or resistant isolates metronidazole MICs declined to within the susceptible range 
(0.25-1.0 mg/L) in the absence of hemin and that Fe2+ and the heme catabolites biliverdin and 
bilirubin had no effect on MICs. It was also noted by the authors that the effect of hemin on 
metronidazole MICs was not consistent across all of the ribotypes studied, again reflecting 
observations from the present study. The decline in MICs observed in the present study in the 
absence of hemin-supplemented media was less than observed in previous studies, 
approximately a 2-fold reduction in geometric mean MIC compared to a 4 -10-fold reduction 
seen by Wu and Hurdle (2015a). Again, this difference along with the reported stability 
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differences in MICs may be suggestive of differing mechanism of reduced susceptibility to 
metronidazole. Also of note was the moderate difference in the concentration of hemin 
supplemented into Brucella agar; in the present study 5mg/L (7.7 µM) was used, whereas Wu 
and Hurdle (2015a) used 10µM (6.5 mg/L), and this may have potentially affected the results 
observed.  
Notable to point that though the absence of hemin resulted in metronidazole MIC decline, it 
was observed that all reduced susceptible strains still retained the reduced susceptible 
phenotype. Hemin supplementation resulted in MIC increase from 1mg/L to 2mg/L for CDSM 
strains of ribotype 027 (Appendix). As these strains were originally selected as CDSM strains 
their MICs were not involved in the statistical analysis thus there MIC fluctuation was only 
mentioned in result section but it had no effect on the statistical result presented.  
Also as earlier stated the observed hemin effect on metronidazole susceptibility could be 
associated with the effect of iron related factors on gene expression/hypermutability in C. 
difficile. Some C. difficile strains passaged in the presence of metronidazole were cultured at 
passage 10, 13 and 15 with and without hemin. At passage 15, hemin addition resulted in an 
increase of metronidazole MIC much more than at passages 10 and 13 and the authors 
demonstrated mutations in the iron sulfur cluster regulator IscR (Wu and Hurdle, 2015b). IscR 
is a global gene regulator confirmed by its role in P. aeruginosa one of its roles is intracellular 
iron homeostasis modulation (Romsang et al, 2014). Though one of the known roles of IscR is 
heme metabolism, more research is required to detect the role of IscR mutations in C. difficile.  
In the study of Chong et al (2014), two genes related to iron were observed to have been linked 
to reduce susceptibility to metronidazole and resistance in C. difficile. FeoB, a ferrous iron 
transporter protein B, and an iron compound ABC transporter substrate protein decreased in 
expression in the metronidazole-resistant C. difficile strain analysed after addition of 
metronidazole.   
While the ferric uptake regulator (Fur), an iron homeostasis central regulator, was observed in 
the absence of metronidazole to be more highly expressed in the resistant and reduced 
susceptible C. difficile compared to the susceptible phenotype tested, addition of metronidazole 
did not elicit much changes in Fur expression (Chong et al, 2014).  
Conclusion and future work 
Further research analyzing of the genome sequence of reduced susceptible phenotype would 
provide more in-depth information on factors contributing to metronidazole reduced 
susceptibility. The results from the present study clearly demonstrate that hemin affects the 
susceptibility of CDRM to metronidazole, and offers an intriguing possibility that heme 
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containing substances (e.g. occult blood) might contribute to reduced efficacy of metronidazole 






















10.0 Whole genome sequencing (WGS) of Clostridium difficile  
 
10.1 INTRODUCTION   
Whole genome sequencing (WGS) can be employed to elucidate possible genetic variations in 
bacterial genomes including single nucleotide polymorphisms (SNPs) which could be a 
possible cause of phenotype traits including resistance to antimicrobials, and can also be used 
as a molecular typing approach which has a similar resolution to highly discriminatory 
techniques such as MLVA.   
Dominguez et al (2015) typed C .difficile strains using next generation sequencing to analyse 
27 C .difficile isolates from children during a clinical outbreak (Dominguez et al, 2015). Whole 
genome sequencing was also used to analyse samples of C .difficile obtained from adult patients 
showing C. difficile infection symptoms, in the hospital and community settings in the UK.  
Single nucleotide variants (SNV) were detected and C. difficile isolates in 3 years were 
observed to be different genetically from earlier isolates (Eyre et al., 2013). WGS has also been 
used in the Netherlands to detect the similarity of the ribotype 078 isolates isolated from 
animals and farmers, and the researchers demonstrated no SNP differences in the genome 
sequences of C. difficile isolates, thus removing the possibility of an intermediate host (Knetsch 
et al., 2014). Additionally, the same insertion of tetracycline and streptomycin resistance 
determinants were reported in the ribotype in both animals and human. The authors postulated 
that transmission between human and animals might be possible based on these data, through 
the faecal oral route especially from pigs to humans. However it was not ruled out that it was 
possible that both populations could have been infected from the same source since both are 
exposed to similar environment (Knetsch et al., 2014).   
Analysis of short gene sequences have been used to replace susceptibility testing of the 
phenotype as it tends to be more rapid and practicable in clinical sampling, although genotypic 
variations do not always confer phenotypic resistance to antimicrobials. Whole genome 
sequence for susceptibility testing, though not yet in practice, could be advantageous in 
obtaining a variety of antimicrobial susceptibility profile rapidly (Feuerriegel et al, 2014). This 
was demonstrated in an earlier research by Koser et al., (2013) where Illumina MiSeq was used 
for rapid whole genome sequencing and 39 genes known to confer resistance in Mycobacterium 
tuberculosis were interrogated. Other than the susceptibility profile, a mutation in a gene 
responsible for the activation of one of the drugs- paraaminosalicyclic acid was identified. The 
use of WGS for susceptibility testing is more advantageous when certain mutations have 
already been linked to resistance to specific antimicrobial agent. Thus, the use of WGS may 
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not be fully aimed at replacing phenotypic testing but only to get a rapid antimicrobial 
susceptibility profile of a clinical sample (Koser et al., 2013), which is important as not all 
mutations confer resistance. The maximal analysis of a sample sequence is advised to prevent 
false positives or false negatives that could be as a result of silent genetic variations in the 
genome (Koser et al., 2013). An earlier study mapped out 18 genes linked to resistance to ten 
antimicrobial agent in Mycobacterium spp. Seventy one bacterial strains were analysed and 
121 polymorphisms were found; 58 of which were markers linked phylogenetic properties and 
these data was suggested to aid future genotypic assays design (Feuregelle et al, 2013).  
WGS was also used to identify resistance genes in Bacteroides thetaiotamicron to 
metronidazole as well as other antibiotics such as tetracycline and the results showed a number 
of resistance genes including tetX, tetQ, and ermF. Additionally, a plasmid-located nimD was 
identified along with a second nim-like sequence (Sadarangani et al, 2014)  
In a 2012 study, a novel method of detecting resistance genes was developed using ResFinder, 
which was developed to screen published genomes for resistance genes. The study indicated 
that though Polymerase chain reaction (PCR) has been in use but this can only detect specific 
genes targeted by PCR primers, thus excluding other resistance genes that could be present 
(Zankari et al., 2012). Analysing the whole genome gives this benefit and new genes can be 
found. The use ResFinder gives the advantage to high weight data as is generated by whole 
genome sequence. Resfinder was used to analyse some NCBI stored whole genome sequences 
of 30 isolates, and the genes were identified accurately (Zankari et al., 2012).  
A novel organism Bacteroides genomospecies was identified in United States using WGS; the 
organism was earlier wrongly identified as Bacteroides fragilis using known accurate 
techniques MALDI-TOF mass spectrometry and 16S RNA sequencing. Thus, the inclusion of 
WGS in bacterial identification might be of clinical importance as it could aid accurate detailed 
specification of the offending pathogen (Salipante et al., 2015). Genome sequencing was used 
along with experimental evolution and functional analysis was used to map out E. coli 
antimicrobial cross resistance and detected the underlying cause (Lazar et al, 2014)  
  
Whole genome sequencing has been used to characterize the metronidazole susceptibility 
profile of hypervirulent C .difficile ribotype 027 (Lynch et al., 2013). Identifying genetic 
variations that could have led to phenotypic changes for the resistant strain (Lynch et al., 2013). 
Moura et al, 2014 also characterised the resistance to metronidazole phenotype in C .difficile 
non toxigenic ribotype by sequencing and analysing the genome.  
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The present study was performed in order to assess the whole genome sequences of two 
Clostridium difficile strains with reduced susceptibility to metronidazole in order to gain an 
insight into the potential molecular mechanisms which may contribute to metronidazole 
reduced susceptibility when genomes were analysed comparatively with metronidazole 
susceptible strains.   
10.1.1 Aim   
To analyse the genome of two C. difficile isolates with the reduced susceptibility to 
metronidazole phenotype, with the aim of detecting mutations that can be linked to reduced 
susceptibility to metronidazole.   
10.1.2 Objectives  
To extract, purify, and quantify genomic DNA of Clostridium difficile strains 80 (ribotype 001) 
and E4 (ribotype 010 coded as 110) such that it is suitable for WGS.  
To use PacBio sequencing and genome assembly and annotation of Clostridium difficile strains 
80 (ribotype 001) and E4 (ribotype 010) and bioinformatics analysis to interrogate the genomes 
for potential genetic variations that might contribute to the metronidazole reduced susceptible 












10.2 METHOD  
10.2.1 DNA extraction  
Overnight brain heart infusion broth (CM1135, Oxoid, Basingstoke, UK) cultures of individual 
CDRM strains of ribotype 001 and ribotype 010, strains 80 and 110 respectively, were 
centrifuged at 16000 rpm for 2mins to pellet the cells. To the cells was added: 120µL of 20 
mg/ml lysozyme (L6876, Sigma-Aldrich, Poole, Dorset, UK), 3µL of 10µg/µL RNase A and 
89 µL of TE was added to lyse cells. The mixture was incubated overnight at 37oC and vortexed 
after the addition of 150µl of Promega WizardTM lysis solution and 10µL of proteinase K 
(A1120, Promega UK, Southampton, UK).   
The lysed cell mixture was then incubated at 70oC for 15 minutes on a heating block (Grant  
Dry Block, Grant Instruments, Royston, UK), vortexing every 5 minutes. Then the cell extracts 
were chilled on ice for 5 minutes and 175µL of protein precipitation solution from the Promega 
WizardTM extraction kit was added and extracts were vortexed for 10 seconds, and centrifuged 
at 4oC at 16000rpm for 15 minutes. The supernatant was then transferred to a new tube 
containing 3µL of Rnase A, mixed gently, and then incubated at 37oC for 30 minutes. To the 
supernatant 500µL of isopropanol (I9516, Sigma Aldrich, Poole, UK) was added and the tubes 
were inverted several times. Tubes were then centrifuged at 4oC at a speed of 16000 rpm to 
pellet DNA. The supernatant was then carefully decanted to avoid removing the pellet and the 
pellet was washed with 500µL 70% ethanol (652261, Sigma Aldrich, Poole, Dorset, UK). 
Residual ethanol was removed following centrifugation at 16000rpm for 2 minutes and the 
DNA pellet was the air-dried for 5 minutes at room temperature and resuspended in 35-50µL 
of Rnase-free water.  
The purity and quantity of DNA was detected using Nano drop (1000 3.8.1, Thermo Scientific, 
UK) and qubit fluorimeter (3, Invitrogen life technologies, UK). The DNA was then sent for 
sequencing, using a Pacific Biosciences RSII sequencer along with subsequent genome 
assembly and annotation at the Earlham Institute (Norwich Science Park, University of East 
Anglia, Norwich UK)   
10.2.2 Bioinformatics analysis  
Nucleic acid sequence data obtained from the Earlham Institute was viewed using File Viewer 
Plus (Sharpened productions, US) and Snap gene software (GSL Biotech Kenwood Avenue, 
Chicago). These were used to search for 33 genes of interest (Table 10.1) that have previously 
been associated with metronidazole resistance (Lynch et al., 2013; Chong et al., 2014). 
Identified genes were aligned with reference genome Clostridium difficile strain 630 known to 
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be susceptible to metronidazole (MIC = 0.25 mg/L). C. difficile strain 110 (E4) sequences were 
also compared with the previously published genome of a metronidazole resistant ribotype 010, 
strain 7032989 (MIC = 32 mg/L), which was a non-toxigenic C. difficile strain isolated from 
Spain (Moura et al., 2014). Nucleotide sequences were aligned using National center for 
biotechnology information (NCBI) basic local alignment search tool (BLAST). 
To determine the effect of the identified SNPs on amino acid sequence, further analysis was 
carried out on the genes detected to possess SNPs. The amino acid sequence of these genes of 
were aligned with that of CD 630 using pair wise alignment tool on Geneious software (R10 
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Table 10. 1 Gene targets assessed using bioinformatics tools for C. difficile PCR ribotype 001 (strain 80) 
and ribotype 010 (strain 110, E4) with reduced susceptibility to metronidazole.  
 
GENE DESCRIPTION  GENE  
Gyrase A  gyrA  
Anti-sigma factor protein  rsbW  
DNA directed RNA polymerase  rpoA  
Glycerol-3-phosphate dehydrogenase  glyC  
UDP-N-acetylmuramoyl-L-alanine:D-glutamate ligase  murD  
V-type ATP synthase subunit C  ntpC  
Homoserine dehydrogenase  Hom1  
Stage 0 sporulation protein A  Spo0A  
DNA topoisomerase 1  topA  
Ferric uptake regulation protein  fur  
Thiamine biosynthesis protein  thiH  
Putative germination specific protease  cspC  
Endonuclease IV  nfo  
Toxin A  tcdA  
Rubrerythrin   rbr  
Endonuclease subunit C  sbcC  
Anaerobic nitric oxide reductase flavorubredoxin  norV  
exodeoxyribonuclease  exoA  
5-nitroimidazole reductase  nimB  
Ferrous iron transport protein A  feoA1  
Ferrous iron transport protein B  feoB1  
thioredoxin  trxA1  
Thioredoxin reductase  trxB1  
Thiol peroxidase  bcp  
Thioredoxin reductase  trxB2  
Thioredoxin   trxA2  
Thioredoxin reductase  trxB3  
Electron transfer protein  prdC  
Excinuclease ABC subunit B  uvrB  
Excinuclease ABC subunit C  uvrC  
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GENE DESCRIPTION  GENE  
Excinuclease ABC subunit A  uvrA  
Pyruvate flavodoxin oxidoreductase  nifJ  

























10.3 RESULTS  
  
Table 10. 2 DNA yield and purity for DNA preparations from C .difficile PCR ribotypes 001 and 010, strains 
80 and 110.  
Strains  Ribotype  DNA(ng/ 
µl)  
Approx. 
volume (µl)  
total  260/280  260 /230  
110  010  296  200  59200  1.83  2.35  
80  001  272  100  27200  1.85  1.90  
  
  
Figure 10. 1 Purified high molecular weight DNA from C. difficile strains 110 (A, ribotype 010) and 80 
(B, ribotype 001) visualised on an agarose gel (1% w/V) alongside a lambda DNA high molecular ladder 
(11873943, Fisher Scientific, Loughborough, UK) the X lane are DNA in tubes not sent for sequencing.  
10.3.1 Whole Genome Sequence (WGS) Analysis  
Strain 110 of ribotype 010, had 16 genes aligned successfully, alignment with metronidazole 
susceptible reference strain CD630, yielded 10 genes with SNPs, the other genes had 100% 
identity. While alignment with metronidazole resistant strain of ribotype 010 CD7032989 






Table 10. 3 Gene analysis for sample 110 with reference genome, identifying percentage similarity and 
identifying SNPs  
 
Protein  GENE  Nucleotide 










gyrase A  gyrA  2425/2427  
(99%)   
2106     
(C-T)  
245       
(T-C)  





glyC  1018/1020  
(99%)  
495(A-G),  
351 (T-A)  
100%    
V-type ATP 
synthase subunit  
C  
ntpC  100%    100%    
Stage 0 
sporulation 
protein A  
Spo0A  100%    100%    
DNA  
topoisomerase 1  
topA  2084/2088  
(99%)  
 
572 (C-T)  
651 (g-A)  
1141     
(A-G)  
1743(G-T)  
  1016   
(a- gap)  
Ferric uptake 
regulation protein  
fur  100%     100%    
Endonuclease IV  nfo  835/837(99%)  765(G-A),  
797 (A-G)  








Protein  GENE  Nucleotide 
identity (%)   












norV  1192/1194  
(99%)  
45(T-A),  
861 (T-C)  
100%    
exodeoxyribonucl 
ease  
exoA  752/753 
(99%)  
  
747 (G-A),  
  
100%    
5-nitroimidazole 
reductase  
nimB  467/468 
(99%)  
389  (C-A)  100%    
Thiol peroxidase  bcp  465/465           
(100%)  
  465/466 





prdC  100%    100%    
Excinuclease  
ABC subunit B  
uvrB  1966/1971 
(99%)  
1374     (T-C)  100%    
Excinuclease  
ABC subunit C  
uvrC  1818/1818 
(100%)  
  100%    
Pyruvate 
flavodoxin 
oxidoreductase   
nifJ  3532/3540 
(99%)  
  
813 (C-T)  
2796     (A-G)  
2946     (T-C)  
2607(T-C)  
3223     (C-T)  
3290(T-C)  
3462(G-A)  
3174     (T-C)  







Protein  GENE  Nucleotide 













en III oxidase  





891 (C-T)  

























10.3.2 Amino acid sequence analysis.  
 
The genes with observed SNPs were selected to undergo amino acid sequence analysis, silent 
mutations and point mutations were identified as shown below.   
Mutations in genes with SNPs of strain 110   
 
  
Figure 10. 2 Alignment of Oxygen independent coproporphyrinogen III oxidase gene of sample 110 with 
same gene in CD630 detecting point mutations  
  
Figure 10. 3 Alignment of Exodeoxyribonuclease gene of sample 110 with same gene in CD630 detecting 
point mutations  
 









Figure 10. 6 Alignment of 5-nitroimidazole reductase gene of sample 110 with same gene in CD630 




Figure 10. 7 Alignment of Gyrase A gene of sample 110 with same gene in CD7032989 detecting 
point mutations  
 
 
10.3.4 Sample 80  
Ten genes from C. difficile strain 80 (ribotype 001) were aligned to those of comparator C. 
difficile genes, others were either not present or had multi subunits. Six genes were observed 
to have SNPs while the remaining genes demonstrated 100% identity with the same gene in 











Table 10.3: Gene analysis for sample 80 with reference genome, identifying percentage 
similarity and identifying SNPs  
  
  
Protein  GENE  Nucleotide identity  
(%) CD630   
Position /snp(q-s)  
Stage 0 sporulation 
protein A  
Spo0A  824/825(99%)   802 (T-C)  
Ferric uptake 
regulation protein  
fur  459/459(100%)    
Endonuclease IV  nfo  837/837(100%)    
Toxin A  tcdA  8130/8133(99%)  
  





norV  1193/1194(99%)  861(T-C)   
exodeoxyribonuclease  exoA  752/753(99%)  603 (G-A)  
5-nitroimidazole 
reductase  
nimB  468/468(100%)    
Thiol peroxidase  bcp  463/465(99%)   84(C-T),  
171 (A-T)  
Electron transfer 
protein  
prdC  1314/1314(100%)    
pyruvate flavodoxin 
oxidoreductase  
nifJ  3523/3540(99%)   1587 (G-A), 1674 (T-C)  
1794 (C-T), 2358 (G-A),  






10.3.5 Gene of sample 80 with same gene in CD630 detecting point mutations  
 
Figure 10. 8 Alignment of Pyruvate flavodoxin oxidoreductase showing mutations gene of sample 80 with 















Figure 10. 9 Alignment of Toxin A first point mutation gene of sample 80 with same gene in CD630 




Figure 10. 10 Alignment of Toxin A second point mutation gene of sample 80 with same gene in CD630 
detecting point mutations  
  
  
Silent mutations in genes with SNPs of strain 110 (E4) on alignment with CD630 was observed 
in excinuclease ABC subunit B gene, Glycerol-3-phosphate dehydrogenase, Anaerobic nitric 
oxide reductase flavorubredoxin, DNA topoisomerase 1, Pyruvate flavodoxin oxidoreductase. 
Silent mutations in genes with SNPs of strain 80 on alignment with CD630 was observed in 
anaerobic nitric oxide reductase flavorubredoxin, Thiol peroxidase, exodeoxyribonuclease and 
SpoA gene.   
  
Both strains 110 and 80 had SNPs observed in anaerobic nitric oxide reductase flavorubredoxin 
(norV), exodeoxyribonuclease and pyruvate flavodoxin oxidoreductase gene relative to 
CD630. In addition, strain 80 had SNPs in Stage 0 sporulation protein A (Spo0A) gene, Toxin 
A tcdA, thiol peroxidase (bcp).  
While for strain 110, the genes SNPs relative to strain CD630 were gyrase A (gyrA), Glycerol-
3-phosphate dehydrogenase (glyC), Homoserine dehydrogenase (Hom1), Thiamine 
biosynthesis protein (thiH), Endonuclease IV (nfo), exodeoxyribonuclease(exoA), 
5nitroimidazole reductase (nimB), Ferrous iron transport protein A (feoA1), Ferrous iron 
transport protein B(feoB1), Thioredoxin reductase (trxB3), Excinuclease ABC subunit B 




10. 4 DISCUSSION  
Metronidazole reduced susceptibility and resistance presents a clinical issue for the treatment 
of CDI, as metronidazole is a cost-effective first-line therapy. Since metronidazole achieves 
only low luminal concentrations in the colon of CDI patients following oral dosing, even small 
MIC increases may be clinically significant. Resistance to metronidazole in C. difficile has 
been reported previously (Pelaez, et al., 2002, Pelaez, et al., 2008, Brazier et al., 2001) but the 
mechanisms of resistance were not determined, other than ruling out the involvement of nim 
genes. Several recent reports have suggested potential mechanisms of resistance in C. difficile 
following whole genome sequencing bioinformatics analysis (Lynch et al., 2013, Chong, et al., 
2014, Moura et al., 2014).  
Lynch et al, (2013), characterized a stable metronidazole resistant C. difficile strain of ribotype 
027 phenotypically and at the genomic level. Some phenotypic features were linked to gene 
mutations, one of which was the aberrant growth in vitro. The high level metronidazole 
resistant C. difficile strain had low cell density and an extended lag phase compared to the 
reduced susceptible and susceptible strain, thus depicting a nutrient limitation. At the genetic 
level, a mutation in thiamine biosynthesis protein (thiH) and Oxygen independent 
coproporphyrinogen III oxidase (hemN) genes were observed (Lynch et al., 2013), in line with 
Lynch et al, (2013), mutations were also observed in the present research in thiH and hemN 
gene in strain 110 (E4). Lynch et al., (2013), also showed a point mutation in Spo0A that was 
present in the resistant phenotype (CD26A54_R) but absent in the reduced susceptible 
phenotype tested which was indicated to be a possible cause of lack of sporulation up to 
48hours in CD26A54_R. The absence of mutation in the reduced susceptible phenotype on the 
Spo0A gene was in line with our research as no mutation was found for strain 110 (E4) Spo0A 
gene. Contrastingly, the clinical ribotype 001 isolate analysed did possess a SNP in spo0A, but 
the phenotypic impact of this mutation remains to be determined given that sporulation capacity 
was not evaluated in the present study.   
Also genome analysis of a metronidazole resistant ribotype 027 has previously led to the 
identifications of mutations in Pyruvate flavodoxin oxidoreductase (nifJ) and glycerol-
3phosphate dehydrogenase (glyC), these genes has also been observed to be linked to the 
electron transport (Lynch et al, 2013). Mutations in these genes as was observed in the present 
experiment could predispose to alteration of the electron transport which has been reported to 
affect redox potential within the cell and production of energy thus could affect the activation 
and diffusion of metronidazole into the cell (Lynch et al, 2013).  
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Mutations in DNA repair proteins such as excinuclease and endonuclease IV were observed in 
strain 110 which were also observed previously in the metronidazole resistant and reduced 
susceptible 027 ribotype, thus increased levels of DNA repair can predispose to reduced 
susceptibility in metronidazole (Lynch et al, 2013). Chong et al, (2014) also reported increase 
in gene expression in DNA repair proteins such as excinnuclease ABC, endonuclease IV, 
exodeoxyribonuclease after carrying out a proteomic assay to detect changes that could affect 
susceptibility to metronidazole in C. difficile. Lynch et al, (2013) also observed point mutation 
in the ferric uptake regulator gene (fur) as well as increase in expression of the gene in a C. 
difficile proteomic assay as a contributor to metronidazole resistance (Chong et al, 2014). 
However, in the present study 100% alignment with the fur gene in CD630 was observed in 
both strains 80 and 100. Thus at genomic level mutations in the fur gene have not contributed 
to metronidazole reduced susceptibility which is in line with the findings of Moura et al, (2014), 
where the genome of C. difficile strains of the ribotype 010 were analysed and no genetic 
mutations were observed in the fur gene.  
Point mutations were further observed  in anaerobic nitric oxide reductase flavorubredoxin 
(norV) and thiol peroxidase that codes for redox active proteins which was suggested to protect 
against nitric oxide (Emerson et al, 2008) and has been earlier reported to increase in 
expression, in reduced susceptible and metronidazole resistant C. difficile (Chong et al., 2014).  
NimB was observed by Chong et al, (2014) to increase in expression by 3 fold more in reduced 
susceptible and metronidazole resistant C. difficile compared to the susceptible strain. These 
expression increases were observed without pre-exposure to metronidazole (Chong et al., 
2014).  Nim genes have been observed to convert nitro-imidazole to a nontoxic derivative, 
therefore contributing directly to metronidazole resistance in Bacteroides fragilis and other 
anaerobes (Gal and Brazier, 2004, Theron et al., 2004). The mutation in this gene reported in 
the present study in strain E4 (110) could have activated the gene as this SNP exist in the 
resistant reference strain CD7032989 thus 100% alignment was observed with the strain E4 
(110) sequence. Therefore, metronidazole may be up-taken and converted into an amino radical 
by nimB and not a nitroradical which would affect the toxicity of the antibiotic (Carlier et al, 
1997). Further studies involving knocking out nimB and complementing nimB back into the 
CDRM strain E4, would be required in order to determine if this is indeed the case.    
Silent mutations and four single nucleotide polymorphisms were as well observed in the present 
research in the hemN gene in strain E4 (110). The hemN gene codes for a protein that is part of 
heme biosynthesis, coproporphyroinogen 111 oxidase. Mutations in this gene could account 
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for slow growth, decrease in hemin biosynthesis and affect electron transport which could 
decrease the amount of metronidazole activated (Roggenkamp et al., 2004, Chong et al., 2014).  
Conclusion and future work 
 
In summary, the action of metronidazole as reported by Edward et al, (1980, 1993) was 
dependent on the DNA of the cell and activation of the drug which influences the uptake, and 
subsequent toxicity of the nitro-radical formed. The activation is dependent on the electron 
transfer occurring within the cell. In this chapter we have identified single nucleotide 
polymorphisms in some of the genes linked to electron transfer, activation, oxidative stress and 
DNA repair. Thus indicating that the multifactorial feature of metronidazole resistance earlier 
observed in 027 ribotypes (Lynch et al, 2013) and in Spanish strains of 010 ribotype (Moura et 
al, 2014) is also present in metronidazole reduced susceptible UK isolates of 010 and 001 
ribotype as observed in this current research.   
Future work, could entail analysis of non-protein coding regions for example the enhancer, 
regulatory DNA and promoter regions to identify mutations linked to metronidazole reduced 
susceptbility.  Future work may also involve WGS of additional clinical C. difficile strains in 
order to look for consistency in the postulated genomic components that might be involved in 
CDRM as well as others. Structural analysis identifying the potential impacts of SNPs on 
protein structures of the relevant proteins evaluated in this study would enlighten as to the 
domains in the proteins/enzymes where mutations occurred and therefore predictions might be 
made about their functionality. Unpicking the factors that contribute most strongly to CDRM 
would be a complex process and is beyond the scope of this current study, but is certainly 
warranted to enhance the knowledge of the C. difficile community with relation to the activity 











This research has studied the phenotypic and genotypic features of metronidazole reduced 
susceptible Clostridium difficile (CDRM) UK isolates. Metronidazole is a cost-effective 
firstline therapy for CDI, so metronidazole reduced susceptibility and resistance presents a 
clinical issue for the treatment of CDI, thus indicating the importance of characterising the 
metronidazole reduced susceptible phenotype of Clostridium difficile.    
In this present study it was observed that the CDRM phenotype is heterogeneous and the 
phenotype is unstable in the absence of metronidazole, except for the control CDRM strain 110 
(E4) which was stable. The MIC heterogeneity assay gave an insight to the MIC distribution 
of CDRM and CDSM strains of varying ribotypes, thus depicting the variability of the 
susceptibility phenotype in distinct clones of the same C. difficile isolate. The serial passage 
experiments evaluating CDRM and CDSM clones in the presence and absence of sub-
inhibitory concentrations of metronidazole led to a consistent decrease in MIC in the absence 
of a selection pressure, thereby confirming the unstable nature of the reduced susceptible 
phenotype of UK C. difficile isolates. The AUC data obtained from the population analysis 
profile has further characterised the metronidazole reduced susceptibility phenotype of the 
colony forming units in the ribotypes analysed, indicating that the greatest AUCs were 
observed for ribotype 001 CDRM strains, which was the first ribotype identified in which 
CDRM emerged in 2008 (Baines et al., 2008). Confirming the susceptibility test that ribotype 
001 had a higher reduced susceptible level compared to the other ribotypes analysed.  
The serial passage experiments highlighted the instability of the reduced susceptible phenotype 
to be only in the absence of metronidazole, where the highest level of instability was also 
observed in C. difficile ribotype 001, which showed a decline in metronidazole MIC50 from 
4mg/L – 0.5mg/L after passage experiment without sub-inhibitory concentrations of 
metronidazole. Although not much literature is available on Clostridium difficile serial passage 
experiments with a metronidazole selection pressure, the MIC stability observed under 
selective antibiotic pressure in the present study was also reported in a serial passage 
experiments with surotomycin and SMT19969 against C. difficile (Mascio et al., 2014; Vickers 
et al., 2011). However this study has done 5 serial passages, future work might increase the 
number of passages to detect the effect on the CDRM phenotype.  
  
Metronidazole is a prodrug that requires activation following entry into the cell in order to 
demonstrate antimicrobial activity, therefore, a nitroreductase assay was performed in the 
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present study to assess the activation of metronidazole in CDRM. Nitroreductase activity was 
not consistently detected in C. difficile using method of Rafil et al., (1991), this may be 
attributed to the substrate specificity in nitroreduction processes described by Sisson et al., 
(2002). The cell death observed in the PAP test confirmed that metronidazole is activated in 
the UK C. difficile isolates tested. This is further confirmed by the metronidazole uptake assay, 
as more than 50% of strain analysed were observed to uptake metronidazole such that residual 
metronidazole in the cell-free medium was below the limits of experimental detection.  
Consequently, there were no deficiencies in metronidazole uptake in most CDRM strains 
evaluated in the present study and although nitroreduction was studied, there needs to be 
refinement in the nitroreduction assay in order to gain a more definitive assessment of the 
efficacy of nitroreduction in CDRM strains. All strains were able to reduce metronidazole, 
since metronidazole was active at the MIC, however, there may potentially be deficiencies in 
the efficacy of nitroreduction which could not be definitively evaluated in the present research.   
The metronidazole uptake assay also clarified that the CDRM phenotype was not related to 
deficiencies in drug reduction and uptake. It does not however eliminate possibility of 
metronidazole being reduced to its non-toxic amino radical as earlier observed by Carlier et al., 
(1997). This function was observed to be carried out by nim genes, and although no nim genes 
were observed by using PCR amplification of universal primers against C. difficile, which also 
reflected the nim PCR results observed in the present study.  NimB has been observed in earlier 
proteomic studies of C. difficile ribotype 027 (Chong et al., 2014). Furthermore, in the present 
research using WGS, a nimB gene was identified in the CDRM strain E4 (coded as 110 of 
ribotype 010) which possessed a SNP when aligned with CD630 metronidazole susceptible 
strain nimB. Contrastingly, 100% alignment was observed when CDRM strain E4 nimB was 
aligned with a metronidazole-resistant C. difficile strain in this current study. This does not just 
confirm the presence of the nim gene in C. difficile but also highlights the possibility that the 
SNP detected could activate the conversion of metronidazole to its non-toxic amino radical, as 
nimB gene has been observed both in susceptible and resistant C. difficile but with SNP.  
Additionally, mutations in the hemN gene that encodes coproporphyroinogen 111 oxidase 
which is involved in heme biosynthesis, were detected in this study in CDRM strain E4 (110), 
mutation in this gene has earlier been observed by Lynch et al., (2013). It was also observed in 
this study that supplementation of hemin predisposed to increase in MIC of the CDRM strains 
of ribotype 027 and 001 UK isolates, which is in line with Chong et al., (2014) where addition 
of hemin was observed to aid the growth of resistant 027 C. difficile ribotype.  
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The WGS study also identified SNPs in other genes in the CDRM strains analysed which may 
be linked to metronidazole mechanism of action, which were in pyruvate flavodoxin 
oxidoreductase (nifJ) and glycerol-3-phosphate dehydrogenase (glyC). Mutations in these 
genes observed in the present experiment, could predispose to alterations of electron transport 
which has been reported to affect redox potential within the cell and production of energy thus 
could affect the activation and diffusion of metronidazole into the cell (Lynch et al, 2013). 
Mutations in DNA repair proteins such as excinuclease and endonuclease IV were also 
identified in strain E4 (110). Metronidazole is converted to its nitro radical that damages the 
DNA, so increased DNA repair can predispose to reduced susceptibility in metronidazole 
(Lynch et al, 2013).  
Future work, will be needed to detect the expression of these genes as well as other genes such 
as fur gene where no SNP was observed in this study, as change in the expression of these 
genes could as well affect the susceptibility to metronidazole (Chong et al, 2014). Also protein 
structure of these genes would be a useful addition to detect the actual locations of the SNPs 
which would provide more knowledge on the impact of the SNPs detected.   
This is the first known study to identify the nimB gene in a genomic assay of CDRM C. difficile 
UK isolates, as well as the SNP that could be responsible for its activation into a nontoxic 
variant. Further studies would be required in the analysis of the genome and amino acid 
sequence, to design its primers as it has been confirmed in this study, as well as in previous 
study that the universal nim primers that have been observed to amplify other nimB genes, does 
not amplify these nimB in C. difficile. Also a nimB gene knockout experiments would identify 
the actual functionality of this gene alongside complementing back into a CDRM strain a wild-
type nimB to see if the metronidazole susceptible phenotype is restored. A similar approach 
could also be undertaken for the other genome components linked to the activity of 
metronidazole.  
In summary, this study aimed to characterize reduced metronidazole susceptibility in UK C. 
difficile isolates, which has been achieved by characterizing phenotypic and genotypic features 
of these isolates detecting its level of heterogeneity and instability in the absence of 
metronidazole, as well as hemin nutrient dependence and the presence of SNPs in genes linked 
to the metronidazole mechanism of action which could predispose to reduced susceptibility to 





 Reflective feed back 
The aim of this work is to characterize the metronidazole reduced susceptibility phenotype of C. 
difficile isolates. A reflection of my study on completion, has shown that if I was to do the work again, 
I would change the order in which I carried out my research. I would carry out the whole genome 
experiment after doing the susceptibility test but before detecting factors that could predispose to the 
metronidazole reduced susceptibility phenotype, as that would have changed the dynamics of the 
work. 
The whole genome sequence (WGS) analysis has highlighted genes linked to the metronidazole 
reduced susceptibility phenotype for example snps were observed in PFOR. Thus instead of just doing 
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APPENDIX 1.0  
  
Table A.1.1: MIC results for CDRM strains tested using agar incorporation method   
Ribotype  Strain  Metronidazole  
(mg/L)  
Vancomycin    
(mg/L)              
001  73  4  2  
  74  8  0.5  
  75  4  0.5  
  76  4  4  
  77  4  0.5  
  78  4  0.25  
  79  4  0.5  
  80  8  0.5  
  81  4  0.5  
  82  4  0.5  
  83  4  0.5  
  84  0.125  0.5  
  85  4  0.5  
  86  8  1  
  87  4  0.5  
  88  4  0.5  
  89  2  1  
  90  4  0.5  
  91  4  0.5  
  92  4  0.25  
  93  4  0.25  








Ribotype  Strain  Metronidazole  
(mg/L)  
Vancomycin    
(mg/L)              
027  95  2  0.5  
  96  2  0.5  
  97  4  0.5  
  98  4  0.5  
  99  4  0.5  
  100  4  0.5  
  101  2  0.5  
  102  2  0.5  
  103  2  0.5  
106  104  4  0.5  
  105  2  0.5  
  106  2  0.5  
  107  4  0.5  
  108  4  0.5  
  109  4  0.5  
  110  8  1  
  111  0.125  0.5  















Table A.1.2. MIC results for CDSM strains tested using agar incorporation method   




001  114  0.5  2  
  115  0.25  0.5  
  116  0.5  2  
  117  0.5  0.5  
106  118  2  1  
  119  1  0.5  
  120  0.125  0.5  
027  35  0.5  0.5  
  37  0.5  0.5  
  41  0.5  0.5  





















APPENDIX 2.0  
POPULATION ANALYSIS PROFILE  
  
  
Figure A.2.1:  Serial dilution of neat culture from the right to left for PAP test.  
  













Fig A.2.4. Population analysis profile in ribotype 001 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of metronidazole (mg/L) in 














































Fig A.2.5 Population analysis profile in ribotype 027 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of metronidazole (mg/L) in 
Oxoid Wilkin’s Chalgren Agar  
 
 
Fig A.2.6 Population analysis profile in ribotype 106 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of metronidazole (mg/L) in 


















































































Fig A.2.7. Population analysis profile in control strain 110 CDRM (blue) and 
CDSM (GREY) strains, exposed to doubling concentrations of Antibiotics (mg/L) 




Fig A.2.8. Population analysis profile in Ribotype 001 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of vancomycin (mg/L) in 

















































































Fig A.2.9 Population analysis profile in Ribotype 027 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of vancomycin (mg/L) in 








Fig A.2.10 Population analysis profile in Ribotype 106 CDRM (blue) and CDSM 
(GREY) strains, exposed to doubling concentrations of vancomycin (mg/L) in 



















































































APPENDIX 3.0  
Serial passage results for all strains in the C. difficile ribotypes analysed in exposure to 
metronidazole. Fig 3.1-3.6 has some strains with yellow bars these indicate CDSM strains.  
  
 
Figure A.3.1: serial passage of 001 ribotype strains without subinhibitory concentrations of 
metronidazole. CDSM strains were the set bars with yellow colour strain 114, 115, 116, 117  
 
Figure A.3.2: serial passage of 001 ribotype strains without subinhibitory concentrations of 





Figure A.3.3: serial passage of 027 ribotype strains without subinhibitory concentrations of 
metronidazole. CDSM strains were the set bars with yellow colour strain 41, 37, 35, 12  
 
Figure A.3.4: serial passage of 027 ribotype strains without subinhibitory concentrations of 
Vancomycin. CDSM strains were the set bars with yellow colour strain 41, 37, 35, 12  




Figure A.3.5: serial passage of 106 ribotype strains without subinhibitory concentrations of 
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Figure A.3.6: serial passage of 027 ribotype strains without subinhibitory concentrations of 
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APPENDIX 4  
Hemin effect on Clostridium difficile susceptibility to metronidazole  
 
Figure A.4.1: Hemin effect on Clostridium difficile susceptibility to metronidazole 
incorporated in Wilkin Chalgren agar.  
  
  
Figure A.4.2: Hemin effect on Clostridium difficile susceptibility to metronidazole 
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